After I-Adverse_event.Trigger
therapy O
with O
parenteral I-Treatment.Route
amiodarone I-Treatment.Drug
( I-Treatment
2300 I-Treatment.Dosage
mg I-Treatment.Dosage
in I-Treatment.Dosage
3 I-Treatment.Dosage
days I-Treatment.Dosage
) I-Treatment
and I-Treatment
other I-Treatment
measures I-Treatment
, O
signs O
of O
congestive I-Treat_Disorder
heart I-Treat_Disorder
failure I-Treat_Disorder
disappeared O
; O
subsequently O
the O
patient O
developed O
jaundice I-Effect
, I-Effect
marked I-Effect
increase I-Effect
in I-Effect
serum I-Effect
transaminase I-Effect
levels I-Effect
and I-Effect
fall I-Effect
in I-Effect
prothrombin I-Effect
time I-Effect
, I-Effect
and I-Effect
histologic I-Effect
changes I-Effect
of I-Effect
severe I-Effect
centrilobular I-Effect
necrosis I-Effect
were I-Effect
observed I-Effect
in I-Effect
hepatic I-Effect
biopsy I-Effect
. O

We O
report O
one O
case O
of O
non I-Effect
- I-Effect
Hodgkin I-Effect
lymphoma I-Effect
in O
a I-Subject.Population
patient I-Subject
, I-Subject
with I-Subject
a I-Subject
30 I-Subject
- I-Subject
year I-Subject
history I-Subject
of I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
, O
taking I-Adverse_event.Trigger
low I-Treatment.Dosage
dose I-Treatment.Dosage
methotrexate I-Treatment.Drug
weekly I-Treatment.Freq
over I-Treatment
a I-Treatment
10 I-Treatment.Duration
- I-Treatment.Duration
month I-Treatment.Duration
period I-Treatment.Duration
. I-Duration

We O
recommend O
the O
cautious O
use O
of O
alum I-Treatment.Drug
irrigation I-Treatment.Route
in O
patients I-Subject
with O
renal I-Treat_Disorder
impairment I-Treat_Disorder
and O
monitoring O
of O
serum O
aluminum O
levels O
to I-Adverse_event.Trigger
prevent O
excessive I-Effect
accumulation I-Effect
and I-Effect
toxicity I-Effect
. I-Effect

RESULTS O
: O
A O
44 O
- O
year O
- O
old O
man O
taking O
naproxen O
for O
chronic O
low O
back O
pain O
and O
a I-Subject
20 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
on O
oxaprozin I-Treatment.Drug
for O
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
presented I-Adverse_event.Trigger
with O
tense I-Effect
bullae I-Effect
and I-Effect
cutaneous I-Effect
fragility I-Effect
on I-Effect
the I-Effect
face I-Effect
and I-Effect
the I-Effect
back I-Effect
of I-Effect
the I-Effect
hands I-Effect
. O

CASE O
REPORT O
: O
We O
report O
a O
case O
of O
intracerebral I-Effect
hemorrhage I-Effect
occurring I-Adverse_event.Trigger
in O
a O
middle I-Subject.Age
- I-Subject.Age
aged I-Subject.Age
man I-Subject.Gender
who I-Subject
suffered I-Subject
from I-Subject
chronic I-Treat_Disorder
sinusitis I-Treat_Disorder
and O
had O
been O
ingesting I-Treatment.Route
pseudoephedrine I-Treatment.Drug
daily I-Treatment.Freq
for I-Treatment.Duration
one I-Treatment.Duration
year I-Treatment.Duration
. O

Lymphoma I-Effect
developing I-Adverse_event.Trigger
in O
a I-Subject
patient I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
taking O
methotrexate I-Treatment.Drug
. O

The O
Naranjo O
probability O
scale O
suggests O
a O
highly O
probable O
relationship I-Adverse_event.Trigger
between O
AIN I-Effect
and O
pantoprazole I-Treatment.Drug
therapy O
in O
this O
patient I-Subject
. O

In O
one O
case O
, O
disulfiram I-Treatment.Drug
was O
the O
only O
potential O
teratogen I-Effect
exposed I-Adverse_event.Trigger
to O
the O
fetus I-Subject.Age
. O

Pancreatitis I-Effect
has O
been O
noted O
to O
be O
a O
complication I-Adverse_event.Trigger
in I-Subject
2 I-Subject.Population
- I-Subject.Population
16 I-Subject.Population
% I-Subject.Population
of I-Subject
patients I-Subject
undergoing O
treatment O
with O
L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
for I-Treatment
a I-Treatment.Treat_Disorder
variety I-Treatment.Treat_Disorder
of I-Treatment.Treat_Disorder
pediatric I-Treatment.Treat_Disorder
neoplasms I-Treatment.Treat_Disorder
. O

Myopathy I-Effect
, I-Effect
including I-Effect
rhabdomyolysis I-Effect
, O
is O
a O
well O
- O
known O
, O
albeit O
rare O
complication I-Adverse_event.Trigger
of O
statin I-Treatment.Drug
therapy O
. O

Management O
and O
successful O
desensitization O
in O
methotrexate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
anaphylaxis I-Effect
. O

Mitomycin I-Treatment.Drug
- I-Treatment.Drug
C I-Treatment.Drug
induced I-Adverse_event.Trigger
hemolytic I-Effect
uremic I-Effect
syndrome I-Effect
: O
a O
case O
report O
. O

Acute I-Effect
hepatic I-Effect
failure I-Effect
is O
a O
rare O
and O
potentially O
lethal O
complication I-Adverse_event.Trigger
of O
propylthiouracil I-Treatment.Drug
( I-Treatment
PTU I-Treatment
) I-Treatment
use O
for O
hyperthyroidism I-Treat_Disorder
. O

Monoclonal I-Effect
gammopathy I-Effect
and I-Effect
subsequent I-Effect
multiple I-Effect
myeloma I-Effect
in O
a I-Subject
patient I-Subject
on I-Adverse_event.Trigger
chronic I-Treatment.Dosage
diphenylhydantoin I-Treatment.Drug
therapy I-Treatment
. I-Treatment

Unexpected O
severe O
reversible O
cyclosporine I-Treatment.Drug
A I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
nephrotoxicity I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
systemic I-Treat_Disorder
lupus I-Treat_Disorder
erythematosus I-Treat_Disorder
and I-Subject
tubulointerstitial I-Treat_Disorder
renal I-Treat_Disorder
disease I-Treat_Disorder
. O

As O
far O
as O
we O
know O
, O
this O
is O
the O
first O
case O
report O
of O
acute I-Effect
hemorrhagic I-Effect
gastritis I-Effect
associated I-Adverse_event.Trigger
with O
AZ I-Treatment.Drug
intoxication I-Effect
. O

Toxic I-Effect
epidermal I-Effect
necrolysis I-Effect
resulted O
after I-Adverse_event.Trigger
19 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
of I-Treatment
treatment I-Treatment
with I-Treatment
5 I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
fluorocytosine I-Treatment.Combination.Drug
and I-Treatment
amphotericin I-Treatment.Combination.Drug
B. I-Treatment.Combination.Drug

Since O
1979 O
, O
over O
30 O
published O
case O
reports O
have O
documented O
the O
relationship I-Adverse_event.Trigger
between O
phenylpropanolamine I-Treatment.Drug
and O
stroke I-Effect
. O

CASE O
SUMMARY O
: O
A I-Subject
61 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
no I-Subject
apparent I-Subject
risk I-Subject
factors I-Subject
for I-Subject
liver I-Subject
injury I-Subject
developed I-Adverse_event.Trigger
acute I-Effect
hepatitis I-Effect
one O
week O
after O
the O
final O
dose O
of O
a O
long I-Treatment
- I-Treatment
term I-Treatment
course I-Treatment
of I-Treatment
pulse I-Treatment
itraconazole I-Treatment.Drug
therapy I-Treatment
( I-Treatment
200 I-Treatment.Dosage
mg I-Treatment.Dosage
orally I-Treatment.Route
twice I-Treatment.Freq
daily I-Treatment.Freq
, I-Treatment
1 I-Treatment
wk I-Treatment
on I-Treatment
, I-Treatment
3 I-Treatment
wk I-Treatment
off I-Treatment
, I-Treatment
for I-Treatment
24 I-Treatment
wk I-Treatment
) I-Treatment
for O
onychomycosis I-Treat_Disorder
. O

We O
experienced O
a I-Subject
case I-Subject
of I-Subject
chronic I-Subject.Sub_Disorder
renal I-Subject.Sub_Disorder
failure I-Subject.Sub_Disorder
in I-Subject
a I-Subject
patient I-Subject
suffering O
from O
acute I-Effect
hemorrhagic I-Effect
gastritis I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
AZ I-Treatment.Drug
intoxication O
. O

Rhabdomyolysis I-Effect
caused I-Adverse_event.Trigger
by O
tocolysis I-Treatment
with I-Treatment
oral I-Treatment.Route
ritodrine I-Treatment.Drug
hydrochloride I-Treatment.Drug
in O
a I-Subject
pregnant I-Subject
patient I-Subject
with I-Subject
myotonic I-Subject.Sub_Disorder
dystrophy I-Subject.Sub_Disorder
. O

While O
sulindac I-Treatment.Combination.Drug
failed O
to O
affect O
significantly O
warfarin O
- O
induced O
hypoprothrombinemia O
in O
normal O
male O
volunteers O
, O
it O
markedly I-Effect
prolonged I-Effect
prothrombin I-Effect
time I-Effect
in I-Adverse_event.Trigger
a I-Subject
patient I-Subject
with I-Subject
a I-Subject
renal I-Subject.Sub_Disorder
tubular I-Subject.Sub_Disorder
defect I-Subject.Sub_Disorder
who O
had I-Treatment
been I-Treatment
anticoagulated I-Treatment
with I-Treatment
warfarin I-Treatment.Combination.Drug
. O

Painful I-Effect
erosion I-Effect
of I-Effect
psoriatic I-Treat_Disorder
plaques I-Treat_Disorder
is O
a O
less O
common O
sign I-Adverse_event.Trigger
of O
methotrexate I-Treatment.Drug
toxicity I-Effect
that O
may O
precede O
evidence O
of O
bone I-Effect
marrow I-Effect
suppression I-Effect
. O

Drug O
- O
induced I-Adverse_event.Trigger
hepatitis I-Effect
in O
an I-Subject
acromegalic I-Treat_Disorder
patient I-Subject
during O
combined I-Treatment
treatment I-Treatment
with I-Treatment
pegvisomant I-Treatment.Combination.Drug
and I-Treatment
octreotide I-Treatment.Combination.Drug
long I-Treatment
- I-Treatment
acting I-Treatment
repeatable I-Treatment
attributed O
to O
the O
use O
of O
pegvisomant O
. O

We O
report O
the O
first O
case O
of O
a I-Subject
patient I-Subject
in I-Subject
a I-Subject
promethazine I-Drug
- I-Subject
induced I-Subject
coma I-Treat_Disorder
responding I-Potential_therapeutic_event.Trigger
to I-Potential_therapeutic_event.Trigger
treatment I-Treatment
with I-Treatment
flumazenil I-Treatment.Drug
. O

Ocular I-Effect
hypertension I-Effect
occurred I-Adverse_event.Trigger
1 I-Treatment.Time_elapsed
month I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
the I-Treatment.Time_elapsed
second I-Treatment.Time_elapsed
ranibizumab I-Treatment.Drug
injection I-Treatment.Route
in O
patients I-Subject
1 I-Subject
and I-Subject
3 I-Subject
, O
and O
1 I-Time_elapsed
month I-Time_elapsed
after I-Time_elapsed
the I-Time_elapsed
first I-Time_elapsed
ranibizumab I-Drug
in I-Subject
patient I-Subject
2 I-Subject
. O

Priapism I-Effect
associated I-Adverse_event.Trigger
with O
zuclopenthixol I-Treatment.Drug
. O

Reversible I-Effect
MR I-Effect
imaging I-Effect
and I-Effect
MR I-Effect
spectroscopy I-Effect
abnormalities I-Effect
in O
association I-Adverse_event.Trigger
with O
metronidazole I-Treatment.Drug
therapy I-Treatment
. O

PURPOSE O
: O
The O
aim O
of O
this O
study O
was O
to O
report O
on O
the O
possible O
development O
of O
corneal I-Effect
endothelial I-Effect
deposits I-Effect
resulting I-Adverse_event.Trigger
from O
the O
use O
of O
rifabutin I-Treatment.Drug
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
calcineurin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pain I-Effect
syndrome I-Effect
( I-Effect
CIPS I-Effect
) I-Effect
in O
a I-Subject
child I-Subject.Age
undergoing I-Subject
his I-Subject.Gender
second I-Subject
hematopoietic I-Treat_Disorder
stem I-Treat_Disorder
cell I-Treat_Disorder
transplant I-Treat_Disorder
( I-Subject
HSCT I-Subject
) I-Subject
. O

We O
experienced O
a I-Subject
male I-Subject.Gender
patient I-Subject
with I-Subject
psoriasis I-Treat_Disorder
and I-Subject
hypertension I-Treat_Disorder
whose O
conditions O
were O
treated O
with O
tacalcitol I-Treatment.Combination.Drug
ointment I-Treatment.Route
and I-Treatment
thiazide I-Treatment.Combination.Drug
, O
respectively O
, O
resulting I-Adverse_event.Trigger
in O
hypercalciuria I-Effect
and I-Effect
hypercalcemia I-Effect
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
granulomatous I-Effect
reaction I-Effect
described O
after I-Adverse_event.Trigger
calcium I-Treatment.Drug
hydroxylapatite I-Treatment.Drug
injection I-Treatment.Route
. O

Previous O
studies O
have O
demonstrated O
the O
interaction O
of O
MTX I-Treatment.Drug
and I-Treatment
a I-Treatment
variety I-Treatment
of I-Treatment
non I-Treatment.Drug
- I-Treatment.Drug
steroidal I-Treatment.Drug
, I-Treatment.Drug
anti I-Treatment.Drug
- I-Treatment.Drug
inflammatory I-Treatment.Drug
drugs I-Treatment.Drug
( I-Treatment
NSAIDs I-Treatment
) I-Treatment
with O
various O
clinical O
manifestations I-Adverse_event.Trigger
including O
acute I-Effect
renal I-Effect
failure I-Effect
, I-Effect
pancytopenia I-Effect
, I-Effect
vomiting I-Effect
, I-Effect
diarrhea I-Effect
, I-Effect
elevated I-Effect
liver I-Effect
transaminases I-Effect
, I-Effect
jaundice I-Effect
, I-Effect
mucosal I-Effect
ulcerations I-Effect
, I-Effect
and I-Effect
pyrexia I-Effect
. O

We O
present O
a O
case O
report O
of O
a I-Subject
patient I-Subject
with I-Subject
alveolar I-Treat_Disorder
hydatid I-Treat_Disorder
disease I-Treat_Disorder
, O
whose O
treatment O
with O
mebendazole I-Treatment.Drug
was O
brief O
due I-Adverse_event.Trigger
to O
side O
effects O
of O
alopecia I-Effect
and I-Effect
granulocytopenia I-Effect
; O
and O
review O
the O
features O
of O
this O
disease O
which O
, O
with O
increasing O
international O
migration O
, O
may O
be O
encountered O
more O
frequently O
in O
Australia O
. O

Niacin I-Treatment.Drug
causes I-Adverse_event.Trigger
a O
reversible I-Effect
toxic I-Effect
cystoid I-Effect
maculopathy I-Effect
that O
occurs O
in O
approximately I-Subject
0.67 I-Subject.Population
% I-Subject.Population
of I-Subject
patients I-Subject
taking O
high I-Treatment.Dosage
doses I-Treatment.Dosage
of O
the O
drug O
. O

When O
tuberculosis I-Treat_Disorder
patients I-Subject
on O
isoniazid I-Treatment.Drug
eat O
certain O
varieties O
of O
fish O
they O
may O
develop I-Adverse_event.Trigger
a O
histamine I-Effect
reaction I-Effect
. O

CONCLUSIONS O
: O
Priapism I-Effect
is O
an O
uncommon O
but O
potentially O
serious I-Adverse_event.Trigger
adverse I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
zuclopenthixol I-Treatment.Drug
that O
practitioners O
, O
as O
with O
many O
other O
antipsychotics O
, O
should O
be O
aware O
of O
. O

To O
report O
a O
case O
of O
possible I-Effect
interaction I-Effect
of I-Effect
smokeless I-Effect
tobacco I-Effect
with I-Effect
warfarin I-Treatment.Drug
in O
a O
patient O
treated I-Adverse_event.Trigger
after O
several I-Treat_Disorder
thromboembolic I-Treat_Disorder
events I-Treat_Disorder
. O

Hepatotoxicity I-Effect
induced I-Adverse_event.Trigger
by I-Adverse_event.Trigger
cyproterone I-Treatment.Drug
acetate I-Treatment.Drug
: O
a O
report O
of O
three O
cases O
. O

Neurotoxicity I-Effect
of I-Adverse_event.Trigger
intrathecal I-Treatment.Route
methotrexate I-Treatment.Drug
: O
MR O
imaging O
findings O
. O

Isonicotinic I-Treatment.Drug
acid I-Treatment.Drug
hydrazide I-Treatment.Drug
induced I-Adverse_event.Trigger
anagen I-Effect
effluvium I-Effect
and I-Effect
associated I-Effect
lichenoid I-Effect
eruption I-Effect
. O

Only O
one I-Subject.Population
case I-Subject
of O
severe I-Effect
symptomatic I-Effect
hepatitis I-Effect
occurring I-Adverse_event.Trigger
after O
pulse I-Treatment
therapy I-Treatment
with I-Treatment
itraconazole I-Treatment.Drug
for O
onychomycosis I-Treat_Disorder
and O
requiring O
transplantation O
has O
been O
reported O
previously O
. O

The O
elicitation O
of O
a O
movement I-Effect
disorder I-Effect
by I-Adverse_event.Trigger
trazodone I-Treatment.Drug
: O
case O
report O
. O

Pulmonary I-Effect
fibrosis I-Effect
subsequent I-Adverse_event.Trigger
to O
high I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
CCNU I-Treatment.Drug
for O
chronic I-Treat_Disorder
myeloid I-Treat_Disorder
leukemia I-Treat_Disorder
. O

PURPOSE O
/ O
OBJECTIVES O
: O
To O
describe O
the O
pharmacogenetic O
syndrome O
of O
dihydropyrimidine I-Subject.Sub_Disorder
dehydrogenase I-Subject.Sub_Disorder
( I-Subject.Sub_Disorder
DPD I-Subject.Sub_Disorder
) I-Subject.Sub_Disorder
deficiency I-Subject.Sub_Disorder
, O
which O
predisposes I-Adverse_event.Trigger
patients O
with O
cancer I-Treat_Disorder
to O
potentially O
lethal I-Effect
adverse I-Effect
reactions I-Effect
following O
5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
( I-Treatment
5 I-Treatment
- I-Treatment
FU) I-Treatment
- I-Treatment
based I-Treatment
chemotherapy I-Treatment.Route
. O

We O
report O
a O
case O
of O
sustained I-Effect
hypotension I-Effect
after I-Adverse_event.Trigger
administration I-Treatment
of I-Treatment
parenteral I-Treatment
verapamil I-Treatment.Drug
. O

Methadone I-Treatment.Drug
has I-Potential_therapeutic_event.Trigger
two I-Potential_therapeutic_event.Trigger
roles I-Potential_therapeutic_event.Trigger
in O
human I-Treat_Disorder
immunodeficiency I-Treat_Disorder
viral I-Treat_Disorder
infection I-Treat_Disorder
: O
pain I-Effect
management I-Effect
and I-Effect
treatment I-Effect
of I-Effect
opioid I-Effect
abuse I-Effect
. O

Each O
time O
he O
arrived O
at O
the O
anticoagulation O
clinic O
after O
his O
BCG I-Treatment.Combination.Drug
therapy O
, O
his O
INR I-Effect
was I-Effect
supratherapeutic I-Effect
, O
except O
after I-Time_elapsed
his I-Time_elapsed
fourth I-Time_elapsed
treatment I-Time_elapsed
( O
INR O
of O
2.5 O
) O
, O
which O
can O
be O
explained O
by O
residual I-Adverse_event.Trigger
effects I-Adverse_event.Trigger
from O
the O
phytonadione I-Treatment.Combination.Drug
he O
received O
a I-Time_elapsed
week I-Time_elapsed
earlier I-Time_elapsed
. O

A I-Subject
70 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
had O
been O
treated I-Potential_therapeutic_event.Trigger
with O
warfarin I-Treatment.Drug
for O
atrial I-Treat_Disorder
fibrillation I-Treat_Disorder
. O

This O
is O
a O
case O
report O
of O
fatal I-Effect
cryptococcal I-Effect
meningitis I-Effect
in I-Adverse_event.Trigger
a I-Subject
child I-Subject.Age
with I-Subject
systemic I-Treat_Disorder
lupus I-Treat_Disorder
erythematosus I-Treat_Disorder
being O
treated O
with O
prednisolone I-Treatment.Combination.Drug
and I-Treatment
azathioprine I-Treatment.Combination.Drug
. O

Acute I-Effect
hemorrhagic I-Effect
gastritis I-Effect
associated I-Adverse_event.Trigger
with O
acetazolamide I-Treatment.Drug
intoxication O
in O
a I-Subject
patient I-Subject
with I-Subject
chronic I-Subject.Sub_Disorder
renal I-Subject.Sub_Disorder
failure I-Subject.Sub_Disorder
. O

Although O
the O
movement I-Effect
disorder I-Effect
could O
not O
with O
certainty O
be O
attributed I-Adverse_event.Trigger
to O
trazodone I-Treatment.Drug
alone O
, O
the O
drug O
at O
least O
acted O
as O
an O
eliciting O
agent O
. O

CONCLUSIONS O
: O
Prolonged I-Treatment.Dosage
exposure I-Treatment.Dosage
to I-Treatment
itraconazole I-Treatment.Drug
, I-Treatment
administered I-Treatment
either I-Treatment
continuously I-Treatment.Route
or I-Treatment.Route
intermittently I-Treatment.Route
, O
may O
precipitate I-Adverse_event.Trigger
severe I-Effect
and I-Effect
irreversible I-Effect
hepatotoxic I-Effect
events I-Effect
. O

In O
two I-Subject.Population
patients I-Subject
with I-Subject
mycosis I-Treat_Disorder
fungoides I-Treat_Disorder
, O
a O
squamous I-Effect
cell I-Effect
carcinoma I-Effect
developed I-Adverse_event.Trigger
during O
therapy O
with O
psoralens I-Treatment.Drug
plus I-Treatment
long I-Treatment
- I-Treatment
wave I-Treatment
ultraviolet I-Treatment
radiation I-Treatment
( I-Treatment
PUVA I-Treatment
) I-Treatment
. O

Scrotal I-Effect
ulceration I-Effect
induced I-Adverse_event.Trigger
by O
all I-Treatment.Drug
- I-Treatment.Drug
trans I-Treatment.Drug
retinoic I-Treatment.Drug
acid I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
acute I-Treat_Disorder
promyelocytic I-Treat_Disorder
leukemia I-Treat_Disorder
. I-Subject

A I-Subject
61 I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
patient I-Subject
developed I-Adverse_event.Trigger
gynecomastia I-Effect
after O
starting O
theophylline I-Treatment.Drug
. O

Several O
possible O
explanations O
of O
the O
mechanism O
of O
renal I-Effect
failure I-Effect
associated I-Adverse_event.Trigger
with O
the O
use O
of O
dextran I-Treatment.Drug
- I-Treatment.Drug
40 I-Treatment.Drug
are O
discussed O
. O

We O
present O
a O
case O
of O
the O
syndrome I-Effect
of I-Effect
inappropriate I-Effect
antidiuretic I-Effect
hormone I-Effect
( I-Effect
SIADH I-Effect
) I-Effect
secondary I-Adverse_event.Trigger
to O
cisplatin I-Treatment.Drug
therapy I-Treatment
in O
a I-Subject
patient I-Subject
with I-Subject
advanced I-Treat_Disorder
- I-Treat_Disorder
stage I-Treat_Disorder
large I-Treat_Disorder
cell I-Treat_Disorder
neuroendocrine I-Treat_Disorder
carcinoma I-Treat_Disorder
of I-Treat_Disorder
the I-Treat_Disorder
cervix I-Treat_Disorder
. O

An I-Subject
80 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
female I-Subject.Gender
, O
followed O
up O
at O
the O
Memory O
Clinic O
for O
mild I-Sub_Disorder
cognitive I-Sub_Disorder
impairment I-Sub_Disorder
, O
had O
been O
taking O
propafenone I-Treatment.Drug
900 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
d I-Treatment.Dosage
for I-Treatment
> I-Treatment.Duration
10 I-Treatment.Duration
years I-Treatment.Duration
for I-Potential_therapeutic_event.Trigger
paroxysmal I-Treat_Disorder
atrial I-Treat_Disorder
fibrillation I-Treat_Disorder
without O
adverse O
effects O
. O

A O
total O
of O
109 I-Subject.Population
patients I-Subject
had I-Adverse_event.Trigger
a O
cardiovascular I-Effect
event I-Effect
, O
with O
event O
rates O
of O
4.9 I-Treatment
% I-Treatment
with I-Treatment
omeprazole I-Treatment.Drug
and I-Treatment
5.7 I-Treatment
% I-Treatment
with I-Treatment
placebo I-Treatment.Drug
( O
hazard O
ratio O
with O
omeprazole O
, O
0.99 O
; O
95 O
% O
CI O
, O
0.68 O
to O
1.44 O
; O
P O
= O
0.96 O
) O
; O
high O
- O
risk O
subgroups O
did O
not O
show O
significant O
heterogeneity O
. O

The O
mechanism O
of O
anaphylactoid I-Effect
reaction I-Adverse_event.Trigger
to O
zomepirac I-Treatment.Drug
in O
this O
case O
, O
therefore O
, O
remains O
unclear O
. O

New O
onset O
of O
CD I-Effect
may O
be O
considered O
as O
an O
immune I-Effect
- I-Effect
mediated I-Effect
injury I-Effect
induced I-Adverse_event.Trigger
by O
etanercept I-Treatment.Drug
. O

This O
supports O
the O
well O
- O
reported O
potential O
of O
bleomycin I-Treatment.Drug
to O
trigger I-Adverse_event.Trigger
acral I-Effect
vascular I-Effect
toxicity I-Effect
. O

Results O
of O
a O
Phase O
III O
, O
double O
- O
blind O
, O
randomized O
, O
parallel O
- O
group O
, O
non O
- O
inferiority O
study O
evaluating I-Effect
the I-Effect
safety I-Effect
and I-Effect
efficacy I-Effect
of I-Potential_therapeutic_event.Trigger
isotretinoin I-Treatment.Drug
- I-Treatment.Drug
Lidose I-Treatment.Drug
in O
patients I-Subject
with I-Subject
severe I-Treat_Disorder
recalcitrant I-Treat_Disorder
nodular I-Treat_Disorder
acne I-Treat_Disorder
. O

This O
treatment O
has O
the O
potential O
to O
cause O
severe I-Effect
vision I-Effect
loss I-Effect
as O
a O
result O
of O
intractable O
corticosteroid I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
glaucoma I-Effect
. O

Therefore O
, O
parenteral I-Treatment.Route
amiodarone I-Treatment.Drug
was O
implicated O
as O
the O
cause I-Adverse_event.Trigger
of O
acute I-Effect
hepatitis I-Effect
in O
this I-Subject
patient I-Subject
. O

Twenty I-Time_elapsed
- I-Time_elapsed
four I-Time_elapsed
hours I-Time_elapsed
after I-Adverse_event.Trigger
the O
administration I-Treatment
of I-Treatment
gemcitabine I-Treatment.Drug
, O
a I-Effect
symmetric I-Effect
, I-Effect
bullous I-Effect
, I-Effect
herpetiform I-Effect
eruption I-Effect
appeared I-Effect
on I-Effect
his I-Effect
trunk I-Effect
and I-Effect
upper I-Effect
limbs I-Effect
. O

The O
rate O
of O
overt O
upper I-Treat_Disorder
gastrointestinal I-Treat_Disorder
bleeding I-Treat_Disorder
was O
also O
reduced I-Potential_therapeutic_event.Trigger
with O
omeprazole I-Treatment.Drug
as O
compared O
with O
placebo I-Drug
( O
hazard O
ratio O
, O
0.13 O
; O
95 O
% O
CI O
, O
0.03 O
to O
0.56 O
; O
P O
= O
0.001 O
) O
. O

The O
association I-Adverse_event.Trigger
of O
phenothiazine I-Treatment.Drug
overdose I-Treatment.Dosage
and O
respiratory I-Effect
distress I-Effect
syndrome I-Effect
merits O
consideration O
. O

Patients I-Subject
from O
endemic O
areas O
referred O
to O
transplant O
centers O
may O
be O
at O
high O
risk O
for O
disseminated I-Effect
histoplasmosis I-Effect
when O
treated O
with I-Adverse_event.Trigger
long I-Treatment
- I-Treatment
term I-Treatment
prednisone I-Treatment.Drug
for O
graft I-Treat_Disorder
- I-Treat_Disorder
versus I-Treat_Disorder
- I-Treat_Disorder
host I-Treat_Disorder
disease I-Treat_Disorder
. I-Treat_Disorder

Atypical O
endometriosis O
may O
act O
as O
a O
precancerous O
lesion O
in O
the O
process O
of O
tamoxifen I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
malignant I-Effect
transformation I-Effect
of I-Effect
endometriosis I-Effect
. O

A I-Subject
28 I-Subject.Age
year I-Subject.Age
old I-Subject.Age
white I-Subject.Race
schizophrenic I-Treat_Disorder
male I-Subject.Gender
has O
been O
under O
risperidone I-Treatment.Drug
monotherapy I-Treatment
for O
about I-Duration
one I-Duration
year I-Duration
when O
he O
developed I-Adverse_event.Trigger
dyskinetic I-Effect
movements I-Effect
. O

Subjects O
receiving I-Potential_therapeutic_event.Trigger
ivacaftor I-Treatment.Drug
were O
55 O
% O
less O
likely O
to O
have O
a O
pulmonary I-Treat_Disorder
exacerbation I-Treat_Disorder
than O
were O
patients O
receiving O
placebo O
, O
through O
week O
48 O
( O
P<0.001 O
) O
. O

Spinal I-Effect
cord I-Effect
infarction I-Effect
during I-Adverse_event.Trigger
use I-Treatment
of I-Treatment
zolmitriptan I-Treatment.Drug
: O
a O
case O
report O
. O

Case O
2 O
, O
a I-Subject
29 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
, O
developed O
bilateral I-Effect
optic I-Effect
neuritis I-Effect
combined I-Effect
with I-Effect
numbness I-Effect
of I-Effect
the I-Effect
lower I-Effect
extremities I-Effect
as I-Effect
well I-Effect
as I-Effect
bowel I-Effect
and I-Effect
bladder I-Effect
dysfunction I-Effect
after I-Adverse_event.Trigger
a O
22 I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
month I-Treatment.Time_elapsed
use I-Treatment
of I-Treatment
recombinant I-Treatment
interferon I-Treatment.Drug
alpha I-Treatment.Drug
- I-Treatment.Drug
2b I-Treatment.Drug
for O
chronic I-Treat_Disorder
myelogenous I-Treat_Disorder
leukemia I-Treat_Disorder
. O

These O
features O
have O
not O
previously O
been O
reported O
as O
side O
effects O
of O
glibenclamide O
therapy O
, O
but O
intrahepatic I-Effect
cholestasis I-Effect
may O
occur I-Adverse_event.Trigger
with O
chlorpropamide I-Treatment.Drug
, O
a O
similar O
sulphonylurea O
agent O
. O

Risperidone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
tardive I-Effect
dyskinesia I-Effect
. O

Caution O
in O
longterm O
usage O
and O
early O
recognition O
of O
pentazocine I-Treatment.Drug
toxicity I-Effect
as O
a O
neuromuscular O
complication I-Adverse_event.Trigger
are O
important O
in O
order O
to O
prevent O
irreversible O
drug O
- O
induced O
fibrous O
myopathy O
and O
localized O
neuropathy O
. O

Based O
upon O
the O
observed I-Adverse_event.Trigger
fall I-Effect
of I-Effect
the I-Effect
filtration I-Effect
fraction I-Effect
, I-Effect
the I-Effect
rise I-Effect
in I-Effect
the I-Effect
relative I-Effect
clearance I-Effect
of I-Effect
99Tc I-Effect
- I-Effect
dimercaptosuccinic I-Effect
acid I-Effect
and I-Effect
the I-Effect
increase I-Effect
in I-Effect
proteinuria I-Effect
, O
we O
suggest O
that O
in O
this O
case O
the O
tubules O
and/or O
interstitium O
are O
the O
main O
targets O
for O
cyclosporine I-Treatment.Drug
A I-Treatment.Drug
nephrotoxicity O
. O

Niacin I-Treatment.Drug
maculopathy I-Effect
. O

We O
report O
a O
case O
in O
which O
a O
potential O
drug O
interaction I-Treatment
between I-Treatment
clobazam I-Treatment.Combination.Drug
and I-Treatment
etravirine I-Treatment.Combination.Drug
may O
have O
led I-Adverse_event.Trigger
to O
increased I-Effect
concentrations I-Effect
of I-Effect
clobazam I-Effect
and I-Effect
its I-Effect
pharmacologically I-Effect
active I-Effect
metabolite I-Effect
, I-Effect
N I-Effect
- I-Effect
desmethylclobazam I-Effect
, O
causing O
neurotoxic I-Effect
symptoms I-Effect
. O

A O
review O
of O
the O
literature O
revealed O
two O
other O
cases O
of O
hepatic I-Effect
angiosarcoma I-Effect
in O
patients I-Subject
after I-Adverse_event.Trigger
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
cyclophosphamide I-Treatment.Drug
treatment I-Treatment
. O

We O
present O
a I-Subject
case I-Subject
of O
cutaneous I-Effect
leucocytoclastic I-Effect
vasculitis I-Effect
in O
which O
amphotericin I-Treatment.Drug
B I-Treatment.Drug
might O
presumably O
be I-Adverse_event.Trigger
the O
aetiological O
factor O
. O

There O
have O
been O
numerous O
case O
reports O
of O
hyperglycemia I-Effect
with I-Adverse_event.Trigger
olanzapine I-Treatment.Drug
in O
the O
literature O
, O
but O
none O
reported O
hyperglycemia O
within I-Time_elapsed
days I-Time_elapsed
of I-Time_elapsed
initiation I-Time_elapsed
of O
the O
medication O
. O

This O
case O
report O
describes O
two O
severe O
antiretroviral I-Treatment.Drug
drug I-Treatment.Drug
adverse I-Effect
reactions I-Effect
that O
occurred I-Adverse_event.Trigger
in O
the O
same I-Subject
patient I-Subject
. O

We O
report O
the O
first O
case O
presenting O
with O
successive I-Effect
anaphylactic I-Effect
reaction I-Effect
and I-Effect
extra I-Effect
- I-Effect
pyramidal I-Effect
syndrome I-Effect
after I-Adverse_event.Trigger
treatment I-Treatment
with I-Treatment
thiethylperazine I-Treatment.Drug
maleate I-Treatment.Drug
( I-Treatment
thiethylperazine I-Treatment
) I-Treatment
. O

Renal I-Effect
failure I-Effect
associated I-Adverse_event.Trigger
with O
the O
use O
of O
dextran I-Treatment.Drug
- I-Treatment.Drug
40 I-Treatment.Drug
. O

Acute I-Effect
lung I-Effect
injury I-Effect
associated I-Adverse_event.Trigger
with O
5 I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
fluorouracil I-Treatment.Combination.Drug
and I-Treatment
oxaliplatinum I-Treatment.Combination.Drug
combined I-Treatment
chemotherapy I-Treatment.Route
. O

Type I-Treatment
II I-Treatment
heparin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thrombocytopenia I-Effect
( O
HIT O
) O
is O
an O
immunological O
disorder O
characterized O
by O
antibodies O
to O
heparin O
- O
platelet O
factor O
4 O
complexes O
and O
a O
high O
risk O
of O
thrombotic O
complications O
. O

RESULTS O
: O
Similar O
to O
previous O
findings O
of O
drug O
- O
induced O
vortex O
keratopathy O
, O
atovaquone I-Treatment.Drug
vortex I-Effect
keratopathy I-Effect
is O
presumably O
caused I-Adverse_event.Trigger
by O
its I-Treatment
lipophilic I-Treatment
properties I-Treatment
. O

Gangrene I-Effect
of I-Effect
the I-Effect
fingertips I-Effect
after I-Adverse_event.Trigger
bleomycin I-Treatment.Combination.Drug
and I-Treatment
methotrexate I-Treatment.Combination.Drug
. O

These O
cases O
demonstrate O
that O
CBZ I-Treatment.Drug
can O
induce I-Adverse_event.Trigger
simple I-Effect
motor I-Effect
tics I-Effect
in O
children I-Subject.Age
. O

Esophageal I-Effect
spasm I-Effect
following I-Adverse_event.Trigger
propranolol I-Treatment.Drug
overdose I-Treatment.Dosage
relieved O
by O
glucagon O
. O

She I-Subject.Gender
was O
thus O
diagnosed O
as O
having I-Adverse_event.Trigger
AZ I-Treatment.Drug
intoxication I-Effect
. O

Severe O
rhabdomyolysis O
following I-Adverse_event.Trigger
massive I-Treatment.Dosage
ingestion I-Treatment.Route
of I-Treatment
oolong I-Treatment.Drug
tea I-Treatment.Drug
: O
caffeine I-Drug
intoxication I-Effect
with I-Effect
coexisting I-Effect
hyponatremia I-Effect
. O

The O
ulcer I-Treat_Disorder
did O
not O
respond O
to O
antibiotic O
treatment O
and O
healed I-Potential_therapeutic_event.Trigger
shortly O
after O
withholding I-Treatment
ATRA I-Treatment.Drug
. O

Gemfibrozil I-Treatment.Combination.Drug
- I-Treatment
warfarin I-Treatment.Combination.Drug
drug I-Treatment
interaction I-Treatment
resulting I-Adverse_event.Trigger
in O
profound I-Effect
hypoprothrombinemia I-Effect
. O

Drug O
- O
induced I-Adverse_event.Trigger
eosinophilia I-Effect
is O
a O
non I-Dosage
- I-Dosage
dose I-Dosage
- I-Dosage
dependent I-Dosage
side O
effect O
of O
clozapine I-Treatment.Drug
. O

Vortex I-Effect
keratopathy I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
atovaquone I-Treatment.Drug
. O

DIAGNOSIS O
: O
Sustained I-Effect
ventricular I-Effect
tachycardia I-Effect
possibly O
owing I-Adverse_event.Trigger
to I-Adverse_event.Trigger
thalidomide I-Treatment.Drug
treatment O
. O

In O
one O
instance O
a O
systemic I-Effect
hypoglycemic I-Effect
reaction I-Effect
resulting I-Effect
in I-Effect
head I-Effect
trauma I-Effect
and I-Effect
confusion I-Effect
ended O
in O
an O
emegency O
hospital O
admission O
following I-Adverse_event.Trigger
the O
substitution O
of O
acetohexamide I-Treatment.Drug
for O
acetazolamide I-Drug
. O

However O
, O
an O
association I-Adverse_event.Trigger
of O
Ritalin I-Treatment.Drug
with O
glaucoma I-Effect
has O
been O
reported O
. O

After O
a O
two O
- O
month O
interruption O
of O
interferon O
administration O
, O
natural O
interferon I-Treatment.Drug
alpha I-Treatment.Drug
was O
given O
but O
followed I-Adverse_event.Trigger
by I-Adverse_event.Trigger
another O
episode O
of O
the O
same O
neurological I-Effect
manifestations I-Effect
. O

This O
article O
discusses O
the O
clinical O
manifestations O
of O
the O
serotonin O
syndrome O
and O
highlights O
reported O
cases I-Subject
of O
serotonin I-Effect
syndrome I-Effect
specifically O
related I-Adverse_event.Trigger
to O
an O
interaction O
between O
SSRIs I-Treatment.Combination.Drug
and I-Treatment
fentanyl I-Treatment.Combination.Drug
, O
a O
commonly O
used O
opioid O
in O
anesthesia O
practice O
. O

While O
the O
mechanism O
of O
dextran I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
renal I-Effect
failure I-Effect
remains O
unsolved O
, O
plasma O
exchange O
seems O
to O
be O
effective O
therapy O
. O

The O
use O
of O
pamidronate I-Treatment.Drug
for I-Potential_therapeutic_event.Trigger
hypercalcemia I-Treat_Disorder
secondary I-Treat_Disorder
to I-Treat_Disorder
acute I-Treat_Disorder
vitamin I-Treat_Disorder
D I-Treat_Disorder
intoxication I-Treat_Disorder
. O

Early I-Effect
overanticoagulation I-Effect
with I-Adverse_event.Trigger
acenocoumarol I-Treatment.Drug
due O
to O
a O
genetic O
polymorphism O
of O
cytochrome O
P450 O
CYP2C9 O
. O

We O
report O
an O
unusual O
pattern O
of O
supravenous I-Effect
hyperpigmentation I-Effect
occurring O
after I-Adverse_event.Trigger
CHOP I-Treatment.Drug
chemotherapy O
. O

Proton O
MRS O
examination O
demonstrated O
a O
persistent I-Effect
lactate I-Effect
elevation I-Effect
during I-Adverse_event.Trigger
metronidazole I-Treatment.Drug
treatment O
. O

Encephalopathy I-Effect
and I-Effect
seizures I-Effect
induced I-Adverse_event.Trigger
by O
intravesical I-Treatment.Route
alum I-Treatment.Drug
irrigations I-Treatment.Route
. O

Dermal I-Effect
side I-Effect
reactions I-Effect
to I-Adverse_event.Trigger
SSRI I-Treatment.Drug
- I-Treatment
drugs I-Treatment
in O
these I-Subject
patients I-Subject
may O
be O
due O
to O
high O
activity O
in O
the O
serotonergic O
system O
at O
the O
dermal O
and O
epidermo O
- O
dermal O
junctional O
area O
rather O
than O
a O
hypersensitivity O
to O
the O
drug O
molecule O
itself O
. O

CASE O
SUMMARY O
: O
A I-Subject
febrile I-Subject.Sub_Disorder
36 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
seaman I-Subject
from I-Subject
Mumbai I-Subject.Race
( I-Subject.Race
Bombay I-Subject.Race
) I-Subject.Race
was O
prescribed I-Potential_therapeutic_event.Trigger
> I-Treatment.Dosage
5 I-Treatment.Dosage
times I-Treatment.Dosage
the I-Treatment.Dosage
usual I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
chloroquine I-Treatment.Drug
for O
malaria I-Treat_Disorder
diagnosed O
empirically O
onboard O
ship O
. O

MATERIALS O
AND O
METHODS O
: O
We O
present O
two I-Subject.Population
cases I-Subject
of O
significant I-Effect
morbidity I-Effect
related I-Effect
to I-Effect
primary I-Effect
and I-Effect
secondary I-Effect
perforation I-Effect
of I-Effect
the I-Effect
bladder I-Effect
following I-Adverse_event.Trigger
two I-Treatment
instillations I-Treatment.Route
of I-Treatment
epirubicin I-Treatment.Drug
. O

Angio I-Effect
- I-Effect
oedema I-Effect
as I-Adverse_event.Trigger
an O
unusual O
tolerable O
side O
effect O
of O
voriconazole I-Treatment.Drug
therapy O
. O

Oxycodone I-Treatment.Combination.Drug
- I-Treatment
gabapentin I-Treatment.Combination.Drug
reduced I-Effect
pain I-Treat_Disorder
score I-Effect
by I-Effect
33 I-Effect
% I-Effect
from I-Effect
baseline I-Effect
to O
end O
of O
treatment O
. O

OBJECTIVE O
: O
We O
report O
a I-Subject
patient I-Subject
who O
developed I-Adverse_event.Trigger
neutropenia I-Effect
on O
clozapine I-Treatment.Drug
, O
but O
behind O
the O
cell O
count O
decrease O
showed O
to O
be O
a O
diurnal I-Effect
variation I-Effect
of I-Effect
the I-Effect
white I-Effect
blood I-Effect
cells I-Effect
( I-Effect
WBC I-Effect
) I-Effect
. O

RESULTS O
: O
Five I-Subject.Population
of I-Subject.Population
70 I-Subject.Population
patients I-Subject
who O
had O
begun O
leflunomide I-Treatment.Drug
therapy O
had I-Adverse_event.Trigger
significant I-Effect
weight I-Effect
loss I-Effect
that O
could O
not O
be O
linked O
to O
other O
identifiable O
etiologies O
. O

Only O
one O
report O
links I-Adverse_event.Trigger
phenylpropanolamine I-Treatment.Drug
consumption O
to O
an O
intracerebral I-Effect
hemorrhage I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
an I-Subject
AVM I-Subject.Sub_Disorder
. O

Anaphylactic I-Effect
reaction I-Effect
and O
unrelated O
, O
subsequent O
, O
known O
side O
effects O
during I-Adverse_event.Trigger
therapy O
with O
thiethylperazine I-Treatment.Drug
. O

PURPOSE O
: O
To O
investigate O
the O
concentration O
- O
side O
effect O
relationship O
in O
a O
patient O
with O
severe O
acyclovir I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
neurotoxicity I-Effect
and O
to O
summarize O
the O
information O
available O
in O
the O
literature O
about O
central I-Effect
nervous I-Effect
system I-Effect
side I-Effect
effects I-Effect
due O
to O
acyclovir O
. O

Radiation I-Effect
recall I-Effect
from I-Adverse_event.Trigger
gemcitabine I-Treatment.Drug
is O
rare O
, O
but O
can O
potentially O
arise O
in O
any O
site O
that O
has O
been O
previously O
irradiated O
. O

Most I-Subject
cases I-Subject
of O
pancreatitis I-Effect
associated I-Adverse_event.Trigger
with O
L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
toxicity O
are O
self O
- O
limiting O
and O
respond O
favorably O
to O
nasogastric O
decompression O
and O
intravenous O
hyperalimentation O
. O

Shortly I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
commencing I-Treatment
the I-Treatment
drug I-Treatment
, O
the I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
a O
severe I-Effect
adverse I-Effect
drug I-Effect
reaction I-Effect
manifesting I-Effect
as I-Effect
Drug I-Effect
Reaction I-Effect
( I-Effect
or I-Effect
Rash I-Effect
) I-Effect
with I-Effect
Eosinophilia I-Effect
and I-Effect
Systemic I-Effect
Symptoms I-Effect
( I-Effect
DRESS I-Effect
) I-Effect
syndrome I-Effect
. O

This O
report O
presents O
a I-Subject
potential I-Subject
case I-Subject
of O
risperidone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
tardive I-Effect
dyskinesia I-Effect
. O

The I-Subject
patient I-Subject
described O
feeling I-Effect
cold I-Effect
with I-Effect
worsening I-Effect
headache I-Effect
and I-Effect
chills I-Effect
approximately O
one I-Treatment.Time_elapsed
hour I-Treatment.Time_elapsed
after I-Treatment
infusion I-Treatment.Route
of I-Treatment
the I-Treatment
first I-Treatment
dose I-Treatment
of I-Treatment
penicillin I-Treatment.Drug
. O

Early I-Effect
- I-Effect
onset I-Effect
pentamidine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
second I-Effect
- I-Effect
degree I-Effect
heart I-Effect
block I-Effect
and I-Effect
sinus I-Effect
bradycardia I-Effect
: O
case I-Subject
report O
and O
review O
of O
the O
literature O
. O

Fatal O
pulmonary I-Effect
fibrosis I-Effect
associated I-Adverse_event.Trigger
with O
BCNU I-Treatment.Drug
: O
the O
relative O
role O
of O
platelet O
- O
derived O
growth O
factor O
- O
B O
, O
insulin O
- O
like O
growth O
factor O
I O
, O
transforming O
growth O
factor O
- O
beta1 O
and O
cyclooxygenase O
- O
2 O
. O

CONCLUSIONS O
: O
This O
case O
suggests O
that O
losartan I-Treatment.Drug
can O
induce I-Adverse_event.Trigger
late I-Effect
- I-Effect
onset I-Effect
angioedema I-Effect
in O
patients I-Subject
with I-Subject
normal I-Subject
renal I-Subject
function I-Subject
and O
that O
the O
reaction O
can O
recur O
after O
initial O
resolution O
of O
the O
symptoms O
. O

Two O
cases O
of O
widespread I-Effect
cutaneous I-Effect
vasculitis I-Effect
are O
described O
in O
association I-Adverse_event.Trigger
with O
diltiazem I-Treatment.Drug
, I-Treatment
a I-Treatment
recently I-Treatment
introduced I-Treatment
calcium I-Treatment
antagonist I-Treatment
. O

The O
incidence O
of O
angioedema I-Effect
secondary I-Adverse_event.Trigger
to O
losartan I-Treatment.Drug
, I-Treatment
an I-Treatment
angiotensin I-Treatment
II I-Treatment
receptor I-Treatment
antagonist I-Treatment
, O
is O
unknown O
. O

We O
report O
the O
case O
of O
a I-Subject
young I-Subject.Age
man I-Subject
, O
affected O
by O
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
a I-Effect
rapid I-Effect
- I-Effect
onset I-Effect
short I-Effect
- I-Effect
of I-Effect
- I-Effect
breath I-Effect
, I-Effect
hemoptysis I-Effect
, I-Effect
and I-Effect
severe I-Effect
weakness I-Effect
, O
about I-Treatment
2 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
the I-Treatment.Route
administration I-Treatment.Route
of I-Treatment
leflunomide I-Treatment.Drug
. O

Toxicity I-Effect
related I-Adverse_event.Trigger
to O
chloroquine I-Treatment.Drug
treatment O
of O
resistant I-Treat_Disorder
vivax I-Treat_Disorder
malaria I-Treat_Disorder
. O

Patients I-Subject
with I-Subject
vitamin I-Subject.Sub_Disorder
B12 I-Subject.Sub_Disorder
deficiency I-Subject.Sub_Disorder
are O
exceedingly O
sensitive O
to O
neurologic I-Effect
deterioration I-Effect
following I-Adverse_event.Trigger
nitrous I-Treatment.Drug
oxide I-Treatment.Drug
anesthesia I-Treatment
. O

However O
here O
we O
reported O
two I-Subject.Population
patients I-Subject
, I-Subject
presenting O
with O
PD I-Effect
during I-Adverse_event.Trigger
high I-Treatment.Dosage
dose I-Treatment.Dosage
colchicine I-Treatment.Drug
treatment I-Treatment
for O
familiar O
mediterranean O
fever O
( O
FMF O
) O
. O

We O
report O
two I-Subject.Population
patients I-Subject
with O
infectious I-Effect
mononucleosis I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
induced I-Adverse_event.Trigger
by O
salazosulfapyridine I-Treatment.Drug
( I-Treatment
SASP I-Treatment
) I-Treatment
. I-Treatment

Myocardial I-Effect
ischemia I-Effect
associated I-Adverse_event.Trigger
with O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
carmustine I-Treatment.Drug
infusion I-Treatment.Route
. O

Hepatic I-Effect
drug I-Effect
interaction I-Effect
between I-Adverse_event.Trigger
tacrolimus I-Treatment.Combination.Drug
and I-Treatment
lansoprazole I-Treatment.Combination.Drug
in O
a I-Subject
bone I-Treat_Disorder
marrow I-Treat_Disorder
transplant I-Treat_Disorder
patient I-Subject
receiving I-Subject
voriconazole I-Treatment.Combination.Drug
and I-Subject
harboring I-Subject
CYP2C19 I-Subject.Sub_Disorder
and I-Subject.Sub_Disorder
CYP3A5 I-Subject.Sub_Disorder
heterozygous I-Subject.Sub_Disorder
mutations I-Subject.Sub_Disorder
. O

Gabapentin I-Treatment.Drug
withdrawal I-Treatment
presenting I-Adverse_event.Trigger
as O
status I-Effect
epilepticus I-Effect
. O

Atypical I-Effect
ventricular I-Effect
tachycardia I-Effect
( I-Effect
torsade I-Effect
de I-Effect
pointes I-Effect
) I-Effect
induced I-Adverse_event.Trigger
by O
amiodarone I-Treatment.Drug
: O
arrhythmia O
previously O
induced O
by O
quinidine O
and O
disopyramide O
. O

Colchicine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
rhabdomyolysis I-Effect
is O
a O
rare O
complication O
, O
and O
the O
postulated O
mechanisms O
and O
risk O
factors O
for O
this O
severe O
complication O
are O
discussed O
. O

Spindle I-Effect
coma I-Effect
in I-Adverse_event.Trigger
benzodiazepine I-Treatment.Drug
toxicity O
: O
case O
report O
. O

A O
typical O
case O
of O
dextran I-Treatment.Drug
- I-Treatment.Drug
40 I-Treatment.Drug
associated I-Adverse_event.Trigger
acute I-Effect
renal I-Effect
failure I-Effect
is O
presented O
. O

After O
the O
second O
infliximab I-Treatment.Drug
infusion I-Route
, O
he I-Subject.Gender
was O
found I-Adverse_event.Trigger
to O
have O
a O
severe I-Effect
transient I-Effect
neutropenia I-Effect
( I-Effect
0.5 I-Effect
x I-Effect
10(9)/L I-Effect
) I-Effect
. O

Lithium I-Treatment.Drug
for I-Potential_therapeutic_event.Trigger
irritability I-Treat_Disorder
in I-Treat_Disorder
post I-Treat_Disorder
- I-Treat_Disorder
traumatic I-Treat_Disorder
stress I-Treat_Disorder
disorder I-Treat_Disorder
. O

Iatrogenic I-Effect
hypercalcemia I-Effect
due I-Adverse_event.Trigger
to O
vitamin I-Treatment.Combination.Drug
D3 I-Treatment.Combination.Drug
ointment I-Treatment.Route
( I-Treatment
1,24(OH)2D3 I-Treatment
) I-Treatment
combined I-Treatment
with I-Treatment
thiazide I-Treatment.Combination.Drug
diuretics I-Treatment.Combination.Drug
in O
a O
case O
of O
psoriasis I-Treat_Disorder
. O

A I-Subject
case I-Subject
of O
mania I-Effect
associated I-Adverse_event.Trigger
with O
fluoxetine I-Treatment.Drug
. O

RESULTS O
: O
Extensive I-Effect
squamous I-Effect
metaplasia I-Effect
was I-Effect
found I-Effect
in I-Effect
endometrial I-Effect
glands I-Effect
following I-Adverse_event.Trigger
progestin I-Treatment.Drug
therapy I-Treatment
. O

Acute I-Effect
generalized I-Effect
exanthematous I-Effect
pustulosis I-Effect
caused I-Adverse_event.Trigger
by O
morphine I-Treatment.Drug
, O
confirmed O
by O
positive O
patch O
test O
and O
lymphocyte O
transformation O
test O
. O

Eleven I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
initiation I-Treatment
of I-Treatment
therapy I-Treatment
with I-Treatment
amiodarone I-Treatment.Drug
, O
the I-Subject
patient I-Subject
experienced I-Adverse_event.Trigger
syncope I-Effect
and I-Effect
was I-Effect
noted I-Effect
to I-Effect
have I-Effect
recurrent I-Effect
episodes I-Effect
of I-Effect
polymorphous I-Effect
ventricular I-Effect
tachycardia I-Effect
. O

Prolonged I-Freq
used I-Freq
of O
hydroxyurea I-Treatment.Drug
in O
patients I-Subject
with I-Subject
ET I-Treat_Disorder
may O
lead O
to O
therapy I-Effect
- I-Effect
associated I-Effect
acute I-Effect
leukemia I-Effect
. O

Metastatic I-Effect
osteomyelitis I-Effect
following I-Adverse_event.Trigger
BCG I-Treatment.Drug
vaccination I-Treatment.Drug
. O

Carbamyl I-Effect
phosphate I-Effect
synthetase I-Effect
- I-Effect
1 I-Effect
deficiency I-Effect
discovered O
after O
valproic I-Treatment.Drug
acid I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
coma I-Effect
. O

We O
describe O
two I-Subject.Population
patients I-Subject
in O
whom O
painful I-Effect
erosions I-Effect
of I-Effect
their I-Effect
psoriasis I-Treat_Disorder
developed O
as O
the O
presenting O
sign O
of I-Adverse_event.Trigger
methotrexate I-Treatment.Drug
toxicity O
and O
review O
the O
literature O
, O
emphasizing O
the O
risk O
factors O
associated O
with O
this O
manifestation O
. O

Methysergide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
retroperitoneal I-Effect
fibrosis I-Effect
: O
successful O
outcome O
and O
two O
new O
laboratory O
features O
. O

We O
describe O
2 I-Subject.Population
children I-Subject.Age
with I-Subject
cerebral I-Treat_Disorder
palsy I-Treat_Disorder
who O
suffered I-Adverse_event.Trigger
significant I-Effect
morbidity I-Effect
immediately I-Effect
after O
treatment I-Treatment
with I-Treatment
hyperbaric I-Treatment.Drug
oxygen I-Treatment.Drug
. O

A I-Subject
patient I-Subject
is O
described O
with O
polycythemia I-Effect
vera I-Effect
who O
was O
taking O
anticoagulants I-Treatment.Drug
and O
developed I-Adverse_event.Trigger
a I-Effect
spontaneous I-Effect
retropharyngeal I-Effect
hemorrhage I-Effect
after I-Effect
a I-Effect
violent I-Effect
sneezing I-Effect
episode I-Effect
. O

CD4 I-Effect
T I-Effect
- I-Effect
lymphocyte I-Effect
depletion I-Effect
, I-Effect
myelosuppression I-Effect
, I-Effect
and I-Effect
subsequent I-Effect
severe I-Effect
infections I-Effect
are O
the O
major O
side O
effects O
of I-Adverse_event.Trigger
fludarabine I-Treatment.Drug
phosphate I-Treatment.Drug
therapy O
. O

Penicillin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
Jarisch I-Effect
- I-Effect
Herxheimer I-Effect
reaction I-Effect
. O

The O
authors O
suggest O
that O
risperidone I-Treatment.Drug
may O
increase I-Effect
affect I-Effect
in O
patients I-Subject
with I-Subject
schizophrenia I-Treat_Disorder
and O
that O
some O
patients O
, O
especially O
those O
with O
anxiety O
, O
may O
have O
difficulty O
managing O
the O
increase O
. O

We O
cared O
for O
a I-Subject
patient I-Subject
with I-Subject
progressive I-Subject.Sub_Disorder
renal I-Subject.Sub_Disorder
impairment I-Subject.Sub_Disorder
who O
presented O
with O
blurred I-Effect
vision I-Effect
, I-Effect
QRS I-Effect
broadening I-Effect
and I-Effect
cardiac I-Effect
failure I-Effect
due I-Adverse_event.Trigger
to O
chronic I-Treatment.Duration
cibenzoline I-Treatment.Drug
intoxication I-Treatment.Dosage
. O

In O
a I-Subject
postoperative I-Subject
patient I-Subject
with I-Subject
pre I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
existent I-Subject.Sub_Disorder
myasthenia I-Subject.Sub_Disorder
gravis I-Subject.Sub_Disorder
, O
oral I-Treatment.Route
verapamil I-Treatment.Drug
caused I-Adverse_event.Trigger
a O
marked I-Effect
exacerbation I-Effect
in I-Effect
myasthenic I-Effect
weakness I-Effect
. O

An O
objective O
causality O
assessment O
suggests O
that O
the O
JHR I-Effect
in O
our O
patient I-Subject
was O
probably O
related I-Adverse_event.Trigger
to O
penicillin I-Treatment.Drug
. O

RESULTS O
: O
A I-Subject
34 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
acquired O
visual I-Effect
field I-Effect
defects I-Effect
and I-Effect
severe I-Effect
vision I-Effect
loss I-Effect
in I-Effect
both I-Effect
eyes I-Effect
after I-Adverse_event.Trigger
intravitreal I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
triamcinolone I-Treatment.Drug
for O
diabetic I-Treat_Disorder
macular I-Treat_Disorder
edema I-Treat_Disorder
. O

Simvastatin I-Treatment.Combination.Drug
- I-Treatment
amiodarone I-Treatment.Combination.Drug
interaction I-Treatment
resulting I-Adverse_event.Trigger
in O
rhabdomyolysis I-Effect
, I-Effect
azotemia I-Effect
, I-Effect
and I-Effect
possible I-Effect
hepatotoxicity I-Effect
. O

A I-Subject
73 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
receiving O
high I-Treatment.Dosage
- I-Treatment.Dosage
dosage I-Treatment.Dosage
olanzapine I-Treatment.Drug
for O
bipolar I-Treat_Disorder
disorder I-Treat_Disorder
developed O
parkinsonism I-Effect
after I-Adverse_event.Trigger
smoking I-Treatment.Drug
cessation I-Treatment
. O

Fatal O
pulmonary I-Effect
fibrosis I-Effect
induced I-Adverse_event.Trigger
by O
paclitaxel I-Treatment.Drug
: O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

Raltegravir I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
Drug O
Reaction O
with O
Eosinophilia I-Effect
and I-Effect
Systemic I-Effect
Symptoms I-Effect
( I-Effect
DRESS I-Effect
) I-Effect
syndrome I-Effect
- O
implications O
for O
clinical O
practice O
and O
patient O
safety O
. O

A O
10 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
with I-Subject
osteosarcoma I-Treat_Disorder
and I-Subject
normal I-Subject
renal I-Subject
function I-Subject
manifested O
laboratory O
evidence O
of O
impending I-Effect
renal I-Effect
toxicity I-Effect
and I-Effect
extreme I-Effect
elevation I-Effect
of I-Effect
aspartate I-Effect
aminotrasferase I-Effect
and I-Effect
alanine I-Effect
aminotransferase I-Effect
within I-Time_elapsed
2 I-Time_elapsed
hours I-Time_elapsed
after O
the O
completion O
of O
a O
4 I-Treatment.Duration
- I-Treatment.Duration
hour I-Treatment.Duration
infusion I-Treatment.Route
of I-Treatment
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
methotrexate I-Treatment.Drug
( I-Treatment
MTX I-Treatment
) I-Treatment
( I-Treatment
12 I-Treatment.Dosage
g I-Treatment.Dosage
/ I-Treatment.Dosage
m2 I-Treatment.Dosage
) I-Treatment
, O
and O
went O
on O
to O
develop I-Adverse_event.Trigger
acute I-Effect
renal I-Effect
failure I-Effect
with I-Effect
life I-Effect
- I-Effect
threatening I-Effect
hyperkalemia I-Effect
29 I-Time_elapsed
hours I-Time_elapsed
later I-Time_elapsed
. O

Transient O
trazodone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypomanic I-Effect
symptoms I-Effect
occurred O
in O
three I-Subject.Population
depressed I-Treat_Disorder
patients I-Subject
. O

We O
describe O
a I-Subject
case I-Subject
of O
disseminated I-Effect
muscular I-Effect
cysticercosis I-Effect
followed I-Effect
by I-Effect
myositis I-Effect
( I-Effect
fever I-Effect
, I-Effect
diffuse I-Effect
myalgia I-Effect
, I-Effect
weakness I-Effect
of I-Effect
the I-Effect
lower I-Effect
limbs I-Effect
, I-Effect
and I-Effect
inflammatory I-Effect
reaction I-Effect
around I-Effect
dying I-Effect
cysticerci I-Effect
) I-Effect
induced I-Adverse_event.Trigger
by O
praziquantel I-Treatment.Drug
therapy I-Treatment
, O
an O
event O
not O
described O
previously O
. O

Drug O
- O
induced I-Adverse_event.Trigger
fever I-Effect
should O
be O
considered O
in O
patients O
who O
have O
unexplained I-Effect
high I-Effect
temperatures I-Effect
during O
diltiazem I-Treatment.Drug
therapy I-Treatment
. O

Hemodialysis O
was O
also O
shown O
to O
reverse O
ifosfamide I-Treatment.Drug
- O
related I-Adverse_event.Trigger
neurotoxicity I-Effect
. O

Palpable I-Effect
purpuric I-Effect
skin I-Effect
lesions I-Effect
on I-Effect
the I-Effect
anterior I-Effect
surface I-Effect
of I-Effect
both I-Effect
legs I-Effect
appeared I-Adverse_event.Trigger
on O
the O
55th I-Treatment.Duration
day I-Treatment.Duration
of I-Treatment
amphotericin I-Treatment.Drug
B I-Treatment.Drug
treatment I-Treatment
. O

Transient I-Effect
left I-Effect
homonymous I-Effect
hemianopsia I-Effect
and I-Effect
encephalopathy I-Effect
following I-Adverse_event.Trigger
treatment O
of O
testicular I-Treat_Disorder
carcinoma I-Treat_Disorder
with O
cisplatinum I-Treatment.Combination.Drug
, I-Treatment
vinblastine I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
bleomycin I-Treatment.Combination.Drug
. O

We O
report O
a I-Subject
46 I-Subject.Age
- I-Subject.Age
yr I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
ovarian I-Treat_Disorder
carcinoma I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
porphyria I-Effect
cutanea I-Effect
tarda I-Effect
while O
undergoing O
treatment O
with O
cisplatin I-Treatment.Combination.Drug
and I-Treatment
cyclophosphamide I-Treatment.Combination.Drug
. O

In O
one I-Subject.Population
child I-Subject.Age
, O
a I-Treatment
second I-Treatment.Duration
course I-Treatment.Duration
of I-Treatment
carbamazepine I-Treatment.Drug
resulted I-Adverse_event.Trigger
in O
a I-Effect
return I-Effect
of I-Effect
the I-Effect
dystonia I-Effect
. O

Does O
acyclovir I-Treatment.Combination.Drug
increase I-Adverse_event.Trigger
serum I-Effect
lithium I-Treatment.Combination.Drug
levels I-Effect
? O

Sulfadiazine I-Treatment.Drug
crystalluria I-Effect
revisited I-Adverse_event.Trigger
. O

Administration O
of O
sumatriptan I-Treatment.Drug
in O
subarachnoid I-Treat_Disorder
haemorrhage I-Treat_Disorder
( O
SAH O
) O
patients I-Subject
, O
misdiagnosed O
as O
migraine O
patients O
, O
may O
induce I-Adverse_event.Trigger
symptomatic I-Effect
cerebral I-Effect
vasospasm I-Effect
with O
potentially O
dangerous O
consequences O
. O

Six I-Subject.Population
of I-Subject.Population
13 I-Subject.Population
outpatients I-Subject
with I-Subject
schizophrenia I-Treat_Disorder
who O
participated O
in O
a I-Treatment.Duration
ten I-Treatment.Duration
- I-Treatment.Duration
week I-Treatment.Duration
open I-Treatment
trial I-Treatment
of I-Treatment
risperidone I-Treatment.Drug
had O
an O
initial O
good O
response O
to O
the O
medication O
followed O
by O
development I-Adverse_event.Trigger
of O
intolerable I-Effect
affect I-Effect
, I-Effect
including I-Effect
feelings I-Effect
of I-Effect
agitation I-Effect
and I-Effect
depression I-Effect
and I-Effect
periods I-Effect
of I-Effect
crying I-Effect
and I-Effect
insomnia I-Effect
. O

Pulmonary O
edema O
during I-Adverse_event.Trigger
acute I-Treatment.Route
infusion I-Treatment.Route
of I-Treatment
epoprostenol I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
pulmonary I-Treat_Disorder
hypertension I-Treat_Disorder
and I-Treat_Disorder
limited I-Treat_Disorder
scleroderma I-Treat_Disorder
. O

Recent O
reports O
have O
shown O
that O
Decadron I-Treatment.Drug
( O
dexamethasone O
; O
Merck O
Sharp O
& O
Dohme O
, O
West O
Point O
, O
Pa O
) O
has O
a O
significant O
antiemetic I-Potential_therapeutic_event.Trigger
effect O
on O
cisplatin I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
vomiting I-Treat_Disorder
. O

Pleuropulmonary I-Effect
fibrosis I-Effect
after I-Adverse_event.Trigger
long I-Treatment
- I-Treatment
term I-Treatment
treatment I-Treatment
with I-Treatment
the I-Treatment
dopamine I-Treatment
agonist I-Treatment
pergolide I-Treatment.Drug
for O
Parkinson I-Treat_Disorder
Disease I-Treat_Disorder
. O

An I-Subject
infertile I-Subject.Sub_Disorder
patient I-Subject
with I-Subject
amenorrhea I-Treat_Disorder
- I-Treat_Disorder
galactorrhea I-Treat_Disorder
syndrome I-Treat_Disorder
lost I-Effect
vision I-Effect
during O
a O
pregnancy O
occurring O
after I-Adverse_event.Trigger
Bromocryptine I-Treatment.Drug
treatment O
. O

CONCLUSIONS O
: O
The O
observation O
that O
neurotoxicity I-Effect
developed I-Adverse_event.Trigger
with O
a O
delay O
of O
24 I-Time_elapsed
to I-Time_elapsed
48 I-Time_elapsed
hours I-Time_elapsed
after I-Time_elapsed
acyclovir I-Treatment.Drug
peak O
serum O
concentrations O
could O
explain O
the O
wide O
range O
of O
acyclovir O
levels O
reported O
in O
similar O
cases O
. O

Two O
cases O
of O
mequitazine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
photosensitivity I-Effect
reactions I-Effect
. O

Rhabdomyolysis I-Effect
associated O
with I-Adverse_event.Trigger
clozapine I-Treatment.Drug
treatment O
in O
a I-Subject
patient I-Subject
with I-Subject
decreased I-Subject.Sub_Disorder
calcium I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
dependent I-Subject.Sub_Disorder
potassium I-Subject.Sub_Disorder
permeability I-Subject.Sub_Disorder
of I-Subject.Sub_Disorder
cell I-Subject.Sub_Disorder
membranes I-Subject.Sub_Disorder
. O

A I-Subject
47 I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
who O
had O
a I-Treatment
4 I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
year I-Treatment.Time_elapsed
history I-Treatment
of I-Treatment
intramuscular I-Treatment.Route
pentazocine I-Treatment.Drug
injections I-Treatment.Route
in I-Treatment
the I-Treatment
lower I-Treatment
extremities I-Treatment
, O
developed I-Adverse_event.Trigger
gradual I-Effect
stiffness I-Effect
and I-Effect
weakness I-Effect
of I-Effect
the I-Effect
lower I-Effect
extremities I-Effect
. O

The O
possibility O
of O
severe I-Effect
rhabdomyolysis I-Effect
should O
be O
considered O
in O
a I-Subject
patient I-Subject
with O
water I-Effect
intoxication I-Effect
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
massive I-Treatment.Dosage
ingestion I-Treatment.Route
of I-Treatment
caffeine I-Treatment.Drug
- I-Treatment
containing I-Treatment
beverages I-Treatment
. O

CASE O
SUMMARY O
: O
A I-Subject
25 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
postpartum I-Subject.Sub_Disorder
white I-Subject.Race
woman I-Subject.Gender
developed I-Adverse_event.Trigger
multiple I-Effect
watery I-Effect
stools I-Effect
and I-Effect
abdominal I-Effect
cramping I-Effect
on O
day I-Time_elapsed
6 I-Time_elapsed
of O
therapy O
with O
clindamycin I-Treatment.Drug
vaginal I-Treatment.Route
cream I-Treatment.Route
for I-Treatment
bacterial I-Treatment.Treat_Disorder
vaginosis I-Treatment.Treat_Disorder
. O

Dose O
- O
dependent O
olanzapine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
leukopenia I-Effect
: O
three I-Subject.Population
case I-Subject
reports O
. O

He I-Subject.Gender
became O
completely O
premorbid I-Effect
2 I-Time_elapsed
weeks I-Time_elapsed
after I-Adverse_event.Trigger
administration O
of O
levodopa I-Treatment.Drug
. O

The O
authors O
describe O
a O
case O
of O
interstitial I-Effect
granulomatous I-Effect
dermatitis I-Effect
associated I-Adverse_event.Trigger
with O
darifenacin I-Treatment.Drug
. O

Amiodarone I-Treatment.Drug
was O
the O
third O
drug O
to O
induce I-Adverse_event.Trigger
AVT I-Effect
in O
this O
patient I-Subject
; O
she I-Subject.Gender
received O
200 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
six I-Treatment.Freq
days I-Treatment.Freq
per I-Treatment.Freq
week I-Treatment.Freq
for I-Treatment
six I-Treatment.Freq
months I-Treatment.Freq
. O

A I-Subject
young I-Subject.Age
diamond I-Subject
dealer I-Subject
developed O
visual I-Effect
impairment I-Effect
attributed I-Effect
to I-Effect
bilateral I-Effect
posterior I-Effect
subcapsular I-Effect
cataracts I-Effect
following I-Adverse_event.Trigger
only I-Treatment
four I-Treatment.Dosage
courses I-Treatment.Dosage
of I-Treatment
intermittent I-Treatment
Decadron I-Treatment.Combination.Drug
used I-Treatment
as I-Treatment
part I-Treatment
of I-Treatment
a I-Treatment
five I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
drug I-Treatment.Combination.Drug
antiemetic I-Treatment.Combination.Drug
regimen I-Treatment.Combination.Drug
for O
cisplatin I-Treat_Disorder
- I-Treat_Disorder
associated I-Treat_Disorder
nausea I-Treat_Disorder
. O

OBJECTIVE O
: O
To O
report O
a I-Subject
case I-Subject
of O
angioedema I-Effect
associated I-Adverse_event.Trigger
with O
losartan I-Treatment.Drug
administration I-Treatment
. O

The O
authors O
present O
a I-Subject
case I-Subject
report I-Subject
of O
a O
granulomatous I-Effect
reaction I-Effect
leading I-Adverse_event.Trigger
to O
urethral I-Effect
prolapse I-Effect
, O
3 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
after I-Treatment
the I-Treatment
transurethral I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
calcium I-Treatment.Drug
hydroxylapatite I-Treatment.Drug
. O

Epstein I-Effect
- I-Effect
Barr I-Effect
virus I-Effect
- I-Effect
associated I-Effect
lymphoproliferative I-Effect
disorder I-Effect
in I-Adverse_event.Trigger
a I-Subject
patient I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
on O
methotrexate I-Treatment.Drug
and I-Treatment
rofecoxib I-Treatment.Drug
: O
idiosyncratic O
reaction O
or O
pharmacogenetics O
? O

On O
the O
other O
hand O
, O
aspirin I-Treatment.Drug
may O
have O
promoted I-Adverse_event.Trigger
the O
enlargement I-Effect
of I-Effect
spontaneous I-Effect
hemorrhage I-Effect
from I-Effect
meningioma I-Effect
. O

The O
two O
groups O
did O
not O
differ O
significantly O
in O
the O
rate O
of O
serious O
adverse O
events O
, O
though O
the O
risk I-Effect
of I-Effect
diarrhea I-Effect
was I-Effect
increased I-Effect
with O
omeprazole I-Treatment.Drug
. O

Treatment I-Potential_therapeutic_event.Trigger
of O
a I-Subject
patient I-Subject
with I-Subject
severe I-Subject
digitoxin I-Treat_Disorder
intoxication I-Treat_Disorder
by O
Fab I-Treatment.Drug
fragments I-Treatment.Drug
of I-Treatment.Drug
anti I-Treatment.Drug
- I-Treatment.Drug
digitalis I-Treatment.Drug
antibodies I-Treatment.Drug
. O

Development O
of O
porphyria I-Effect
cutanea I-Effect
tarda I-Effect
after I-Adverse_event.Trigger
treatment O
with O
cyclophosphamide I-Treatment.Drug
. I-Drug

We O
report O
a I-Subject
premature I-Subject.Sub_Disorder
infant I-Subject.Age
who O
developed O
seizures I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
intraventricular I-Treatment.Route
administration I-Treatment
of I-Treatment
nafcillin I-Treatment.Drug
and O
discuss O
the O
need O
for O
electroencephalographic O
monitoring O
of O
patients O
receiving O
intraventricular O
antibiotics O
. O

OBJECTIVE O
: O
To O
present O
a O
single O
case O
of O
zuclopenthixol I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
priapism I-Effect
and O
a O
literature O
review O
. O

CASE O
REPORT O
: O
We O
hereby O
report O
a O
case O
of O
radiation I-Effect
recall I-Effect
dermatitis I-Effect
and I-Effect
myositis I-Effect
occurring I-Adverse_event.Trigger
on O
gemcitabine I-Treatment.Drug
monotherapy I-Treatment
, I-Treatment
five I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
completing I-Treatment
chemoradiation I-Treatment
for O
locally I-Treat_Disorder
advanced I-Treat_Disorder
pancreatic I-Treat_Disorder
cancer I-Treat_Disorder
. O

Stroke I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
after I-Adverse_event.Trigger
gold I-Treatment.Drug
sodium I-Treatment.Drug
thiomalate I-Treatment.Drug
induced O
vasomotor I-Effect
reaction I-Effect
. O

MTX O
- O
induced O
hepatic O
injury O
and O
liver O
enzyme O
elevations O
have O
been O
demonstrated I-Potential_therapeutic_event.Trigger
after O
treatment I-Treatment
of I-Treatment
leukemia I-Treatment.Treat_Disorder
, I-Treatment
gestational I-Treatment.Treat_Disorder
disease I-Treatment.Treat_Disorder
and I-Treatment
during I-Treatment
treatment I-Treatment
of I-Treatment
psoriasis I-Treatment.Treat_Disorder
and I-Treatment
rheumatoid I-Treatment.Treat_Disorder
arthritis I-Treatment.Treat_Disorder
. O

An I-Effect
adverse I-Effect
drug I-Effect
reaction I-Effect
( I-Effect
ADR I-Effect
) I-Effect
induced I-Adverse_event.Trigger
by O
fluoxetine I-Treatment.Drug
was O
suspected O
and O
fluoxetine I-Drug
treatment O
was O
discontinued O
. O

New I-Effect
onset I-Effect
of I-Effect
Crohn I-Effect
's I-Effect
disease I-Effect
during I-Adverse_event.Trigger
treatment O
of O
active I-Treat_Disorder
ankylosing I-Treat_Disorder
spondylitis I-Treat_Disorder
with O
etanercept I-Treatment.Drug
. O

Fatal I-Effect
hepatitis I-Effect
after I-Adverse_event.Trigger
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
pulse I-Treatment.Dosage
itraconazole I-Treatment.Drug
treatment I-Treatment
for O
onychomycosis I-Treat_Disorder
. O

Fatal I-Effect
outcome I-Effect
of I-Adverse_event.Trigger
intravesical I-Treatment.Route
formalin I-Treatment.Drug
instillation I-Treatment.Route
, O
with I-Effect
changes I-Effect
mimicking I-Effect
renal I-Effect
tuberculosis I-Effect
. O

Both O
reactions O
were O
caused O
due O
to O
this O
anti O
- O
emetic O
drug O
, O
but O
an O
additive I-Effect
effect I-Effect
of O
clemastine I-Treatment.Drug
fumarate I-Treatment.Drug
, O
prescribed O
to O
treat O
the O
anaphylactic I-Treat_Disorder
reaction I-Treat_Disorder
, O
is O
suggested I-Adverse_event.Trigger
by O
the O
sequence O
of O
events O
. O

Reversible O
posterior O
leukoencephalopathy O
syndrome O
in O
systemic I-Treat_Disorder
lupus I-Treat_Disorder
erythematosus I-Treat_Disorder
with I-Treat_Disorder
thrombocytopenia I-Treat_Disorder
treated I-Potential_therapeutic_event.Trigger
with O
cyclosporine I-Treatment.Drug
. O

Among O
patients I-Subject
receiving I-Subject
aspirin I-Combination.Drug
and I-Subject
clopidogrel I-Combination.Drug
, O
prophylactic I-Potential_therapeutic_event.Trigger
use I-Potential_therapeutic_event.Trigger
of O
a O
PPI I-Treatment.Combination.Drug
reduced I-Effect
the I-Effect
rate I-Effect
of I-Effect
upper I-Effect
gastrointestinal I-Effect
bleeding I-Effect
. O

Clofazimine I-Treatment.Drug
enteropathy I-Effect
in I-Adverse_event.Trigger
a I-Subject
pediatric I-Subject
bone I-Subject
marrow I-Subject
transplant I-Subject
recipient I-Subject
. O

Anisocoria I-Effect
from I-Adverse_event.Trigger
transdermal I-Treatment.Drug
scopolamine I-Treatment.Drug
. O

His O
fever O
resolved O
, O
but O
he I-Subject.Gender
developed I-Adverse_event.Trigger
symptoms I-Effect
consistent I-Effect
with I-Effect
those I-Effect
of I-Effect
chloroquine I-Treatment.Drug
toxicity I-Effect
. O

A I-Subject
36 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
being O
treated O
with O
cisplatinum I-Treatment.Combination.Drug
, I-Treatment
vinblastine I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
bleomycin I-Treatment.Combination.Drug
for O
testicular I-Treat_Disorder
carcinoma I-Treat_Disorder
developed I-Adverse_event.Trigger
a O
dense I-Effect
left I-Effect
homonymous I-Effect
hemianopsia I-Effect
, I-Effect
encephalopathy I-Effect
, I-Effect
and I-Effect
a I-Effect
partial I-Effect
nondominant I-Effect
parietal I-Effect
lobe I-Effect
syndrome I-Effect
. O

We O
report O
the O
first O
death I-Effect
associated I-Effect
with I-Effect
rhabdomyolysis I-Effect
in O
a I-Subject
patient I-Subject
treated I-Adverse_event.Trigger
with O
a I-Treatment
statin I-Treatment.Combination.Drug
and I-Treatment
a I-Treatment
protease I-Treatment.Combination.Drug
inhibitor I-Treatment.Combination.Drug
, O
which O
produced O
a O
significant O
drug O
- O
drug O
interaction O
. O

Methotrexate O
( O
MTX O
) O
is O
a O
commonly O
used O
second O
line O
agent O
for O
RA O
, O
and O
there O
have O
been O
several O
recent O
reports I-Adverse_event.Trigger
of O
Epstein I-Effect
- I-Effect
Barr I-Effect
virus I-Effect
( I-Effect
EBV) I-Effect
- I-Effect
associated I-Effect
polyclonal I-Effect
B I-Effect
cell I-Effect
lymphoproliferative I-Effect
disorder I-Effect
in O
MTX I-Treatment.Drug
- I-Treatment
treated I-Treatment
RA I-Treat_Disorder
patients I-Subject
. O

To O
describe O
a O
case O
of O
azathioprine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
warfarin I-Effect
resistance I-Effect
, O
present O
a O
literature O
review O
on O
warfarin O
- O
azathioprine O
interactions O
, O
and O
provide O
recommendations O
on O
appropriate O
management O
of O
this O
clinically O
significant O
interaction O
. O

Pulmonary I-Effect
fibrosis I-Effect
is O
a O
complication I-Adverse_event.Trigger
of O
paclitaxel I-Treatment.Drug
therapy I-Treatment
that O
may O
occur O
despite O
treatments O
with O
corticosteroids O
. O

Two I-Subject.Population
patients I-Subject
with I-Subject
adrenal I-Treat_Disorder
carcinoma I-Treat_Disorder
treated I-Potential_therapeutic_event.Trigger
with O
2,2 I-Treatment.Drug
- I-Treatment.Drug
bis I-Treatment.Drug
( I-Treatment.Drug
2 I-Treatment.Drug
- I-Treatment.Drug
chlorophenyl I-Treatment.Drug
- I-Treatment.Drug
4 I-Treatment.Drug
- I-Treatment.Drug
chlorophenyl) I-Treatment.Drug
- I-Treatment.Drug
1,1 I-Treatment.Drug
- I-Treatment.Drug
dichloroethane I-Treatment.Drug
( I-Treatment
o I-Treatment
, I-Treatment
p' I-Treatment
- I-Treatment
DDD I-Treatment
) I-Treatment
as I-Treatment
adjuvant I-Treatment
therapy I-Treatment
were O
studied O
. O

METHODS O
: O
Repeated O
blood O
samples O
were O
drawn O
in O
a I-Subject
patient I-Subject
with O
severe O
acyclovir I-Treatment.Drug
overdose I-Treatment.Dosage
who O
developed I-Adverse_event.Trigger
coma I-Effect
and I-Effect
nonoliguric I-Effect
renal I-Effect
failure I-Effect
. O

An O
8 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
girl I-Subject.Gender
, O
who O
had O
been O
vaccinated O
with O
BCG I-Treatment.Drug
without O
subsequent O
regional O
reactions O
, O
developed I-Adverse_event.Trigger
osteomyelitis I-Effect
in O
the O
left O
calcaneus O
7 O
months O
later O
. O

Since O
this O
amount O
of O
FAB I-Drug
was O
insufficient O
to O
bind O
all O
DGTX I-Treatment.Drug
present O
in O
the O
serum O
, O
cardiac I-Effect
DGTX I-Effect
toxicity I-Effect
( I-Effect
total I-Effect
AV I-Effect
- I-Effect
block I-Effect
) I-Effect
persisted I-Adverse_event.Trigger
. O

Abnormalities I-Effect
of I-Effect
the I-Effect
pupil I-Effect
and I-Effect
visual I-Effect
- I-Effect
evoked I-Effect
potential I-Effect
in I-Adverse_event.Trigger
quinine I-Treatment.Drug
amblyopia I-Effect
. O

A O
case O
is O
reported O
in O
which O
severe I-Effect
hypocalcemia I-Effect
, I-Effect
with I-Effect
a I-Effect
low I-Effect
plasma I-Effect
parathyroid I-Effect
hormone I-Effect
( I-Effect
PTH I-Effect
) I-Effect
concentration I-Effect
, O
resulted I-Adverse_event.Trigger
from O
the O
therapeutic O
use O
of O
magnesium I-Treatment.Drug
sulfate I-Treatment.Drug
for O
toxemia I-Treat_Disorder
of I-Treat_Disorder
pregnancy I-Treat_Disorder
. O

Concurrent I-Effect
acute I-Effect
megaloblastic I-Effect
anaemia I-Effect
and I-Effect
pneumonitis I-Effect
: O
a O
severe O
side O
- O
effect O
of I-Adverse_event.Trigger
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
methotrexate I-Treatment.Drug
therapy O
during O
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

Patients I-Subject
should O
be O
informed O
about O
the O
risk I-Adverse_event.Trigger
of O
osteonecrosis I-Effect
when O
taking O
dexamethasone I-Treatment.Drug
as O
an O
antiemetic O
drug O
. O

We O
report O
a I-Subject
patient I-Subject
with I-Subject
inoperable I-Treat_Disorder
pancreatic I-Treat_Disorder
cancer I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
gastrointestinal I-Effect
bleeding I-Effect
secondary O
to O
radiation I-Effect
- I-Effect
recall I-Effect
related O
to O
gemcitabine I-Treatment.Drug
and O
review O
literature O
. O

We O
report O
a O
case O
of O
SJS I-Effect
in O
a I-Subject
14 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
with O
nephrotic O
syndrome O
, O
who O
was O
treated O
with I-Adverse_event.Trigger
oral I-Treatment.Route
prednisolone I-Treatment.Drug
for I-Treatment
6 I-Treatment.Duration
weeks I-Treatment.Duration
. O

A I-Subject
45 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
thyrotoxicosis I-Treat_Disorder
developed I-Adverse_event.Trigger
agranulocytosis I-Effect
after O
treatment O
with O
propylthiouracil I-Treatment.Drug
. O

We O
wish O
to O
call O
for O
cautious O
approach O
at O
time O
of I-Adverse_event.Trigger
cessation I-Treatment
of I-Treatment
prolonged I-Treatment
ACTH I-Treatment.Drug
therapy O
because O
of O
possible O
unexpected O
and O
only O
partially O
understood O
hazardous O
side O
effects O
such O
as O
hyperkalemia I-Effect
. O

Haemolytic I-Effect
- I-Effect
uraemic I-Effect
syndrome I-Effect
complicating I-Adverse_event.Trigger
long I-Treatment
- I-Treatment
term I-Treatment
mitomycin I-Treatment.Combination.Drug
C I-Treatment.Combination.Drug
and I-Treatment
5 I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
fluorouracil I-Treatment.Combination.Drug
therapy I-Treatment
for O
gastric I-Treat_Disorder
carcinoma I-Treat_Disorder
. O

Although O
this O
article O
focuses O
on O
serotonin I-Effect
syndrome I-Effect
as O
a O
result I-Adverse_event.Trigger
of O
an O
adverse O
interaction O
of O
selective I-Treatment.Combination.Drug
serotonin I-Treatment.Combination.Drug
reuptake I-Treatment.Combination.Drug
inhibitors I-Treatment.Combination.Drug
( I-Combination.Drug
SSRI I-Combination.Drug
) I-Combination.Drug
and O
fentanyl I-Treatment.Combination.Drug
, O
it O
is O
important O
for O
not O
only O
anesthesia O
professionals O
, O
but O
all O
clinicians O
-- O
such O
as O
those O
in O
emergency O
medicine O
and O
critical O
care O
-- O
to O
be O
aware O
of O
this O
syndrome O
and O
its O
management O
. O

Intrahepatic I-Effect
cholestasis I-Effect
and I-Effect
cutaneous I-Effect
bullae I-Effect
associated I-Adverse_event.Trigger
with O
glibenclamide I-Treatment.Drug
therapy O
are O
described O
in O
a I-Subject
61 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
diabetic I-Treat_Disorder
patient I-Subject
who I-Subject
presented I-Subject
wit I-Subject
hypoglycaemic I-Subject.Sub_Disorder
coma I-Subject.Sub_Disorder
. O

In O
the O
presented O
case I-Subject
, O
the O
temporal O
relationship O
between O
the O
administration I-Adverse_event.Trigger
of O
cloxacillin O
and O
increased I-Effect
INR I-Effect
suggests O
that O
the O
cloxacillin I-Treatment.Combination.Drug
was O
responsible O
for O
the O
enhanced I-Effect
warfarin I-Combination.Drug
activity I-Effect
. I-Effect

Cardiac I-Effect
arrest I-Effect
following I-Adverse_event.Trigger
use O
of O
sumatriptan I-Treatment.Drug
. O

We O
report O
four O
cases O
of O
encephalopathy O
coincident O
with O
elevated O
aluminum O
levels O
as O
well O
as O
one I-Subject.Population
patient I-Subject
who O
developed I-Adverse_event.Trigger
seizures I-Effect
while O
receiving I-Treatment
continuous I-Treatment
bladder I-Treatment
irrigations I-Treatment
with I-Treatment
alum I-Treatment.Drug
. O

Nine I-Subject.Population
azotemic I-Subject.Sub_Disorder
patients I-Subject
who O
developed O
a O
coagulopathy I-Effect
associated I-Adverse_event.Trigger
with O
the O
use O
of O
either O
cephalosporin I-Treatment.Drug
or I-Treatment
moxalactam I-Treatment.Drug
antibiotics I-Treatment
are O
reported O
. O

This O
report O
suggests O
that O
the O
poor I-Effect
prognosis I-Effect
previously O
given O
to O
fetuses I-Subject.Age
exposed I-Adverse_event.Trigger
to O
disulfiram I-Treatment.Drug
in O
the O
first O
trimester O
may O
not O
be O
warranted O
. O

We O
hypothesize O
that O
caffeine I-Treatment.Drug
toxicity I-Treatment
injured I-Adverse_event.Trigger
the O
muscle I-Effect
cells I-Effect
, I-Effect
which I-Effect
were I-Effect
fragile I-Effect
due I-Effect
to I-Effect
the I-Effect
potassium I-Effect
depletion I-Effect
induced I-Effect
by I-Effect
the I-Effect
coexisting I-Effect
hyponatremia I-Effect
, I-Effect
to I-Effect
result I-Effect
in I-Effect
unusually I-Effect
severe I-Effect
rhabdomyolysis I-Effect
. O

The O
aim O
of O
this O
paper O
is O
to O
report O
the O
case O
of O
rosaceiform I-Effect
eruption I-Effect
induced I-Adverse_event.Trigger
by O
erlotinib I-Treatment.Drug
in O
an I-Subject
81 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
- I-Subject
man I-Subject.Gender
and O
to O
discuss O
the O
pathogenetic O
role O
of O
Demodex I-Effect
folliculorum I-Effect
mites I-Effect
, O
found O
in O
the O
present O
patient O
, O
using O
skin I-Treatment
scraping I-Treatment
. O

An I-Subject
11 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
developed I-Adverse_event.Trigger
a O
severe I-Effect
enteropathy I-Effect
2 I-Time_elapsed
years I-Time_elapsed
after O
initiation O
of O
clofazimine I-Treatment.Drug
treatment I-Treatment
for O
graft I-Treat_Disorder
- I-Treat_Disorder
versus I-Treat_Disorder
- I-Treat_Disorder
host I-Treat_Disorder
disease I-Treat_Disorder
. O

The O
authors O
conclude O
that O
among O
patients I-Subject
taking I-Adverse_event.Trigger
high I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
oral I-Treatment.Route
niacin I-Treatment.Drug
only O
those O
who O
experience O
visual I-Effect
symptoms I-Effect
need O
to O
be O
ophthalmologically O
evaluated O
. O

Reflex I-Effect
sympathetic I-Effect
dystrophy I-Effect
syndrome I-Effect
in O
renal I-Subject.Sub_Disorder
transplanted I-Subject.Sub_Disorder
patients I-Subject
under O
immunosuppression O
with I-Adverse_event.Trigger
tacrolimus I-Treatment.Drug
. O

We O
report O
the O
case O
of O
an I-Subject
11 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
treated I-Subject
for I-Subject
mediastinal I-Treat_Disorder
T I-Treat_Disorder
- I-Treat_Disorder
cell I-Treat_Disorder
lymphoma I-Treat_Disorder
who O
presented I-Adverse_event.Trigger
renal I-Effect
failure I-Effect
following I-Treatment
the I-Treatment
second I-Treatment.Freq
cycle I-Treatment.Freq
of I-Treatment
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
methotrexate I-Treatment.Drug
( I-Treatment.Drug
HDMTX I-Treatment.Drug
) I-Treatment.Drug
. O

We O
report O
three I-Subject.Population
cases I-Subject
of I-Subject
patients I-Subject
who O
developed I-Adverse_event.Trigger
leukopenia I-Effect
during O
olanzapine I-Treatment.Drug
treatment I-Treatment
. O

Rapid I-Effect
onset I-Effect
of I-Effect
muscle I-Effect
weakness I-Effect
( I-Effect
rhabdomyolysis I-Effect
) I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
the I-Treatment
combined I-Treatment
use I-Treatment
of I-Treatment
simvastatin I-Treatment.Combination.Drug
and I-Treatment
colchicine I-Treatment.Combination.Drug
. O

A I-Subject
35 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
seropositive I-Treat_Disorder
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
developed O
selective I-Effect
IgA I-Effect
deficiency I-Effect
during I-Adverse_event.Trigger
treatment O
with O
fenclofenac I-Treatment.Drug
. O

In O
this O
report O
, O
two I-Subject.Population
newborns I-Subject.Age
with I-Subject
congenital I-Treat_Disorder
heart I-Treat_Disorder
anomalies I-Treat_Disorder
demonstrated O
the O
harlequin I-Effect
color I-Effect
change I-Effect
, O
one O
whose O
skin O
findings O
showed O
a O
course O
related I-Adverse_event.Trigger
to O
the O
dose O
of O
systemic O
prostaglandin I-Treatment.Drug
E1 I-Treatment.Drug
, O
suggesting O
a O
possible O
association O
. O

Nonspecific O
but O
significant O
abnormalities I-Effect
have O
been O
described O
in O
the O
infants I-Subject.Age
of O
women O
treated I-Adverse_event.Trigger
with O
disulfiram I-Treatment.Drug
in O
the O
first O
trimester O
of O
their O
pregnancies O
. O

These O
data O
indicated O
that O
infliximab I-Treatment.Drug
possibly O
triggered I-Adverse_event.Trigger
production I-Effect
of I-Effect
granulocyte I-Effect
and I-Effect
neutrophil I-Effect
autoantibodies I-Effect
with I-Effect
resultant I-Effect
autoimmune I-Effect
agranulocytosis I-Effect
. O

Ovarian I-Effect
endometrioid I-Effect
adenocarcinoma I-Effect
arising O
from O
an O
endometriotic O
cyst O
in O
a I-Subject
postmenopausal I-Subject.Age
woman I-Subject.Gender
under I-Adverse_event.Trigger
tamoxifen I-Treatment.Drug
therapy I-Treatment
for O
breast I-Treat_Disorder
cancer I-Treat_Disorder
: O
a O
case O
report O
. O

Tacrolimus I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
HUS I-Effect
: O
an O
unusual O
cause O
of O
acute O
renal O
failure O
in O
nephrotic I-Treat_Disorder
syndrome I-Treat_Disorder
. O

OBJECTIVE O
: O
To O
report O
the O
clinical O
course O
of O
a I-Subject
woman I-Subject.Gender
with I-Subject
cryptococcal I-Treat_Disorder
meningitis I-Treat_Disorder
and I-Subject
no I-Subject
previous I-Subject
cardiac I-Subject
disease I-Subject
who O
developed I-Adverse_event.Trigger
a I-Effect
fatal I-Effect
cardiac I-Effect
arrhythmia I-Effect
after O
an I-Treatment
acute I-Treatment
overdose I-Treatment.Dosage
of I-Treatment
amphotericin I-Treatment.Drug
B I-Treatment.Drug
and O
to O
review O
its O
toxicity O
. O

We O
report O
a I-Subject
case I-Subject
of O
a O
bullous I-Effect
lichenoid I-Effect
eruption I-Effect
due I-Adverse_event.Trigger
to O
the O
intake O
of O
captopril I-Treatment.Drug
. O

The I-Treat_Disorder
hypoadrenalism I-Treat_Disorder
was O
overcome I-Potential_therapeutic_event.Trigger
by O
increasing I-Treatment.Dosage
steroid I-Treatment.Drug
replacement I-Treatment
therapy I-Treatment
. O

DIAGNOSIS O
: O
Interferon I-Treatment.Drug
alpha I-Treatment.Drug
- I-Treatment.Drug
2b I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cardiomyopathy I-Effect
. O

Choroidal I-Effect
hemorrhage I-Effect
associated I-Adverse_event.Trigger
with O
systemic I-Treatment.Drug
tissue I-Treatment.Drug
plasminogen I-Treatment.Drug
activator I-Treatment.Drug
. O

Clozapine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
eosinophilia I-Effect
and O
switch O
to O
quetiapine O
in O
a I-Subject
patient I-Subject
with I-Subject
chronic I-Treat_Disorder
schizophrenia I-Treat_Disorder
with I-Treat_Disorder
suicidal I-Treat_Disorder
tendencies I-Treat_Disorder
. O

Adverse I-Effect
effects I-Effect
of O
propafenone I-Combination.Drug
after I-Adverse_event.Trigger
long I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
term I-Treatment.Time_elapsed
therapy I-Treatment
with I-Treatment
the I-Treatment
addition I-Treatment
of I-Treatment
citalopram I-Treatment.Combination.Drug
. O

The O
case O
of O
an I-Subject
adult I-Subject.Age
who O
developed I-Adverse_event.Trigger
both O
hepatic I-Effect
dysfunction I-Effect
and I-Effect
an I-Effect
impaired I-Effect
macrophage I-Effect
migration I-Effect
after O
exposure O
to O
cimetidine I-Treatment.Drug
is I-Treatment
discussed I-Treatment
. O

We O
report O
4 I-Subject.Population
patients I-Subject
who O
developed I-Adverse_event.Trigger
symptoms I-Effect
of I-Effect
myasthenia I-Effect
gravis I-Effect
within I-Treatment
2 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
of I-Treatment
starting I-Treatment
treatment I-Treatment
with I-Treatment
a I-Treatment
statin I-Treatment.Drug
drug O
. O

After I-Adverse_event.Trigger
only O
the O
third I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
pentamidine I-Treatment.Drug
, O
it O
was O
noted O
that O
the O
patient I-Subject
's I-Subject
heart I-Effect
rate I-Effect
had I-Effect
decreased I-Effect
to I-Effect
48 I-Effect
beats I-Effect
/ I-Effect
minute I-Effect
. O

A I-Subject
44 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
is O
described O
in O
whom O
amiodarone I-Treatment.Drug
, I-Treatment
disopyramide I-Treatment.Drug
, I-Treatment
and I-Treatment
quinidine I-Treatment.Drug
, O
administered O
alone O
separately O
, O
induced I-Adverse_event.Trigger
atypical I-Effect
ventricular I-Effect
tachycardia I-Effect
( I-Effect
AVT I-Effect
, I-Effect
torsade I-Effect
de I-Effect
pointes I-Effect
) I-Effect
. O

Azathioprine I-Treatment.Drug
was O
the O
probable O
causative I-Adverse_event.Trigger
agent I-Adverse_event.Trigger
of O
warfarin I-Effect
resistance I-Effect
according O
to O
the O
Naranjo O
probability O
scale O
, O
and O
a O
possible O
causative O
agent O
according O
to O
the O
Drug O
Interaction O
Probability O
Scale O
. O

Disulfiram I-Treatment.Drug
has O
been O
used I-Potential_therapeutic_event.Trigger
effectively O
to O
deter O
alcohol O
consumption O
in O
patients I-Subject
with I-Subject
a I-Subject
history I-Treat_Disorder
of I-Treat_Disorder
alcohol I-Treat_Disorder
abuse I-Treat_Disorder
. O

Nevirapine I-Treatment.Drug
is O
a O
non O
- O
nucleoside O
reverse O
transcriptase O
inhibitor O
used O
in O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
human I-Subject
immunodeficiency I-Treat_Disorder
virus I-Treat_Disorder
( I-Subject
HIV) I-Subject
- I-Subject
infected I-Subject
patients I-Subject
and O
in O
post O
- O
exposure O
prophylaxis O
. O

Vasospasm I-Effect
associated I-Adverse_event.Trigger
with O
ergotamine I-Treatment.Drug
is O
a O
well O
- O
known O
phenomenon O
. O

After I-Treatment
a I-Treatment
six I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
week I-Treatment.Time_elapsed
course I-Treatment.Time_elapsed
of I-Treatment
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
cyclosporine I-Treatment.Drug
A I-Treatment.Drug
, O
she O
developed I-Adverse_event.Trigger
a O
severe O
but O
reversible O
loss I-Effect
of I-Effect
glomerular I-Effect
filtration I-Effect
rate I-Effect
and I-Effect
effective I-Effect
renal I-Effect
plasma I-Effect
flow I-Effect
despite O
of O
low O
cyclosporine O
A O
plasma O
levels O
. O

We O
report O
a O
case O
of O
severe O
simvastatin I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
rhabdomyolysis I-Effect
triggered O
by O
the I-Treatment
addition I-Treatment
of I-Treatment
amiodarone I-Treatment.Combination.Drug
to I-Treatment
previously I-Treatment
well I-Treatment
- I-Treatment
tolerated I-Treatment
chronic I-Treatment.Time_elapsed
statin I-Treatment.Drug
therapy I-Treatment
. O

In O
January O
2010 O
, O
a I-Subject
50 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
transgender I-Subject.Gender
female I-Subject.Gender
with O
HIV I-Treat_Disorder
infection I-Treat_Disorder
and I-Treat_Disorder
recurrent I-Treat_Disorder
deep I-Treat_Disorder
vein I-Treat_Disorder
thrombosis I-Treat_Disorder
began O
treatment I-Potential_therapeutic_event.Trigger
with O
the O
TRIO I-Treatment.Drug
study O
regimen O
. O

In O
vitro O
inhibition O
of O
CYP2C9 O
by O
zafirlukast I-Treatment.Drug
is O
consistent O
with O
clinical O
studies O
showing I-Potential_therapeutic_event.Trigger
impaired I-Effect
clearance I-Effect
of I-Effect
S I-Effect
- I-Effect
warfarin I-Effect
and I-Effect
enhanced I-Effect
anti I-Effect
- I-Effect
thrombotic I-Effect
effects I-Effect
, O
although O
the O
in O
vitro O
IC(50 O
) O
value O
is O
higher O
than O
the O
usual O
range O
of O
clinically O
relevant O
plasma O
concentrations O
. O

Although O
it O
is O
difficult O
to O
solely O
attribute I-Adverse_event.Trigger
intratumoral I-Effect
hemorrhage I-Effect
to O
aspirin I-Treatment.Drug
, O
we O
have O
to O
be O
careful O
when O
prescribing O
aspirin O
for O
patients I-Subject
who I-Subject
have I-Subject
asymptomatic I-Treat_Disorder
meningioma I-Treat_Disorder
. O

CONCLUSIONS O
: O
The O
fundus O
picture O
shown O
in O
these O
cases O
may O
be O
typical O
of O
ASPPC I-Effect
after I-Adverse_event.Trigger
IVTA I-Treatment.Drug
injection I-Treatment.Route
. O

The O
probable O
proarrhythmic I-Effect
action I-Adverse_event.Trigger
of O
amiodarone I-Treatment.Drug
, O
although O
rare O
, O
is O
reviewed O
along O
with O
a O
discussion O
of O
the O
novel O
use O
of O
intravenous O
magnesium O
sulfate O
therapy O
. O

We O
present O
two O
cases O
of O
severe O
, O
atypical I-Effect
ASRs I-Effect
which O
occurred I-Adverse_event.Trigger
during O
NMSC I-Drug
treatment O
with O
imiquimod I-Treatment.Combination.Drug
in I-Treatment
the I-Treatment
context I-Treatment
of I-Treatment
infliximab I-Treatment.Combination.Drug
administration I-Treatment
for O
psoriasis I-Treat_Disorder
, O
and O
consider O
the O
grounds O
supporting O
a O
non O
- O
fortuitous O
association O
. O

A O
case O
of O
propranolol I-Treatment.Drug
overdose I-Treatment.Dosage
complicated I-Adverse_event.Trigger
by O
esophageal I-Effect
spasm I-Effect
preventing I-Effect
extrication I-Effect
of I-Effect
an I-Effect
orogastric I-Effect
lavage I-Effect
tube I-Effect
and O
relieved O
by O
intravenous O
glucagon O
is O
presented O
. O

Fenclofenac I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
selective I-Effect
IgA I-Effect
deficiency I-Effect
in I-Effect
rheumatoid I-Effect
arthritis I-Effect
. O

Naproxen I-Treatment.Drug
, O
the O
most O
common O
offender O
, O
has O
been O
associated I-Adverse_event.Trigger
with O
a O
dimorphic O
clinical O
pattern O
: O
a O
PCT O
- O
like O
presentation O
and O
one O
simulating O
erythropoietic I-Effect
protoporphyria I-Effect
in O
the O
pediatric I-Subject.Age
population I-Subject
. O

Zafirlukast I-Treatment.Drug
is I-Treatment
a I-Treatment
cysteinyl I-Treatment
leukotriene I-Treatment
antagonist I-Treatment
used O
to O
treat I-Potential_therapeutic_event.Trigger
allergic I-Treat_Disorder
and I-Treat_Disorder
exercise I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
asthma I-Treat_Disorder
. O

Rapidly I-Effect
developing I-Effect
hyperglycemia I-Effect
during I-Adverse_event.Trigger
treatment O
with O
olanzapine I-Treatment.Drug
. O

The I-Subject
first I-Subject
patient I-Subject
was I-Subject
a I-Subject
61 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
a I-Subject
30 I-Subject
- I-Subject
year I-Subject
history I-Subject
of I-Subject
fistulizing I-Treat_Disorder
CD I-Treat_Disorder
in O
whom O
B I-Effect
- I-Effect
cell I-Effect
non I-Effect
- I-Effect
Hodgkin I-Effect
's I-Effect
lymphoma I-Effect
was O
diagnosed I-Adverse_event.Trigger
9 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
after I-Treatment
treatment I-Treatment
with I-Treatment
infliximab I-Treatment.Drug
. O

Recognition O
of O
a O
potential O
drug I-Effect
- I-Effect
induced I-Effect
Fanconi I-Effect
syndrome I-Effect
is O
important O
when O
managing O
pediatric I-Subject.Age
oncology I-Treat_Disorder
patients I-Subject
previously O
treated I-Adverse_event.Trigger
with O
ifosfamide I-Treatment.Drug
. O

We O
report O
a I-Subject
patient I-Subject
with I-Subject
chronic I-Treat_Disorder
renal I-Treat_Disorder
failure I-Treat_Disorder
and I-Treat_Disorder
ischemic I-Treat_Disorder
heart I-Treat_Disorder
disease I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
clinically I-Effect
significant I-Effect
methemoglobinemia I-Effect
after O
an I-Treatment
axillary I-Treatment
block I-Treatment
with I-Treatment
bupivacaine I-Treatment.Combination.Drug
and I-Treatment
additional I-Treatment
injection I-Treatment.Route
of I-Treatment
lidocaine I-Treatment.Combination.Drug
in I-Treatment
the I-Treatment
operative I-Treatment
field I-Treatment
. O

Amikacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
type I-Effect
5 I-Effect
Bartter I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
with I-Effect
severe I-Effect
hypocalcemia I-Effect
. O

L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
severe I-Effect
necrotizing I-Effect
pancreatitis I-Effect
successfully O
treated O
with O
percutaneous O
drainage O
. O

This O
report O
describes O
the O
first O
case O
of O
insulin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cardiac I-Effect
failure I-Effect
in O
a I-Subject
patient I-Subject
without I-Subject
underlying I-Subject
heart I-Subject
disease I-Subject
. O

OBJECTIVE O
: O
To O
determine O
the O
frequency O
of O
weight I-Effect
loss I-Effect
in O
patients I-Subject
treated O
with O
leflunomide I-Treatment.Drug
for O
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
at O
an O
arthritis O
referral O
center O
. O

INH I-Treatment.Drug
, O
which O
is O
a I-Adverse_event.Trigger
leading I-Adverse_event.Trigger
cause I-Adverse_event.Trigger
of O
drug I-Effect
eruptions I-Effect
in O
the O
above O
group O
of O
drugs O
was O
withdrawn O
. O

Complications I-Effect
associated I-Effect
with I-Effect
primary I-Effect
and I-Effect
secondary I-Effect
perforation I-Effect
of I-Effect
the I-Effect
bladder I-Effect
following I-Adverse_event.Trigger
immediate O
instillations I-Treatment.Route
of I-Treatment
epirubicin I-Treatment.Drug
after O
transurethral O
resection O
of O
superficial O
urothelial O
tumours O
. O

Ofloxacin I-Treatment.Drug
: O
a O
probable O
cause I-Adverse_event.Trigger
of O
toxic I-Effect
epidermal I-Effect
necrolysis I-Effect
. O

Fatal I-Effect
lung I-Effect
fibrosis I-Effect
caused O
by O
paclitaxel O
toxicity O
has O
not O
been O
reported O
In O
this O
report O
, O
we O
describe O
the O
case O
of O
a O
62 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
who O
received I-Adverse_event.Trigger
six I-Treatment.Dosage
cycles I-Treatment.Dosage
of I-Treatment
paclitaxel I-Treatment.Combination.Drug
and I-Treatment
carboplatin I-Treatment.Combination.Drug
as I-Treatment
combination I-Treatment
chemotherapy I-Treatment.Route
for O
advanced I-Treat_Disorder
ovarian I-Treat_Disorder
cancer I-Treat_Disorder
. O

A I-Subject
21 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
patient I-Subject
developed I-Adverse_event.Trigger
rhabdomyolysis I-Effect
during I-Treatment.Time_elapsed
his I-Treatment.Time_elapsed
nineteenth I-Treatment.Time_elapsed
week I-Treatment.Time_elapsed
of I-Treatment
treatment I-Treatment
with I-Treatment
clozapine I-Treatment.Drug
for O
drug I-Treat_Disorder
- I-Treat_Disorder
resistant I-Treat_Disorder
schizophrenia I-Treat_Disorder
. O

Cisplatin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
syndrome I-Effect
of I-Effect
inappropriate I-Effect
antidiuretic I-Effect
hormone I-Effect
( I-Effect
SIADH I-Effect
) I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
neuroendocrine I-Treat_Disorder
tumor I-Treat_Disorder
of I-Treat_Disorder
the I-Treat_Disorder
cervix I-Treat_Disorder
: O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

Myoglobinuria I-Effect
and I-Effect
acute I-Effect
renal I-Effect
failure I-Effect
associated I-Adverse_event.Trigger
with O
intravenous I-Treatment.Route
vasopressin I-Treatment.Drug
infusion I-Treatment.Route
. O

We O
report O
the O
first O
case O
of O
fulminant O
adult I-Effect
respiratory I-Effect
distress I-Effect
syndrome I-Effect
( I-Effect
ARDS I-Effect
) I-Effect
associated I-Adverse_event.Trigger
with O
pegylated I-Treatment.Drug
interferon I-Treatment.Drug
alpha I-Treatment.Drug
- I-Treatment.Drug
2a I-Treatment.Drug
( I-Treatment
pegIFNalpha I-Treatment
- I-Treatment
2a I-Treatment
) I-Treatment
and I-Treatment
ribavirin I-Treatment.Drug
use O
for O
hepatitis I-Treat_Disorder
C I-Treat_Disorder
, O
complicated O
by O
subsequent O
and O
ultimately O
fatal O
sepsis O
and O
multiorgan O
failure O
. O

Catatonia I-Effect
associated I-Adverse_event.Trigger
with O
disulfiram I-Treatment.Drug
therapy I-Treatment
. O

To O
date O
, O
no O
relation O
has O
ever O
been O
suggested O
between O
TNF I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
alpha I-Treatment.Combination.Drug
inhibitors I-Treatment.Combination.Drug
and O
increased O
susceptibility O
to O
developing I-Adverse_event.Trigger
exaggerated I-Effect
ASRs I-Effect
with O
imiquimod I-Treatment.Combination.Drug
. O

Losartan I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
angioedema I-Effect
. O

However O
, O
dermatologists O
should O
be O
cautious O
about O
a O
photosensitivity I-Effect
reaction O
induced I-Adverse_event.Trigger
by O
mequitazine I-Treatment.Drug
or O
other O
phenothiazine O
- O
derivative O
drugs O
. O

Oxycodone I-Treatment.Combination.Drug
- I-Treatment
gabapentin I-Treatment.Combination.Drug
also O
significantly O
improved I-Potential_therapeutic_event.Trigger
pain I-Treat_Disorder
relief O
vs O
gabapentin O
alone O
( O
P O
= O
0.003 O
) O
. O

In O
2 O
of O
the O
3 O
cases O
the I-Subject
patients I-Subject
were O
also O
taking O
lithium I-Treatment.Combination.Drug
carbonate I-Treatment.Combination.Drug
and I-Treatment
beta I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
blockers I-Treatment.Combination.Drug
, O
both O
of O
which O
could O
have O
contributed I-Adverse_event.Trigger
to O
the O
incontinence I-Effect
. O

Pulmonary I-Effect
fibrosis I-Effect
is I-Effect
a I-Effect
severe I-Effect
complication I-Effect
associated I-Adverse_event.Trigger
with O
bis I-Treatment.Drug
- I-Treatment.Drug
chloronitrosourea I-Treatment.Drug
( I-Treatment
BCNU I-Treatment
) I-Treatment
therapy I-Treatment
. O

We O
report O
here O
a O
26 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
with I-Subject
diffuse I-Treat_Disorder
large I-Treat_Disorder
B I-Treat_Disorder
- I-Treat_Disorder
cell I-Treat_Disorder
lymphoma I-Treat_Disorder
who O
died I-Effect
of I-Effect
severe I-Effect
pulmonary I-Effect
fibrosis I-Effect
81 I-Time_elapsed
days I-Time_elapsed
after I-Time_elapsed
the O
administration I-Adverse_event.Trigger
of O
high I-Treatment
- I-Treatment
dose I-Treatment
BCNU I-Treatment.Drug
( I-Treatment
600 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m2 I-Treatment.Dosage
) I-Treatment
. O

The I-Subject
patient I-Subject
was O
given O
methimazole I-Treatment.Drug
instead O
of O
propylthiouracil I-Drug
but O
, O
10 I-Time_elapsed
weeks I-Time_elapsed
later I-Time_elapsed
, O
agranulocytosis I-Effect
again O
occurred I-Adverse_event.Trigger
. O

Three I-Time_elapsed
months I-Time_elapsed
after O
starting O
citalopram I-Treatment.Drug
, O
she I-Subject.Gender
experienced I-Adverse_event.Trigger
episodes O
of O
chest I-Effect
tightness I-Effect
and I-Effect
dizziness I-Effect
. O

Although O
differential O
diagnostic O
alternatives O
can O
be O
considered O
in O
all O
described O
cases O
it O
is O
very O
likely O
that O
vincristine I-Treatment.Drug
does O
cause I-Adverse_event.Trigger
severe I-Effect
visual I-Effect
loss I-Effect
in O
a I-Subject.Population
small I-Subject.Population
number I-Subject.Population
of I-Subject
patients I-Subject
. O

This O
case O
is O
remarkable O
since O
1 O
) O
ECM O
developed O
after O
subcutaneous O
and O
not O
after O
intramuscular O
injection O
, O
2 O
) O
the O
injection O
was O
given O
by O
the O
patient O
himself O
, O
and O
3 O
) O
glatiramer I-Treatment.Drug
acetate I-Treatment.Drug
can O
induce I-Adverse_event.Trigger
skin I-Effect
necrosis I-Effect
as O
a O
side O
effect O
. O

SSRI I-Treatment.Drug
- I-Treatment
drugs I-Treatment
increase I-Effect
serotonin I-Effect
concentrations I-Effect
and O
are O
known O
to O
have O
pruritus I-Effect
and I-Effect
other I-Effect
dermal I-Effect
side I-Effect
effects I-Effect
. I-Effect

Dabigatran I-Treatment.Combination.Drug
etexilate I-Treatment.Combination.Drug
and I-Treatment
concomitant I-Treatment
use I-Treatment
of I-Treatment
non I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
steroidal I-Treatment.Combination.Drug
anti I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
inflammatory I-Treatment.Combination.Drug
drugs I-Treatment.Combination.Drug
or I-Treatment
acetylsalicylic I-Treatment.Combination.Drug
acid I-Treatment.Combination.Drug
in I-Adverse_event.Trigger
patients I-Subject
undergoing I-Subject
total I-Treat_Disorder
hip I-Treat_Disorder
and I-Treat_Disorder
total I-Treat_Disorder
knee I-Treat_Disorder
arthroplasty I-Treat_Disorder
: O
no I-Effect
increased I-Effect
risk I-Effect
of I-Effect
bleeding I-Effect
. O

Our O
literature O
review O
revealed O
an O
additional O
six I-Subject.Population
cases I-Subject
of O
onset I-Adverse_event.Trigger
of O
inflammatory I-Effect
arthritis I-Effect
in I-Subject
MS I-Treat_Disorder
patients I-Subject
receiving I-Treatment
IFN I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
. O

Two I-Treatment.Duration
years I-Treatment.Duration
later I-Treatment
, I-Treatment
24 I-Treatment.Time_elapsed
hours I-Treatment.Time_elapsed
following I-Treatment
an I-Treatment
increase I-Treatment
in I-Treatment
the I-Treatment
dose I-Treatment
of I-Treatment
disopyramide I-Treatment.Drug
from I-Treatment
300 I-Treatment.Dosage
to I-Treatment.Dosage
600 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
, O
AVT I-Effect
with I-Effect
syncope I-Effect
occurred I-Adverse_event.Trigger
; O
isoproterenol O
abolished O
the O
arrhythmia O
instantly O
. O

The I-Subject
patient I-Subject
was O
initially O
treated O
with O
hydration O
and O
furosemide I-Treatment.Drug
but O
developed I-Adverse_event.Trigger
congestive I-Effect
heart I-Effect
failure I-Effect
. O

We O
present O
an O
interesting O
case O
of O
an I-Subject
HIV I-Treat_Disorder
- I-Treat_Disorder
positive I-Treat_Disorder
woman I-Subject.Gender
on O
antiretroviral I-Treatment.Drug
therapy O
having I-Adverse_event.Trigger
tubal I-Effect
pregnancies I-Effect
on O
two O
separate O
occasions O
with O
Implanon I-Drug
in O
place O
. O

We O
hypothesize O
that O
decreased O
renal O
elimination O
of O
MTX I-Treatment.Drug
induced O
by O
the O
COX O
- O
2 O
inhibitor O
resulted I-Adverse_event.Trigger
in O
enhanced I-Effect
hematopoietic I-Effect
toxicity I-Effect
and I-Effect
immunosuppression I-Effect
causing I-Effect
the I-Effect
EBV I-Effect
- I-Effect
associated I-Effect
lymphoproliferative I-Effect
disease I-Effect
. O

Temsirolimus I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
glomerulopathy I-Effect
. O

OBJECTIVE O
: O
To O
report O
a I-Subject
case I-Subject
of O
linear I-Effect
immunoglobulin I-Effect
( I-Effect
Ig I-Effect
) I-Effect
A I-Effect
bullous I-Effect
dermatosis I-Effect
( I-Effect
LABD I-Effect
) I-Effect
induced I-Adverse_event.Trigger
by O
gemcitabine I-Treatment.Drug
. O

This O
patient I-Subject
developed I-Adverse_event.Trigger
sequential I-Effect
symptoms I-Effect
including I-Effect
alternative I-Effect
hemiparesis I-Effect
, I-Effect
dysarthria I-Effect
and I-Effect
altered I-Effect
consciousness I-Effect
5 I-Time_elapsed
days I-Time_elapsed
after I-Time_elapsed
the I-Treatment.Time_elapsed
second I-Treatment.Time_elapsed
course I-Treatment.Time_elapsed
of I-Treatment
HD I-Treatment
- I-Treatment
MTX I-Treatment.Combination.Drug
( I-Treatment
8 I-Treatment.Dosage
gm I-Treatment.Dosage
/ I-Treatment.Dosage
m2 I-Treatment.Dosage
by I-Treatment.Dosage
6 I-Treatment.Dosage
h I-Treatment.Dosage
continuous I-Treatment.Dosage
infusion I-Treatment.Route
) I-Treatment
with I-Treatment
leucovorin I-Treatment.Combination.Drug
rescue I-Treatment.Combination.Drug
. O

Adult I-Subject.Age
and I-Subject.Age
adolescent I-Subject.Age
patients I-Subject
( O
> O
or O
= O
12 O
years O
old O
; O
n O
= O
141 O
) O
with O
severe O
, O
persistent O
, O
oral I-Treatment.Route
steroid I-Treatment.Drug
( I-Treatment
prednisone) I-Treatment.Drug
- O
dependent I-Adverse_event.Trigger
asthma I-Effect
. O

DISCUSSION O
: O
Amphotericin I-Treatment.Drug
B I-Treatment.Drug
deoxycholate I-Treatment.Drug
has O
been O
reported O
to O
produce I-Adverse_event.Trigger
significant O
cardiac I-Effect
toxicity I-Effect
, I-Effect
with I-Effect
ventricular I-Effect
arrhythmias I-Effect
and I-Effect
bradycardia I-Effect
reported O
in O
overdoses O
in I-Subject.Age
children I-Subject.Age
and I-Subject.Age
in I-Subject.Age
adults I-Subject.Age
with I-Subject
preexisting I-Subject.Sub_Disorder
cardiac I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
, O
even O
when O
administered O
in O
conventional I-Treatment.Dosage
dosages I-Treatment.Dosage
and I-Treatment
infusion I-Treatment.Route
rates I-Treatment
. O

Diarrhoea I-Effect
, I-Effect
T I-Effect
- I-Effect
CD4 I-Effect
+ I-Effect
lymphopenia I-Effect
and I-Effect
bilateral I-Effect
patchy I-Effect
pulmonary I-Effect
infiltrates I-Effect
developed I-Adverse_event.Trigger
in O
a O
male I-Subject.Gender
60 I-Subject.Age
yrs I-Subject.Age
of I-Subject.Age
age I-Subject.Age
, O
who O
was O
treated O
with O
oxaliplatinum I-Treatment.Combination.Drug
and I-Treatment
5 I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
fluorouracil I-Treatment.Combination.Drug
for O
unresectable I-Treat_Disorder
rectum I-Treat_Disorder
carcinoma I-Treat_Disorder
. O

Thus O
, O
tardive I-Effect
seizures I-Effect
in O
our O
cases O
are O
thought O
to O
be O
related I-Adverse_event.Trigger
to O
piperacillin I-Treatment.Combination.Drug
and I-Treatment
cefotiam I-Treatment.Combination.Drug
. O

A I-Subject
55 I-Subject.Age
- I-Subject.Age
yr I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
developed O
prolonged I-Effect
jaundice I-Effect
and I-Effect
sicca I-Effect
complex I-Effect
after I-Adverse_event.Trigger
a I-Treatment
course I-Treatment
of I-Treatment
thiabendazole I-Treatment.Drug
therapy O
. O

Methylphenidate I-Treatment.Drug
( I-Treatment
Ritalin) I-Treatment
- O
associated I-Adverse_event.Trigger
cataract I-Effect
and I-Effect
glaucoma I-Effect
. O

Simvastatin I-Treatment.Combination.Drug
- I-Treatment
nelfinavir I-Treatment.Combination.Drug
interaction I-Treatment
implicated I-Adverse_event.Trigger
in O
rhabdomyolysis I-Effect
and I-Effect
death I-Effect
. O

Uncontrolled I-Effect
headache I-Effect
induced I-Adverse_event.Trigger
by O
oxcarbazepine I-Treatment.Drug
. O

We O
now O
present O
four I-Subject.Population
cases I-Subject
of O
RSDS I-Effect
in O
kidney I-Subject.Sub_Disorder
transplant I-Subject.Sub_Disorder
recipients I-Subject
treated I-Adverse_event.Trigger
with O
tacrolimus I-Treatment.Drug
. O

Transient I-Effect
neurological I-Effect
disturbances I-Effect
induced I-Adverse_event.Trigger
by O
the I-Treatment
chemotherapy I-Treatment
of I-Treatment
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
methotrexate I-Treatment.Drug
for O
osteogenic I-Treat_Disorder
sarcoma I-Treat_Disorder
. O

Long O
- O
term O
safety O
and O
efficacy O
in O
patients I-Subject
with I-Subject
uncontrolled I-Treat_Disorder
partial I-Treat_Disorder
- I-Treat_Disorder
onset I-Treat_Disorder
seizures I-Treat_Disorder
treated I-Potential_therapeutic_event.Trigger
with O
adjunctive I-Treatment
lacosamide I-Treatment.Drug
: O
results O
from O
a O
Phase O
III O
open O
- O
label O
extension O
trial O
. O

A O
variety O
of O
movement I-Effect
disorders I-Effect
are O
known O
to O
occur I-Adverse_event.Trigger
in O
association O
with O
carbamazepine I-Treatment.Drug
( I-Treatment
CBZ I-Treatment
) I-Treatment
therapy I-Treatment
in O
adults I-Subject.Age
and I-Subject
children I-Subject.Age
, O
but O
development O
of O
tics O
has O
been O
described O
infrequently O
and O
only O
in O
patients O
with O
underlying O
Tourette I-Treat_Disorder
's I-Treat_Disorder
syndrome I-Treat_Disorder
or O
other O
movement O
disorders O
. O

On O
the O
day O
before O
this O
visit O
, O
he I-Subject.Gender
had O
received I-Potential_therapeutic_event.Trigger
the I-Treatment
third I-Treatment
of I-Treatment
six I-Treatment
serial I-Treatment
weekly I-Treatment.Freq
BCG I-Treatment.Drug
bladder I-Treatment.Route
instillations I-Treatment.Route
for O
the O
treatment O
of O
bladder I-Treat_Disorder
cancer I-Treat_Disorder
. O

Following O
a O
closed O
mitral O
valvotomy O
, O
she O
received I-Potential_therapeutic_event.Trigger
quinidine I-Treatment.Drug
, I-Treatment
1.2 I-Treatment.Dosage
g I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
, O
without O
interruption O
for O
17 I-Duration
years I-Duration
. O

We O
describe O
a I-Subject
patient I-Subject
in O
whom O
noncardiogenic I-Effect
pulmonary I-Effect
edema I-Effect
developed I-Adverse_event.Trigger
during O
intrabiliary I-Treatment
infusion I-Treatment.Route
of I-Treatment
monooctanoin I-Treatment.Drug
. O

Mitomycin I-Treatment.Drug
- I-Treatment.Drug
C I-Treatment.Drug
is O
used O
widely O
in O
the O
treatment O
of O
malignancies I-Treat_Disorder
and O
is O
associated I-Adverse_event.Trigger
with O
serious O
dose O
related O
adverse O
effects O
including O
the O
occurrence O
of O
hemolytic I-Effect
uremic I-Effect
syndrome I-Effect
. O

Valproic I-Treatment.Drug
acid I-Treatment.Drug
induced I-Adverse_event.Trigger
coma I-Effect
is O
presented O
in O
an O
adult I-Subject.Age
patient I-Subject
without I-Subject
a I-Subject
history I-Subject
of I-Subject
metabolic I-Subject
disease I-Subject
. O

Three I-Subject.Population
patients I-Subject
with I-Subject
no I-Subject
history I-Subject
of I-Subject
asthma I-Subject
or I-Subject
allergy I-Subject
developed I-Adverse_event.Trigger
bronchospasm I-Effect
while O
taking O
propranolol I-Treatment.Drug
for O
hypertension I-Treat_Disorder
. O

To O
report O
two I-Subject.Population
cases I-Subject
of O
warfarin I-Treatment.Combination.Drug
therapy I-Treatment
in I-Treatment
which I-Treatment
the I-Treatment
addition I-Treatment
of I-Treatment
tolterodine I-Treatment.Combination.Drug
resulted I-Adverse_event.Trigger
in O
prolonged I-Effect
international I-Effect
normalized I-Effect
ratios I-Effect
( I-Effect
INRs I-Effect
) I-Effect
. O

In O
addition O
, O
an I-Effect
immediate I-Effect
erythematous I-Effect
macule I-Effect
was O
observed I-Adverse_event.Trigger
on O
the O
photopatch O
test O
site O
of O
mequitazine I-Treatment.Drug
directly I-Treatment
after I-Treatment
UV I-Treatment.Route
exposure I-Treatment.Route
which O
was O
similar O
to O
the O
immediate O
erythema O
noted O
in O
chlorpromazine O
photoallergy O
. O

Acetazolamide I-Treatment.Drug
- O
accelerated I-Adverse_event.Trigger
anticonvulsant I-Drug
osteomalacia I-Effect
. O

Both I-Subject
patients I-Subject
suddenly O
became I-Adverse_event.Trigger
hypotensive I-Effect
after O
injection I-Treatment.Route
of I-Treatment
chymopapain I-Treatment.Drug
into I-Treatment
a I-Treatment
disk I-Treatment
. O

Large O
dose O
of O
methylphenidate I-Treatment.Drug
may O
cause I-Adverse_event.Trigger
cataract I-Effect
and I-Effect
glaucoma I-Effect
. O

Total I-Effect
blindness I-Effect
with I-Effect
a I-Effect
transient I-Effect
tonic I-Effect
pupillary I-Effect
response I-Effect
, I-Effect
denervation I-Effect
supersensitivity I-Effect
, I-Effect
and I-Effect
abnormal I-Effect
visual I-Effect
- I-Effect
evoked I-Effect
potentials O
developed O
in O
a I-Subject
54 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
after I-Adverse_event.Trigger
the O
use O
of O
quinine I-Treatment.Drug
sulfate I-Treatment.Drug
for O
leg I-Treat_Disorder
cramps I-Treat_Disorder
. O

Carbamazepine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
tics I-Effect
. O

Three I-Subject.Population
patients I-Subject
are I-Subject
reported I-Subject
without I-Subject
a I-Subject
history I-Subject
of I-Subject
angina I-Subject
pectoris I-Subject
who O
had I-Adverse_event.Trigger
clinical O
and O
electrocardiographic O
evidence O
of O
myocardial I-Effect
ischemia I-Effect
during I-Treatment
and I-Treatment
immediately I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
BCNU I-Treatment.Drug
infusion I-Treatment.Route
. O

A O
rare O
debilitating I-Effect
neurological I-Effect
adverse I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
ranolazine I-Treatment.Combination.Drug
due O
to O
drug O
interaction O
with O
clarithromycin I-Treatment.Combination.Drug
. O

Septic I-Effect
knee I-Effect
arthritis I-Effect
after I-Adverse_event.Trigger
intra I-Treatment
- I-Treatment
articular I-Treatment
hyaluronate I-Treatment.Drug
injection I-Treatment.Route
. O

The O
concomitant O
use O
, O
however O
, O
of O
colchicine I-Treatment.Combination.Drug
and I-Treatment
statin I-Treatment.Combination.Drug
has O
been O
associated I-Adverse_event.Trigger
with O
the I-Effect
rapid I-Effect
onset I-Effect
of I-Effect
muscle I-Effect
weakness I-Effect
. O

Successful O
treatment I-Potential_therapeutic_event.Trigger
of O
hyperthyroidism I-Treat_Disorder
with O
amiodarone I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
propylthiouracil I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
induced I-Subject.Sub_Disorder
acute I-Subject.Sub_Disorder
hepatic I-Subject.Sub_Disorder
failure I-Subject.Sub_Disorder
. O

Olanzapine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
parkinsonism I-Effect
associated I-Treatment
with I-Treatment
smoking I-Treatment
cessation I-Treatment.Dosage
. O

CASE O
: O
We O
present O
an I-Subject
11 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
with I-Subject
Budd I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
Chiari I-Subject.Sub_Disorder
syndrome I-Subject.Sub_Disorder
who O
experienced I-Adverse_event.Trigger
profound I-Effect
worsening I-Effect
of I-Effect
chronic I-Effect
aphthous I-Effect
ulcers I-Effect
after O
immunosuppressive I-Treatment
therapy I-Treatment
was I-Treatment
changed I-Treatment
from I-Treatment
tacrolimus I-Treatment.Drug
to I-Treatment
sirolimus I-Treatment.Drug
. O

We O
report O
the O
cases O
of O
two I-Subject.Population
patients I-Subject
who O
developed O
acute I-Effect
hepatitis I-Effect
after O
taking I-Adverse_event.Trigger
riluzole I-Treatment.Drug
at I-Treatment
the I-Treatment
recommended I-Treatment
dose I-Treatment
( I-Treatment
100 I-Treatment.Dosage
mg I-Treatment.Dosage
daily I-Treatment.Freq
) I-Treatment
for I-Treatment
7 I-Treatment.Duration
and I-Treatment.Duration
4 I-Treatment.Duration
weeks I-Treatment.Duration
, O
respectively O
. O

An O
interaction O
between O
levodopa I-Treatment.Drug
and I-Treatment
enteral I-Treatment
nutrition I-Treatment
resulting I-Adverse_event.Trigger
in O
neuroleptic I-Effect
malignant I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
and I-Effect
prolonged I-Effect
ICU I-Effect
stay I-Effect
. O

Until O
further O
data O
are O
available O
, O
clinicians O
should O
be O
vigilant O
for O
a O
possible I-Effect
drug I-Effect
interaction I-Effect
when O
tolterodine I-Treatment.Combination.Drug
therapy I-Treatment
is O
initiated I-Adverse_event.Trigger
in O
a I-Subject
patient I-Subject
maintained O
on O
warfarin I-Combination.Drug
therapy O
. O

The I-Subject
itch I-Treat_Disorder
spread I-Subject
to I-Subject
the I-Subject
arms I-Subject
, I-Subject
abdomen I-Subject
and I-Subject
legs I-Subject
and I-Subject
the I-Subject
patient I-Subject
treated O
himself I-Subject.Gender
with O
clemastine I-Treatment.Drug
and O
the O
itch I-Effect
disappeared I-Effect
. O

In O
this O
case O
report O
we O
present O
a I-Treatment
rare I-Treatment
drug I-Treatment
interaction I-Treatment
between I-Treatment
erythromycin I-Treatment.Combination.Drug
and I-Treatment
ergotamine I-Treatment.Combination.Drug
at I-Treatment
normal I-Treatment.Dosage
doses I-Treatment.Dosage
causing I-Adverse_event.Trigger
lower I-Effect
extremity I-Effect
ischemia I-Effect
in O
a I-Subject
36 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
. O

Neutropenia I-Effect
and I-Effect
agranulocytosis I-Effect
are O
risks O
known O
to O
occur I-Adverse_event.Trigger
with O
phenothiazines I-Treatment.Drug
and I-Treatment
clozapine I-Treatment.Drug
. I-Treatment

She I-Subject.Gender
had O
been O
taking I-Potential_therapeutic_event.Trigger
rifampin I-Treatment
prior O
to O
admission O
for O
acid I-Treat_Disorder
- I-Treat_Disorder
fast I-Treat_Disorder
bacilli I-Treat_Disorder
. O

The O
responsibility I-Adverse_event.Trigger
of O
CCNU I-Treatment.Drug
in O
the O
pathogenesis I-Effect
of I-Effect
pulmonary I-Effect
fibrosis I-Effect
seems O
very O
likely O
. O

Malignant I-Effect
mixed I-Effect
mullerian I-Effect
tumor I-Effect
of I-Effect
the I-Effect
uterus I-Effect
in O
a I-Subject
patient I-Subject
taking I-Adverse_event.Trigger
raloxifene I-Treatment.Drug
. O

Fatal I-Effect
overdoses I-Effect
associated I-Adverse_event.Trigger
with O
quetiapine I-Treatment.Drug
. O

Gemcitabine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
rectus I-Effect
abdominus I-Effect
radiation I-Effect
recall I-Effect
. O

We O
report O
on O
a O
serious O
side O
effect O
in O
a O
severely O
depressed I-Treat_Disorder
55 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
, O
who O
presented I-Adverse_event.Trigger
an O
erythematous I-Effect
pigmented I-Effect
skin I-Effect
rash I-Effect
on I-Effect
the I-Effect
whole I-Effect
body I-Effect
under O
combination I-Treatment
treatment I-Treatment
with I-Treatment
antidepressants I-Treatment.Combination.Drug
, I-Treatment
atypical I-Treatment.Combination.Drug
antipsychotic I-Treatment.Combination.Drug
drugs I-Treatment
, I-Treatment
the I-Treatment
mood I-Treatment
stabilizer I-Treatment
lithium I-Treatment.Combination.Drug
and I-Treatment
the I-Treatment
lipid I-Treatment
- I-Treatment
lowering I-Treatment
drug I-Treatment
pravastatin I-Treatment.Combination.Drug
. O

We O
present O
a I-Subject
20 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
Basedow I-Treat_Disorder
- I-Treat_Disorder
Graves I-Treat_Disorder
' I-Treat_Disorder
disease I-Treat_Disorder
who O
developed O
PTU I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
fulminant I-Effect
hepatitis I-Effect
, I-Effect
which I-Effect
progressed I-Effect
to I-Effect
acute I-Effect
hepatic I-Effect
failure I-Effect
with I-Effect
grade I-Effect
III I-Effect
hepatic I-Effect
encephalopathy I-Effect
. O

The O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
58881 O
study O
was O
designed O
to O
test O
in O
a O
prospective O
multicentric O
randomized O
trial O
the O
value O
of O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
( I-Treatment
HD I-Treatment
) I-Treatment
intravenous I-Treatment.Route
( I-Treatment
IV I-Treatment
) I-Treatment
cytarabine I-Treatment.Combination.Drug
( I-Treatment
Ara I-Treatment
- I-Treatment
C I-Treatment
) I-Treatment
added I-Treatment
to I-Treatment
HD I-Treatment
IV I-Treatment
methotrexate I-Treatment.Combination.Drug
( I-Treatment
MTX I-Treatment
) I-Treatment
to I-Potential_therapeutic_event.Trigger
reduce I-Effect
the I-Effect
incidence I-Effect
of I-Effect
CNS I-Effect
and I-Effect
systemic I-Effect
relapses I-Effect
in O
children I-Subject.Age
with I-Subject
increased I-Subject
- I-Subject
risk I-Subject
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
( I-Subject
ALL I-Subject
) I-Subject
or I-Subject
stage I-Treat_Disorder
III I-Treat_Disorder
and I-Treat_Disorder
IV I-Treat_Disorder
lymphoblastic I-Treat_Disorder
lymphoma I-Treat_Disorder
treated O
with O
a O
Berlin O
- O
Frankfurt O
- O
Munster O
( O
BFM) O
- O
based O
regimen O
. O

The O
authors O
postulate O
that O
two O
types O
of O
combined O
lithium O
- O
neuroleptic O
toxicity O
occur O
: O
a I-Effect
neuroleptic I-Effect
malignant I-Effect
extrapyramidal I-Effect
syndrome I-Effect
and I-Effect
a I-Effect
lithium I-Treatment.Combination.Drug
toxicity I-Effect
that O
occurs I-Adverse_event.Trigger
in I-Treatment
combination I-Treatment
with I-Treatment
phenothiazines I-Treatment.Combination.Drug
, I-Treatment
primarily I-Treatment
thioridazine I-Treatment
. O

Trans I-Treatment
- I-Treatment
catheter I-Treatment
hepatic I-Treatment
arterial I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
lipiodol I-Treatment
soluble I-Treatment
anti I-Treatment
- I-Treatment
cancer I-Treatment
agent I-Treatment
SMANCS I-Treatment.Combination.Drug
and I-Treatment
ADR I-Treatment.Combination.Drug
suspension I-Treatment
in I-Treatment
lipiodol I-Treatment
combined I-Treatment
with I-Treatment
arterial I-Treatment
embolization I-Treatment
and I-Treatment
local I-Treatment
hyperthermia I-Treatment
for O
treatment I-Potential_therapeutic_event.Trigger
of O
hepatocellular I-Treat_Disorder
carcinoma I-Treat_Disorder
. O

Gynecomastia I-Effect
associated I-Adverse_event.Trigger
with O
theophylline I-Treatment.Drug
. O

Arthritis O
and O
bursitis O
in O
multiple I-Treat_Disorder
sclerosis I-Treat_Disorder
patients I-Subject
treated I-Potential_therapeutic_event.Trigger
with O
interferon I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
. O

To O
our O
knowledge O
, O
drug I-Treatment
- O
induced I-Adverse_event.Trigger
fever I-Effect
has O
not O
been O
reported O
with I-Treatment
the I-Treatment
use I-Treatment
of I-Treatment
diltiazem I-Treatment.Drug
hydrochloride I-Treatment.Drug
, I-Treatment
a I-Treatment
commonly I-Treatment
prescribed I-Treatment
calcium I-Treatment
channel I-Treatment
blocker I-Treatment
. O

Case O
studies O
in O
heparin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thrombocytopenia I-Effect
. O

We O
describe O
a I-Subject
41 I-Subject.Age
yr I-Subject.Age
old I-Subject.Age
leprosy I-Treat_Disorder
patient I-Subject
treated O
for O
10 I-Treatment.Duration
yrs I-Treatment.Duration
with I-Treatment
clofazimine I-Treatment.Drug
who O
underwent O
laparotomy O
for I-Adverse_event.Trigger
severe I-Effect
abdominal I-Effect
pain I-Effect
. O

Osteonecrosis I-Effect
is O
a O
serious O
side I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
antiemetic I-Treatment
treatment I-Treatment
with I-Treatment
dexamethasone I-Treatment.Drug
and O
this O
serious O
complication O
should O
be O
incorporated O
in O
the O
current O
guidelines O
. O

We O
report O
the O
development I-Adverse_event.Trigger
of O
scrotal I-Effect
ulcer I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
acute I-Treat_Disorder
promyleocytic I-Treat_Disorder
leukemia I-Treat_Disorder
( I-Treat_Disorder
APL I-Treat_Disorder
) I-Treat_Disorder
within I-Treatment.Time_elapsed
10 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
of I-Treatment
treatment I-Treatment
with I-Treatment
ATRA I-Treatment.Drug
at I-Treatment
a I-Treatment
dose I-Treatment
of I-Treatment
40 I-Treatment.Dosage
mg I-Treatment.Dosage
orally I-Treatment.Route
twice I-Treatment.Freq
daily I-Treatment.Freq
. O

After I-Treatment
initiation I-Treatment
of I-Treatment
topical I-Treatment.Route
vitamin I-Treatment.Drug
D3 I-Treatment.Drug
ointment I-Treatment
( I-Treatment
20 I-Treatment.Dosage
micro I-Treatment.Dosage
g I-Treatment.Dosage
/ I-Treatment.Dosage
g I-Treatment.Dosage
of I-Treatment
tacalcitol I-Treatment
) I-Treatment
10 I-Treatment.Dosage
g I-Treatment.Dosage
/ I-Treatment.Freq
day I-Treatment.Freq
for O
the O
skin I-Treat_Disorder
lesions I-Treat_Disorder
, I-Treat_Disorder
both O
the O
serum I-Effect
level I-Effect
of I-Effect
calcium I-Effect
and I-Effect
urinary I-Effect
excretion I-Effect
of I-Effect
calcium I-Effect
increased I-Effect
gradually O
. O

Vancomycin I-Treatment.Drug
is O
the O
most O
frequently O
implicated O
drug O
, O
but O
other O
agents O
have O
been O
reported O
to O
cause I-Adverse_event.Trigger
LABD I-Effect
. O

Vision I-Effect
declined I-Effect
after I-Adverse_event.Trigger
treatment O
with O
methylprednisolone I-Treatment.Drug
, O
after O
which O
fundus O
examination O
became O
consistent O
with O
progressive O
outer O
retinal O
necrosis O
. O

Eight I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment
the I-Treatment
end I-Treatment
of I-Treatment
interferon I-Treatment.Drug
treatment I-Treatment
, O
he I-Subject.Gender
showed O
signs I-Effect
of I-Effect
inability I-Effect
to I-Effect
sit I-Effect
still I-Effect
for I-Effect
ten I-Effect
seconds I-Effect
and I-Effect
walked I-Effect
around I-Effect
constantly I-Effect
. O

Drug I-Effect
- I-Effect
induced I-Effect
agranulocytosis I-Effect
during I-Adverse_event.Trigger
treatment O
with O
infliximab I-Treatment.Drug
in O
enteropathic I-Treat_Disorder
spondyloarthropathy I-Treat_Disorder
. O

Aripiprazole I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hiccups I-Effect
: O
a O
case O
report O
. O

The I-Effect
hepatic I-Effect
enzyme I-Effect
disturbances I-Effect
normalized O
after I-Adverse_event.Trigger
discontinuation O
of O
pegvisomant I-Treatment.Drug
. O

We O
present O
a O
case O
of O
a I-Subject
58 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
patient I-Subject
with I-Subject
Graves I-Subject.Sub_Disorder
' I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
who O
developed I-Adverse_event.Trigger
AA I-Effect
in I-Treatment
the I-Treatment
third I-Treatment
exposure I-Treatment
to I-Treatment
methimazole I-Treatment.Drug
( I-Treatment
MMI I-Treatment
) I-Treatment
. O

CONCLUSIONS O
: O
This O
is O
the O
second O
case O
report O
that O
describes O
gemcitabine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
radiation I-Effect
recall I-Effect
in I-Effect
rectus I-Effect
abdominus I-Effect
muscles I-Effect
after O
gemcitabine O
- O
based O
radiation O
therapy O
. O

One O
patient O
was O
an I-Subject
80 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
who O
was O
admitted O
for O
Staphylococcus I-Effect
aureus I-Effect
knee I-Effect
arthritis I-Effect
after I-Adverse_event.Trigger
several I-Freq
intraarticular O
injections I-Route
of O
sodium I-Treatment.Combination.Drug
hyaluronate I-Treatment.Combination.Drug
and I-Treatment
corticosteroids I-Treatment.Combination.Drug
. O

Association I-Adverse_event.Trigger
of O
zomepirac I-Treatment.Drug
administration O
with O
renal I-Effect
cortical I-Effect
necrosis I-Effect
is O
not O
known O
to O
have O
been O
previously O
demonstrated O
. O

Vasomotor I-Effect
reactions I-Effect
after I-Adverse_event.Trigger
gold I-Treatment.Drug
sodium I-Treatment.Drug
thiomalate I-Treatment.Drug
are O
well O
recognized O
. O

Moxifloxacin I-Treatment.Combination.Drug
- I-Treatment
acetaminophen I-Treatment.Combination.Drug
- I-Treatment
warfarin I-Treatment.Combination.Drug
interaction I-Treatment
during I-Adverse_event.Trigger
bacille I-Treatment.Combination.Drug
Calmette I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
Guerin I-Treatment.Combination.Drug
treatment I-Treatment
for O
bladder I-Treat_Disorder
cancer I-Treat_Disorder
. O

In O
four I-Subject.Population
patients I-Subject
, O
thrombosis I-Effect
occurred I-Effect
2 I-Time_elapsed
- I-Time_elapsed
45 I-Time_elapsed
days I-Time_elapsed
after I-Time_elapsed
severe I-Effect
hepatic I-Effect
veno I-Effect
- I-Effect
occlusive I-Effect
disease I-Effect
( I-Effect
HVOD I-Effect
) I-Effect
secondary I-Adverse_event.Trigger
to O
intensive I-Treatment
chemotherapy I-Treatment
containing I-Treatment
busulfan I-Treatment.Drug
. O

An I-Subject
adolescent I-Subject.Age
male I-Subject.Gender
developed O
acute I-Effect
pancreatitis I-Effect
and I-Effect
pseudocyst I-Effect
of I-Effect
the I-Effect
pancreas I-Effect
16 I-Time_elapsed
weeks I-Time_elapsed
after I-Adverse_event.Trigger
cessation I-Treatment
of I-Treatment
intramuscular I-Treatment.Route
L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
. O

A O
CFTR I-Treatment.Drug
potentiator I-Treatment.Drug
in I-Potential_therapeutic_event.Trigger
patients I-Subject
with I-Subject
cystic I-Treat_Disorder
fibrosis I-Treat_Disorder
and I-Subject
the I-Subject
G551D I-Subject.Sub_Disorder
mutation I-Subject.Sub_Disorder
. O

Quinapril I-Treatment.Drug
is O
an O
angiotensin O
- O
converting O
enzyme O
inhibitor O
( O
ACE O
- O
inhibitor O
) O
and O
overdose I-Dosage
can I-Adverse_event.Trigger
lead I-Adverse_event.Trigger
to I-Adverse_event.Trigger
prolonged I-Effect
hypotension I-Effect
and I-Effect
, I-Effect
less I-Effect
frequently I-Effect
, I-Effect
transient I-Effect
renal I-Effect
impairment I-Effect
. O

We O
describe O
a I-Subject
renal I-Treat_Disorder
transplant I-Treat_Disorder
recipient I-Treat_Disorder
maintained I-Treatment
on I-Treatment
cyclosporine I-Treatment.Combination.Drug
and I-Treatment
prednisone I-Treatment.Combination.Drug
developing I-Adverse_event.Trigger
Nocardia I-Effect
Asteroides I-Effect
brain I-Effect
abscess I-Effect
. O

After O
an O
extensive O
review O
of O
the O
literature O
, O
we O
believe O
that O
this O
is O
the O
first O
communication O
of O
the O
successful O
use O
of O
amiodarone I-Treatment.Drug
to O
control I-Potential_therapeutic_event.Trigger
hyperthyroidism I-Treat_Disorder
in O
a I-Subject
patient I-Subject
with I-Subject
PTU I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
induced I-Subject.Sub_Disorder
fulminant I-Subject.Sub_Disorder
hepatitis I-Subject.Sub_Disorder
. O

After O
identification O
of O
the O
index O
patient O
, O
additional O
inquiry O
revealed O
that O
the I-Subject
patient I-Subject
's I-Subject
mother I-Subject
was O
hospitalized O
previously O
for O
overwhelming I-Effect
sepsis I-Effect
associated I-Adverse_event.Trigger
with O
metamizole I-Treatment.Drug
use O
. O

We O
report O
here O
on O
a O
heretofore O
undescribed O
respiratory I-Effect
syncytial I-Effect
virus I-Effect
( I-Effect
RSV I-Effect
) I-Effect
infection I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
a I-Subject
long I-Subject
- I-Subject
standing I-Subject
history I-Subject
of I-Subject
refractory I-Treat_Disorder
CLL I-Treat_Disorder
that O
was O
treated I-Adverse_event.Trigger
with O
fludarabine I-Treatment.Drug
phosphate I-Treatment.Drug
. O

A I-Subject
77 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
no I-Subject.Sub_Disorder
history I-Subject.Sub_Disorder
of I-Subject.Sub_Disorder
epilepsy I-Subject.Sub_Disorder
presented O
a I-Effect
probable I-Effect
nonconvulsive I-Effect
status I-Effect
epilepticus I-Effect
while O
receiving I-Adverse_event.Trigger
continuous I-Treatment.Freq
intravenous I-Treatment.Route
morphine I-Treatment.Drug
for O
back I-Treat_Disorder
pain I-Treat_Disorder
relating I-Treat_Disorder
to I-Treat_Disorder
vertebral I-Treat_Disorder
metastasis I-Treat_Disorder
of I-Treat_Disorder
a I-Treat_Disorder
malignant I-Treat_Disorder
lymphoma I-Treat_Disorder
. O

Oral I-Treatment.Route
corticosteroids I-Treatment.Drug
( I-Treatment
OCS I-Treatment
) I-Treatment
may O
be O
associated I-Adverse_event.Trigger
with O
systemic I-Effect
adverse I-Effect
events I-Effect
( I-Effect
AEs I-Effect
) I-Effect
, O
which O
can O
be O
reduced O
by O
replacing O
OCS O
with O
inhaled O
corticosteroids O
( O
ICS O
) O
. O

Development O
of O
Peyronie I-Effect
's I-Effect
disease I-Effect
during I-Adverse_event.Trigger
long I-Treatment.Freq
- I-Treatment.Freq
term I-Treatment.Freq
colchicine I-Treatment.Drug
treatment I-Treatment
. O

The O
principle O
treatment O
for O
DPD I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
deficient I-Subject.Sub_Disorder
patients I-Subject
with I-Subject
severe I-Treat_Disorder
acute I-Treat_Disorder
5 I-Treat_Disorder
- I-Treat_Disorder
FU I-Treat_Disorder
reactions I-Treat_Disorder
is O
supportive O
care O
; O
however O
, O
the O
administration O
of O
thymidine I-Treatment.Drug
potentially O
may O
reverse I-Potential_therapeutic_event.Trigger
severe O
5 I-Treat_Disorder
- I-Treat_Disorder
FU I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
neurologic I-Treat_Disorder
symptoms I-Treat_Disorder
such I-Treat_Disorder
as I-Treat_Disorder
encephalopathy I-Treat_Disorder
and I-Treat_Disorder
coma I-Treat_Disorder
. O

Adverse O
reaction O
in O
a I-Subject
patient I-Subject
with O
aspirin I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
asthma I-Effect
treated O
with O
zafirlukast I-Combination.Drug
. O

The O
nephrotic I-Effect
syndrome I-Effect
developed I-Adverse_event.Trigger
in O
a I-Subject
patient I-Subject
receiving O
therapy I-Treatment
with I-Treatment
gold I-Treatment.Drug
for O
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

This O
observation O
adds O
another O
dimension O
to O
the O
previously O
reported I-Adverse_event.Trigger
renal I-Effect
complications I-Effect
of O
nonsteroidal I-Treatment.Drug
anti I-Treatment.Drug
- I-Treatment.Drug
inflammatory I-Treatment.Drug
agents I-Treatment
, I-Treatment
especially I-Treatment
zomepirac I-Treatment.Drug
. O

Clinical I-Effect
, I-Effect
spectroscopic I-Effect
, I-Effect
and I-Effect
imaging I-Effect
abnormalities I-Effect
resolved I-Potential_therapeutic_event.Trigger
with O
discontinuation O
of O
metronidazole I-Treatment.Drug
. O

In O
two I-Subject.Population
other I-Subject
patients I-Subject
( I-Subject
one I-Subject
after I-Subject
OLTX I-Treat_Disorder
and I-Subject
one I-Subject
with I-Subject
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
) I-Subject
, O
a O
raltegravir I-Treatment.Combination.Drug
- O
based O
HIV I-Treat_Disorder
therapy O
was O
started O
while O
patients O
received I-Potential_therapeutic_event.Trigger
1 I-Treatment.Dosage
or I-Treatment.Dosage
2 I-Treatment.Dosage
mg I-Treatment.Dosage
of I-Treatment
tacrolimus I-Treatment.Combination.Drug
twice I-Treatment.Freq
daily I-Treatment.Freq
. I-Treatment

Reversible I-Effect
cardiomyopathy I-Effect
caused I-Adverse_event.Trigger
by I-Adverse_event.Trigger
administration I-Treatment
of I-Treatment
interferon I-Treatment.Drug
alpha I-Treatment.Drug
. O

Metipranolol I-Treatment.Drug
associated I-Adverse_event.Trigger
granulomatous I-Effect
anterior I-Effect
uveitis I-Effect
: O
not O
so O
uncommon O
as O
thought O
. O

There O
was O
an O
increase O
in O
serious O
adverse I-Adverse_event.Trigger
events I-Adverse_event.Trigger
with O
bleeding I-Effect
in O
the O
tifacogin I-Treatment.Drug
group O
in O
both O
cohorts O
( O
6.5 O
% O
tifacogin O
and O
4.8 O
% O
placebo O
for O
high I-Treat_Disorder
INR I-Treat_Disorder
; O
6.0 O
% O
tifacogin O
and O
3.3 O
% O
placebo O
for O
low I-Treat_Disorder
INR I-Treat_Disorder
) O
. O

We O
also O
describe O
a I-Subject
case I-Subject
of O
timolol I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
ocular I-Effect
pemphigoid I-Effect
. O

A I-Subject
70 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
was O
admitted O
to O
our O
hospital O
because O
of O
dyspnea I-Effect
after O
taking I-Adverse_event.Trigger
an I-Treatment
antihistaminic I-Treatment
agent I-Treatment
( I-Treatment
homochlorcyclizine I-Treatment.Drug
hydrochloride I-Treatment.Drug
) I-Treatment
for O
itching I-Treat_Disorder
. O

Methadone I-Effect
withdrawal I-Effect
when O
starting I-Adverse_event.Trigger
an I-Treatment
antiretroviral I-Treatment
regimen I-Treatment
including I-Treatment
nevirapine I-Treatment.Drug
. O

The O
oligohidrosis O
caused O
by O
zonisamide I-Treatment.Drug
was O
reversible O
in O
that O
the I-Subject
patient I-Subject
regained I-Effect
the I-Effect
ability I-Effect
to I-Effect
sweat I-Effect
within I-Time_elapsed
2 I-Time_elapsed
weeks I-Time_elapsed
of I-Potential_therapeutic_event.Trigger
the I-Potential_therapeutic_event.Trigger
cessation I-Treatment.Dosage
of I-Treatment
drug I-Treatment
administration I-Treatment
. O

Radiation I-Effect
recall I-Effect
related I-Adverse_event.Trigger
to O
gemcitabine I-Treatment.Drug
has O
been O
reported O
in O
lung I-Treat_Disorder
and I-Treat_Disorder
breast I-Treat_Disorder
cancer I-Treat_Disorder
. O

It O
carries O
a O
well O
- O
known O
risk I-Adverse_event.Trigger
of O
neutropenia I-Effect
and I-Effect
agranulocytosis I-Effect
, O
which O
necessitates O
the O
immediate O
discontinuation O
of O
clozapine I-Treatment.Drug
. O

Vicriviroc I-Treatment.Drug
( I-Treatment
SCH I-Treatment
417690 I-Treatment
) I-Treatment
, I-Treatment
a I-Treatment
CCR5 I-Treatment
receptor I-Treatment
antagonist I-Treatment
, O
is O
currently O
under O
investigation O
for O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
human I-Treat_Disorder
immunodeficiency I-Treat_Disorder
virus I-Treat_Disorder
infection I-Treat_Disorder
. O

Children I-Subject.Age
receiving O
zonisamide I-Treatment.Drug
should O
be O
monitored I-Adverse_event.Trigger
for O
oligohidrosis I-Effect
and O
the O
development I-Effect
of I-Effect
neurological I-Effect
symptoms I-Effect
associated I-Effect
with O
an O
elevation O
of O
body O
temperature O
. O

This O
concerns O
2 I-Subject.Population
male I-Subject.Gender
patients I-Subject
who O
experienced I-Adverse_event.Trigger
incontinence I-Effect
while O
taking O
venlafaxine I-Treatment.Drug
. O

Polyarthritis I-Effect
, I-Effect
hepatitis I-Effect
and I-Effect
anti I-Effect
- I-Effect
native I-Effect
DNA I-Effect
antibodies I-Effect
after I-Adverse_event.Trigger
treatment O
with O
ethambutol I-Treatment.Combination.Drug
and I-Treatment
rifampicin I-Treatment.Combination.Drug
. O

We O
report O
an O
HIV I-Treat_Disorder
- I-Subject
infected I-Subject
woman I-Subject.Gender
who O
developed I-Adverse_event.Trigger
mild I-Effect
leukopenia I-Effect
as O
the O
first O
sign O
of O
a O
nevirapine I-Treatment.Drug
- O
related O
adverse O
event O
, O
which O
was O
followed I-Effect
by I-Effect
skin I-Effect
and I-Effect
hepatic I-Effect
toxicity I-Effect
associated I-Effect
with I-Effect
a I-Effect
more I-Effect
severe I-Effect
leukopenia I-Effect
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
rapidly O
occurring I-Adverse_event.Trigger
hyperglycemia I-Effect
that O
occurred O
in O
a I-Subject
geriatric I-Subject.Age
patient I-Subject
3 I-Time_elapsed
days I-Time_elapsed
after O
treatment O
with O
olanzapine I-Treatment.Drug
. O

Tifacogin I-Treatment.Drug
administration O
was O
associated I-Adverse_event.Trigger
with O
an I-Effect
increase I-Effect
in I-Effect
risk I-Effect
of I-Effect
bleeding I-Effect
, O
irrespective O
of O
baseline O
INR O
. O

Gynecomastia I-Effect
developed I-Adverse_event.Trigger
in O
two I-Subject.Population
epileptic I-Treat_Disorder
patients I-Subject
some I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
the I-Treatment
addition I-Treatment
of I-Treatment
oral I-Treatment.Route
fluoresone I-Treatment.Combination.Drug
750 I-Treatment.Dosage
mg I-Treatment.Dosage
daily I-Treatment.Freq
to I-Treatment
the I-Treatment
phenobarbital I-Treatment.Combination.Drug
and I-Treatment
phenytoin I-Treatment.Combination.Drug
already I-Treatment
being I-Treatment
administered I-Treatment
. O

The O
authors O
describe O
a O
case O
of O
combined I-Treatment
lithium I-Treatment.Combination.Drug
and I-Treatment
haloperidol I-Treatment.Combination.Drug
toxicity I-Adverse_event.Trigger
characterized O
by O
hyperpyrexia I-Effect
, I-Effect
severe I-Effect
rigidity I-Effect
, I-Effect
mutism I-Effect
, I-Effect
and I-Effect
development I-Effect
of I-Effect
irreversible I-Effect
tardive I-Effect
dyskinesia I-Effect
. O

Occasionally O
, O
despite O
good O
therapeutic O
response O
, O
clozapine I-Treatment.Drug
must O
be O
stopped O
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
dangerous I-Effect
side I-Effect
effects I-Effect
such I-Effect
as I-Effect
agranulocytosis I-Effect
. O

Three O
cases O
of O
pseudocyst I-Effect
of I-Effect
the I-Effect
pancreas I-Effect
in O
two I-Subject.Population
women I-Subject.Gender
and I-Subject
one I-Subject.Population
man I-Subject.Gender
have O
previously O
been O
reported I-Adverse_event.Trigger
with O
the O
use O
of O
intravenous I-Treatment.Route
L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
. O

We O
report O
a O
case O
of O
Ritalin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
cataract I-Effect
and I-Effect
glaucoma I-Effect
. O

We O
discuss O
a O
patient O
who O
developed I-Adverse_event.Trigger
severe I-Effect
renal I-Effect
tubular I-Effect
dysfunction I-Effect
secondary O
to O
short I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
therapy I-Treatment
with I-Treatment
Amikacin I-Treatment.Drug
, O
resulting I-Effect
in I-Effect
refractory I-Effect
hypokalemia I-Effect
, I-Effect
hypocalcemia I-Effect
, I-Effect
hypomagnesemia I-Effect
, I-Effect
metabolic I-Effect
alkalosis I-Effect
, I-Effect
and I-Effect
polyuria I-Effect
. O

Cardiac I-Effect
toxicity I-Effect
related I-Adverse_event.Trigger
to O
BCNU I-Treatment.Drug
has O
not O
been O
described O
well O
. O

Aprepitant I-Treatment.Combination.Drug
is O
a O
neurokinin(1 O
) O
receptor O
antagonist O
that O
enhances I-Potential_therapeutic_event.Trigger
prevention I-Effect
of I-Effect
chemotherapy I-Effect
- I-Effect
induced I-Effect
nausea I-Effect
and I-Effect
vomiting I-Effect
when O
added I-Treatment
to I-Treatment
conventional I-Treatment
therapy I-Treatment
with I-Treatment
a I-Treatment
corticosteroid I-Treatment.Combination.Drug
and I-Treatment
a I-Treatment
5 I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
hydroxytryptamine(3 I-Treatment.Combination.Drug
) I-Treatment.Combination.Drug
( I-Treatment.Combination.Drug
5 I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
HT(3 I-Treatment.Combination.Drug
) I-Treatment.Combination.Drug
) I-Treatment.Combination.Drug
antagonist I-Treatment.Combination.Drug
. O

Thus O
, O
tacrolimus I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
HUS I-Effect
is O
a O
rare O
cause O
of O
ARF O
in O
nephrotic I-Treat_Disorder
syndrome I-Treat_Disorder
. O

Clinicians O
should O
be O
vigilant O
when O
monitoring O
for O
cardiotoxicity I-Effect
in O
patients I-Subject
receiving I-Adverse_event.Trigger
pentamidine I-Treatment.Drug
throughout O
the O
duration O
of O
therapy O
. O

The I-Subject
present I-Subject
case I-Subject
is O
the O
first O
report O
of O
hypercalcemia I-Effect
induced I-Adverse_event.Trigger
by O
vitamin I-Treatment.Combination.Drug
D3 I-Treatment.Combination.Drug
ointment I-Treatment.Route
and I-Treatment
thiazide I-Treatment.Combination.Drug
simultaneously I-Treatment
. O

CONCLUSION O
: O
Significant I-Effect
weight I-Effect
loss I-Effect
is O
a O
potential I-Adverse_event.Trigger
adverse I-Adverse_event.Trigger
event I-Adverse_event.Trigger
in O
patients O
with O
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
treated O
with O
leflunomide I-Treatment.Drug
. O

We O
have O
described O
a I-Subject
man I-Subject.Gender
with I-Subject
classic I-Treat_Disorder
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
who O
had O
membranous I-Effect
nephropathy I-Effect
associated I-Effect
with I-Effect
nephrotic I-Effect
syndrome I-Effect
not I-Adverse_event.Trigger
related I-Adverse_event.Trigger
to O
gold I-Treatment.Drug
or I-Treatment
penicillamine I-Treatment.Drug
therapy I-Treatment
. O

Pharmacokinetics I-Treatment
of I-Treatment
etravirine I-Treatment.Combination.Drug
in O
HIV I-Treat_Disorder
- I-Subject
infected I-Subject
patients I-Subject
concomitantly I-Treatment
treated I-Treatment
with I-Treatment
rifampin I-Treatment.Combination.Drug
for I-Potential_therapeutic_event.Trigger
tuberculosis I-Treat_Disorder
. O

We O
thus O
concluded O
that O
an O
excessive I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
AZ I-Treatment.Drug
had I-Adverse_event.Trigger
probably O
destroyed I-Effect
the I-Effect
gastric I-Effect
mucosal I-Effect
barrier I-Effect
or I-Effect
thrombocytopenia I-Effect
due O
to O
bone O
marrow O
disorder O
and O
thus O
eventually O
led O
to O
the O
development O
of O
hemorrhagic I-Effect
gastritis I-Effect
. O

Acyclovir I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
neurotoxicity I-Effect
: O
concentration O
- O
side O
effect O
relationship O
in O
acyclovir O
overdose I-Dosage
. O

Psoriasis I-Effect
- I-Effect
like I-Effect
skin I-Effect
reaction I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
after I-Adverse_event.Trigger
sulphasalazine I-Treatment.Dosage
therapy I-Treatment
. O

We O
describe O
the O
clinical O
course O
of O
2 I-Subject.Population
patients I-Subject
with I-Subject
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
( I-Subject
CD I-Subject
) I-Subject
in O
whom O
lymphoma I-Effect
was O
diagnosed I-Adverse_event.Trigger
after O
treatment I-Treatment
with I-Treatment
infliximab I-Treatment.Drug
. O

Valproic I-Treatment.Drug
acid I-Treatment.Drug
is O
commonly O
and O
effectively O
used I-Potential_therapeutic_event.Trigger
in O
the O
treatment O
of O
idiopathic I-Treat_Disorder
generalized I-Treat_Disorder
epilepsies I-Treat_Disorder
, O
including O
juvenile I-Treat_Disorder
absence I-Treat_Disorder
epilepsy I-Treat_Disorder
. O

We O
report O
a I-Subject
case I-Subject
of O
intrathecal I-Treatment
methotrexate I-Treatment.Drug
neurotoxicity I-Treatment
manifesting I-Adverse_event.Trigger
as O
left I-Effect
arm I-Effect
weakness I-Effect
and I-Effect
aphasia I-Effect
. O

According O
to O
the O
Drug O
Interaction O
Probability O
Scale O
, O
a O
causal O
relationship I-Adverse_event.Trigger
between O
the O
warfarin I-Treatment.Combination.Drug
- O
cloxacillin I-Treatment.Combination.Drug
interaction O
and O
increased I-Effect
INR I-Effect
value I-Effect
was O
rated O
" O
probable O
" O
. O

We O
present O
the O
cases O
of O
two I-Subject.Population
female I-Subject.Gender
patients I-Subject
diagnosed I-Subject
with I-Subject
relapsing I-Treat_Disorder
- I-Treat_Disorder
remitting I-Treat_Disorder
multiple I-Treat_Disorder
sclerosis I-Treat_Disorder
( I-Subject
RRMS I-Subject
) I-Subject
who O
developed I-Adverse_event.Trigger
inflammatory I-Effect
musculoskeletal I-Effect
manifestations I-Effect
, O
following O
IFN I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
therapy O
. O

Dystonia I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
carbamazepine I-Treatment.Drug
administration I-Treatment
: O
experience O
in O
brain I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
damaged I-Subject.Sub_Disorder
children I-Subject.Age
. O

In O
all O
, O
51 I-Subject.Population
patients I-Subject
had I-Adverse_event.Trigger
a O
gastrointestinal I-Effect
event I-Effect
; O
the O
event O
rate O
was O
1.1 I-Treatment
% I-Treatment
with I-Treatment
omeprazole I-Treatment.Drug
and I-Treatment
2.9 I-Treatment
% I-Treatment
with I-Treatment
placebo I-Treatment.Drug
at O
180 I-Time_elapsed
days I-Time_elapsed
( O
hazard O
ratio O
with O
omeprazole O
, O
0.34 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.18 O
to O
0.63 O
; O
P<0.001 O
) O
. O

CONCLUSION O
: O
We O
report O
a I-Subject
case I-Subject
of O
the O
use O
of O
pamidronate I-Treatment.Drug
for I-Potential_therapeutic_event.Trigger
significant O
hypercalcemia I-Treat_Disorder
secondary O
to O
acute O
vitamin I-Drug
D I-Drug
poisoning O
. O

Clopidogrel I-Treatment.Combination.Drug
with I-Treatment
or I-Treatment
without I-Treatment
omeprazole I-Treatment.Combination.Drug
in I-Potential_therapeutic_event.Trigger
coronary I-Treat_Disorder
artery I-Treat_Disorder
disease I-Treat_Disorder
. O

The O
cases O
are O
important O
in O
documenting O
that O
drug O
- O
induced O
dystonias O
do O
occur O
in O
patients I-Subject
with I-Subject
dementia I-Subject.Sub_Disorder
, O
that O
risperidone I-Treatment.Drug
appears O
to O
have O
contributed I-Adverse_event.Trigger
to O
dystonia I-Effect
among O
elderly I-Subject.Age
patients I-Subject
, O
and O
that O
the O
categorization O
of O
dystonic O
reactions O
needs O
further O
clarification O
. O

In O
addition O
, O
there O
is O
a O
report O
on O
prolonged I-Effect
ECT I-Effect
seizure I-Effect
related I-Adverse_event.Trigger
to O
ciprofloxacin I-Treatment.Drug
, O
which O
has O
an O
epileptogenic O
property O
with O
a O
similar O
action O
to O
beta O
- O
lactam O
antibiotics O
. O

After I-Adverse_event.Trigger
abstinence O
from O
oolong I-Treatment
tea I-Treatment
his O
delirium I-Treat_Disorder
resolved O
. O

Anaphylaxis I-Effect
to I-Adverse_event.Trigger
intrathecal I-Treatment.Route
diamorphine I-Treatment.Drug
. O

This O
case O
suggests O
that O
acyclovir I-Treatment.Drug
when O
given O
intravenously O
in O
doses O
of O
10 I-Dosage
mg I-Dosage
/ I-Dosage
kg I-Dosage
may O
result I-Adverse_event.Trigger
in O
increased I-Effect
serum I-Effect
lithium I-Effect
concentrations I-Effect
. O

After O
approximately O
two I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
of I-Treatment
sertraline I-Treatment.Combination.Drug
treatment O
he O
noted I-Adverse_event.Trigger
an O
intense I-Effect
itching I-Effect
sensation I-Effect
in I-Effect
his I-Effect
scalp I-Effect
after O
eating O
a O
piece O
of O
chocolate I-Combination.Drug
cake O
. O

Pigmentary I-Effect
aberrations I-Effect
are O
well O
known O
side I-Adverse_event.Trigger
effects I-Adverse_event.Trigger
of O
cytostatic I-Treatment.Drug
chemotherapeutic I-Treatment.Drug
agents I-Treatment.Drug
. O

CONCLUSION O
: O
Atovaquone I-Treatment.Drug
should O
be O
added O
to O
the O
list O
of O
agents O
causing I-Adverse_event.Trigger
vortex I-Effect
keratopathy I-Effect
involving I-Effect
the I-Effect
corneal I-Effect
epithelium I-Effect
. O

A O
generalized I-Effect
tonic I-Effect
- I-Effect
clonic I-Effect
seizure I-Effect
occurred I-Adverse_event.Trigger
a I-Treatment.Time_elapsed
few I-Treatment.Time_elapsed
minutes I-Treatment.Time_elapsed
after I-Treatment
injection I-Treatment.Route
of I-Treatment
the I-Treatment
morphine I-Treatment
antagonist I-Treatment
naloxone I-Treatment.Drug
. O

CONCLUSION O
: O
Squamous I-Effect
metaplasia I-Effect
in O
these I-Subject
cases I-Subject
appears O
to O
be O
a O
consequence I-Adverse_event.Trigger
of O
progestin I-Treatment.Drug
therapy I-Treatment
. O

This O
association O
should O
be O
considered O
in O
the O
period O
after I-Adverse_event.Trigger
vasopressin I-Treatment.Drug
- O
treated O
gastrointestinal I-Treat_Disorder
hemorrhage I-Treat_Disorder
. O

The O
gynecomastia I-Effect
regressed O
when O
the O
theophylline I-Treatment.Drug
was O
discontinued I-Adverse_event.Trigger
. O

Renal I-Effect
hypophosphatemia I-Effect
in O
this I-Subject
patient I-Subject
was O
caused I-Adverse_event.Trigger
by O
the I-Treatment
erroneous I-Treatment
intake I-Treatment
of I-Treatment
1 I-Treatment.Dosage
g I-Treatment.Dosage
doxycycline I-Treatment.Drug
. I-Treatment

Despite O
a O
response O
of O
the O
meningeal I-Treat_Disorder
tumor I-Treat_Disorder
the I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
in O
the O
third O
week O
of O
MTX I-Treatment.Combination.Drug
treatment I-Treatment
a I-Effect
progressive I-Effect
visual I-Effect
loss I-Effect
and I-Effect
loss I-Effect
of I-Effect
consciousness I-Effect
which O
worsened O
during O
subsequent I-Treatment
Ara I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
C I-Treatment.Combination.Drug
treatment I-Treatment
and O
led I-Effect
to I-Effect
death I-Effect
within I-Treatment
3 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
. I-Treatment.Time_elapsed

After O
seven I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
' I-Treatment
continuous I-Treatment
treatment I-Treatment
for O
suspected O
tuberculosis I-Treat_Disorder
with I-Treatment
rifampicin I-Treatment.Combination.Drug
and I-Treatment
ethambutol I-Treatment.Combination.Drug
a I-Subject
nine I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
developed I-Adverse_event.Trigger
polyarthritis I-Effect
, I-Effect
rash I-Effect
and I-Effect
hepatitis I-Effect
in I-Effect
association I-Effect
with I-Effect
anti I-Effect
- I-Effect
native I-Effect
DNA I-Effect
antibodies I-Effect
and I-Effect
positive I-Effect
antinuclear I-Effect
factor I-Effect
. O

A I-Subject
few I-Subject
recent I-Subject
individual I-Subject
case I-Subject
reports O
have O
suggested O
that O
a O
myasthenic I-Effect
syndrome I-Effect
may O
be O
associated I-Adverse_event.Trigger
with O
statin I-Treatment.Drug
treatment I-Treatment
, O
but O
this O
association O
is O
not O
well O
described O
. O

Topical I-Treatment.Route
imiquimod I-Treatment.Drug
and O
tumor O
necrosis O
factor O
( O
TNF) O
- O
alpha O
inhibitors O
have O
gained O
wide O
acceptance O
as O
safe O
and O
effective O
treatments I-Potential_therapeutic_event.Trigger
for O
non I-Treat_Disorder
- I-Treat_Disorder
melanoma I-Treat_Disorder
skin I-Treat_Disorder
cancer I-Treat_Disorder
( I-Treat_Disorder
NMSC I-Treat_Disorder
) I-Treat_Disorder
and O
moderate O
to O
severe O
psoriasis O
, O
respectively O
. O

Focal I-Effect
renal I-Effect
cortical I-Effect
necrosis I-Effect
associated I-Adverse_event.Trigger
with O
zomepirac I-Treatment.Drug
. O

We O
experienced O
2 O
cases O
of O
mequitazine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
photosensitivity I-Effect
reaction I-Effect
in O
patients I-Subject
who O
took O
mequitazine O
for O
their O
dermatologic I-Treat_Disorder
problems I-Treat_Disorder
. O

Carboplatin I-Treatment
was I-Treatment
substituted I-Treatment
for I-Treatment
cisplatin I-Treatment.Drug
, O
and O
there O
were O
no O
further O
episodes O
of O
SIADH I-Treat_Disorder
. O

Severe O
steroid I-Drug
- O
induced I-Adverse_event.Trigger
glaucoma I-Effect
following O
intravitreal I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
triamcinolone I-Treatment.Drug
acetonide I-Treatment.Drug
. O

CD20 I-Effect
- I-Effect
negative I-Effect
T I-Effect
- I-Effect
cell I-Effect
- I-Effect
rich I-Effect
B I-Effect
- I-Effect
cell I-Effect
lymphoma I-Effect
as O
a O
progression O
of O
a O
nodular I-Treat_Disorder
lymphocyte I-Treat_Disorder
- I-Treat_Disorder
predominant I-Treat_Disorder
Hodgkin I-Treat_Disorder
's I-Treat_Disorder
lymphoma I-Treat_Disorder
treated I-Adverse_event.Trigger
with O
rituximab I-Treatment.Drug
: O
a O
molecular O
analysis O
using O
laser O
capture O
microdissection O
. O

We O
report O
the O
case O
of O
an I-Subject
adult I-Subject.Age
patient I-Subject
with I-Subject
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
who O
presented I-Adverse_event.Trigger
with O
repeated I-Effect
transient I-Effect
ischemic I-Effect
attacks I-Effect
followed I-Effect
by I-Effect
a I-Effect
seizure I-Effect
during O
consolidation I-Treatment
treatment I-Treatment
with I-Treatment
L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
. O

Gemcitabine I-Treatment.Drug
- O
related I-Adverse_event.Trigger
radiation I-Effect
recall I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
pancreatic I-Treat_Disorder
cancer I-Treat_Disorder
. O

After O
development I-Adverse_event.Trigger
of O
the O
tics I-Effect
in O
2 O
, O
CBZ I-Treatment.Drug
was O
continued O
at O
the I-Dosage
same I-Dosage
or I-Dosage
higher I-Dosage
dose I-Dosage
, O
and O
the O
tics O
abated O
and O
then O
ceased O
spontaneously O
< O
or O
= O
6 O
months O
. O

Thus O
any O
case O
of O
severe I-Effect
neutropenia I-Effect
occurring I-Adverse_event.Trigger
in O
a I-Subject
patient I-Subject
receiving O
olanzapine I-Treatment.Drug
is O
alarming O
to O
clinicians O
. O

We O
describe O
3 I-Subject.Population
AS I-Treat_Disorder
patients I-Subject
treated O
with O
etanercept I-Treatment.Drug
for I-Treatment
active I-Treatment.Treat_Disorder
AS I-Treatment.Treat_Disorder
who O
developed I-Adverse_event.Trigger
new O
onset O
of O
CD I-Effect
while O
AS O
related O
symptoms O
responded O
well O
to O
etanercept O
. O

It O
is O
concluded O
that O
the O
aforementioned O
pathological O
manifestations O
were O
due O
to O
chemotherapy O
and O
included O
a I-Effect
pulmonary I-Effect
adverse I-Effect
reaction I-Effect
, O
a O
feature O
never O
previously O
associated I-Adverse_event.Trigger
with O
oxaliplatinum I-Treatment.Combination.Drug
and I-Treatment
5 I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
fluorouracil I-Treatment.Combination.Drug
regimens I-Treatment
. O

A O
case O
of O
colchicine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
rhabdomyolysis I-Effect
is O
reported O
. O

Because O
of O
a O
recurrence O
of O
paroxysmal I-Subject.Sub_Disorder
atrial I-Subject.Sub_Disorder
fibrillation I-Subject.Sub_Disorder
, O
the I-Treatment
dose I-Treatment
of I-Treatment
the I-Treatment.Drug
drug I-Treatment.Drug
was I-Treatment
increased I-Treatment
to I-Treatment
1.4 I-Treatment.Dosage
g I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
; O
24 I-Time_elapsed
hours I-Time_elapsed
later O
AVT I-Effect
with I-Effect
syncope I-Effect
developed I-Adverse_event.Trigger
but O
responded O
promptly O
to O
atropine O
. O

Three I-Subject.Population
male I-Subject.Gender
patients I-Subject
aged I-Subject
78 I-Subject.Age
- I-Subject.Age
83 I-Subject.Age
years I-Subject.Age
are O
presented O
, O
in O
whom O
severe I-Effect
hepatotoxic I-Effect
reactions I-Effect
emerged O
after I-Adverse_event.Trigger
CPA I-Treatment.Drug
administration O
. O

Exacerbations I-Effect
of I-Effect
the I-Effect
heart I-Effect
failure I-Effect
were O
temporally O
related I-Adverse_event.Trigger
to O
the O
administration O
of O
the O
antitumor I-Treatment
antibiotics I-Treatment
actinomycin I-Treatment.Drug
- I-Treatment.Drug
D I-Treatment.Drug
( I-Treatment
NSC I-Treatment
- I-Treatment
3053 I-Treatment
) I-Treatment
and I-Treatment
mithramycin I-Treatment.Drug
( I-Treatment
NSC I-Treatment
- I-Treatment
24559 I-Treatment
) I-Treatment
. O

Diffuse I-Effect
alveolar I-Effect
hemorrhage I-Effect
after I-Adverse_event.Trigger
leflunomide I-Treatment.Drug
therapy O
in O
a I-Subject
patient I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

We O
report O
a O
case O
of O
a I-Subject
64 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Adverse_event.Trigger
secondary I-Effect
adrenocortical I-Effect
insufficiency I-Effect
who O
has O
been O
on O
a I-Treatment
chronic I-Treatment.Freq
transdermal I-Treatment.Route
fentanyl I-Treatment.Drug
treatment I-Treatment
because O
of O
sciatic I-Treat_Disorder
pain I-Treat_Disorder
syndrome I-Treat_Disorder
. O

A I-Subject
52 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
, O
white I-Subject.Race
female I-Subject.Gender
developed I-Adverse_event.Trigger
low I-Effect
- I-Effect
grade I-Effect
fever I-Effect
, I-Effect
cough I-Effect
, I-Effect
and I-Effect
dyspnea I-Effect
after O
8 I-Time_elapsed
weeks I-Time_elapsed
treatment O
with O
sodium I-Treatment.Drug
aurothiomalate I-Treatment.Drug
for O
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

In I-Subject
both I-Subject.Population
cases I-Subject
, O
high I-Effect
fever I-Effect
, I-Effect
skin I-Effect
rash I-Effect
, I-Effect
liver I-Effect
dysfunction I-Effect
and I-Effect
atypical I-Effect
lymphocytosis I-Effect
developed I-Adverse_event.Trigger
3 O
weeks O
after O
initiating O
treatment O
with O
SASP I-Treatment.Drug
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
severe I-Effect
chloroquine I-Treatment.Drug
toxicity I-Effect
in O
the O
presence O
of O
high I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
grade I-Subject.Sub_Disorder
chloroquine I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
resistant I-Subject.Sub_Disorder
Plasmodium I-Subject.Sub_Disorder
vivax I-Subject.Sub_Disorder
. O

RESULTS O
: O
All I-Subject
cases I-Subject
developed I-Adverse_event.Trigger
corneal I-Effect
endothelial I-Effect
deposits I-Effect
after O
previous O
use O
of O
rifabutin I-Treatment.Drug
. O

Two I-Subject.Population
infants I-Subject.Age
developed I-Adverse_event.Trigger
hyperkalemia I-Effect
shortly I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
cessation I-Treatment.Dosage
of I-Treatment
prolonged I-Treatment
ACTH I-Treatment.Drug
therapy I-Treatment
for O
infantile I-Treat_Disorder
spasms I-Treat_Disorder
. O

In O
this O
case O
, O
CIPS I-Effect
was O
considered O
to O
be O
probably O
associated I-Adverse_event.Trigger
with O
cyclosporine I-Treatment.Drug
according O
to O
the O
Naranjo O
probability O
scale O
. O

Acute I-Effect
syphilitic I-Effect
posterior I-Effect
placoid I-Effect
chorioretinitis I-Effect
following I-Adverse_event.Trigger
intravitreal I-Treatment.Route
triamcinolone I-Treatment.Drug
acetonide I-Treatment.Drug
injection I-Treatment.Route
. O

Delayed I-Effect
pseudocyst I-Effect
of I-Effect
the I-Effect
pancreas I-Effect
can I-Adverse_event.Trigger
be O
a O
complication O
of O
intramuscular I-Treatment.Route
L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
. O

I O
report O
a I-Subject
35 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
occult I-Subject.Sub_Disorder
coronary I-Subject.Sub_Disorder
artery I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
who O
experienced I-Adverse_event.Trigger
cardiac I-Effect
arrest I-Effect
within I-Treatment.Time_elapsed
minutes I-Treatment.Time_elapsed
after I-Treatment
receiving I-Treatment
a I-Treatment.Dosage
first I-Treatment.Dosage
- I-Treatment.Dosage
time I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
subcutaneous I-Treatment.Route
sumatriptan I-Treatment.Drug
for O
migraine I-Treat_Disorder
. O

Epoprostenol I-Treatment.Drug
( I-Treatment
prostacyclin I-Treatment.Drug
) I-Treatment
is O
currently O
approved O
for O
treatment I-Potential_therapeutic_event.Trigger
of O
primary I-Treat_Disorder
pulmonary I-Treat_Disorder
hypertension I-Treat_Disorder
; O
however O
, O
it O
is O
being O
evaluated O
in O
other O
forms O
of O
pulmonary O
hypertension O
, O
particularly O
scleroderma O
. O

OBJECTIVE O
: O
To O
report O
a O
fatal I-Effect
case I-Effect
of I-Effect
toxic I-Effect
epidermal I-Effect
necrolysis I-Effect
in O
a O
man I-Subject.Gender
who O
was O
treated I-Adverse_event.Trigger
with O
oral I-Treatment.Route
ofloxacin I-Treatment.Drug
for O
epididymitis I-Treat_Disorder
. O

Massive I-Effect
pulmonary I-Effect
embolism I-Effect
due I-Adverse_event.Trigger
to O
late O
- O
onset O
heparin I-Treatment.Drug
- O
induced O
thrombocytopenia O
following O
coronary O
artery O
bypass O
graft O
surgery O
: O
successful O
treatment O
with O
lepirudin O
. O

Value I-Potential_therapeutic_event.Trigger
of O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
cytarabine I-Treatment.Drug
during I-Treatment
interval I-Treatment
therapy I-Treatment
of I-Treatment
a I-Treatment
Berlin I-Treatment
- I-Treatment
Frankfurt I-Treatment
- I-Treatment
Munster I-Treatment
- I-Treatment
based I-Treatment
protocol I-Treatment
in O
increased I-Subject
- I-Subject
risk I-Subject
children I-Subject.Age
with I-Subject
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
and I-Subject
lymphoblastic I-Treat_Disorder
lymphoma I-Treat_Disorder
: O
results O
of O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
58881 O
randomized O
phase O
III O
trial O
. O

We O
report O
a I-Subject
case I-Subject
of O
fulminant I-Effect
hepatic I-Effect
failure I-Effect
associated I-Adverse_event.Trigger
with O
didanosine I-Treatment.Drug
and O
masquerading O
as O
a O
surgical O
abdomen O
and O
compare O
the O
clinical O
, O
biologic O
, O
histologic O
, O
and O
ultrastructural O
findings O
with O
reports O
described O
previously O
. O

An O
objective O
causal O
assessment O
suggests O
that O
rhabdomyolysis I-Effect
, I-Effect
renal I-Effect
failure I-Effect
, I-Effect
and I-Effect
possibly I-Effect
hepatotoxicity I-Effect
were O
probably O
related I-Adverse_event.Trigger
to O
an I-Treatment
amiodarone I-Treatment.Combination.Drug
- I-Treatment
simvastatin I-Treatment.Combination.Drug
interaction I-Treatment
. O

Nail I-Effect
staining I-Effect
from I-Adverse_event.Trigger
hydroquinone I-Treatment.Drug
cream I-Treatment.Route
. O

The O
development I-Adverse_event.Trigger
of O
an I-Effect
IgG I-Effect
lambda I-Effect
- I-Effect
type I-Effect
monoclonal I-Effect
gammopathy I-Effect
and I-Effect
subsequent I-Effect
multiple I-Effect
myeloma I-Effect
in O
an I-Subject
epilepsy I-Treat_Disorder
patient I-Subject
on O
diphenylhydantoin I-Treatment.Drug
( I-Treatment
DILANTIN I-Treatment
) I-Treatment
therapy I-Treatment
for I-Treatment.Duration
20 I-Treatment.Duration
years I-Treatment.Duration
is O
reported O
. O

Ibuprofen I-Treatment.Drug
overdose I-Treatment.Dosage
is O
usually O
characterized I-Adverse_event.Trigger
by O
GI I-Effect
upset I-Effect
, I-Effect
dizziness I-Effect
, I-Effect
and I-Effect
mild I-Effect
sedation I-Effect
. O

His I-Subject.Gender
PD I-Treat_Disorder
medications O
( O
pramipexole I-Treatment.Combination.Drug
, I-Treatment
entacapone I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
immediate I-Treatment
- I-Treatment
release I-Treatment
levodopa I-Treatment.Combination.Drug
/ I-Treatment
carbidopa I-Treatment.Combination.Drug
100 I-Treatment.Dosage
mg/25 I-Treatment.Dosage
mg I-Treatment.Dosage
, I-Treatment
1.5 I-Treatment.Dosage
tablets I-Treatment.Dosage
4 I-Treatment.Freq
times I-Treatment.Freq
daily I-Treatment.Freq
) O
were O
administered I-Potential_therapeutic_event.Trigger
via I-Treatment
nasogastric I-Treatment.Route
tube I-Treatment.Route
. O

CONCLUSIONS O
: O
This O
is O
the O
first O
report O
of O
a O
possible O
interaction O
between O
propafenone I-Treatment.Combination.Drug
and O
citalopram I-Treatment.Combination.Drug
, O
which O
caused I-Adverse_event.Trigger
propafenone O
adverse I-Effect
effects I-Effect
( I-Effect
eg I-Effect
, I-Effect
dizziness I-Effect
, I-Effect
falls I-Effect
) I-Effect
and I-Effect
mimicked I-Effect
coronary I-Effect
artery I-Effect
disease I-Effect
. O

We O
report O
the O
case O
of O
a I-Subject
young I-Subject.Age
healthy I-Subject
woman I-Subject.Gender
who O
presented I-Adverse_event.Trigger
an O
early I-Effect
overanticoagulation I-Effect
when O
receiving O
acenocoumarol I-Treatment.Drug
for O
a O
first O
thromboembolic I-Treat_Disorder
episode O
. O

A I-Subject
patient I-Subject
with O
acute I-Effect
changes I-Effect
suggesting I-Effect
acute I-Effect
hepatitis I-Effect
after I-Adverse_event.Trigger
parenteral I-Treatment
amiodarone I-Treatment.Drug
administration I-Treatment
is O
described O
. O

Subsequently O
, O
he O
developed O
hyperglycemia I-Effect
( O
fasting O
blood O
glucose O
138 O
mg O
/ O
dL O
) O
that O
resolved O
when O
olanzapine O
was O
stopped O
and O
recurred I-Effect
( I-Effect
fasting I-Effect
blood I-Effect
glucose I-Effect
150 I-Effect
mg I-Effect
/ I-Effect
dL I-Effect
) I-Effect
after I-Adverse_event.Trigger
2 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
of I-Treatment
rechallenge I-Treatment
with I-Treatment
olanzapine I-Treatment.Drug
2.5 I-Treatment.Dosage
mg I-Treatment.Dosage
twice I-Treatment.Freq
daily I-Treatment.Freq
. O

Fulminant I-Effect
hepatitis I-Effect
with I-Effect
severe I-Effect
lactate I-Effect
acidosis I-Effect
in O
HIV I-Treat_Disorder
- I-Subject
infected I-Subject
patients I-Subject
on I-Adverse_event.Trigger
didanosine I-Treatment.Drug
therapy O
. O

Persisent I-Effect
ocular I-Effect
hypertension I-Effect
following I-Adverse_event.Trigger
intravitreal I-Treatment
ranibizumab I-Treatment.Drug
. O

STUDY O
DESIGN O
: O
Case O
report O
of O
a I-Subject
31 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
who O
presented O
with O
toxic I-Effect
myelopathy I-Effect
due I-Adverse_event.Trigger
to O
intrathecal I-Treatment.Route
administration I-Treatment
of I-Treatment
doxorubicin I-Treatment.Drug
. I-Treatment

The I-Subject
patient I-Subject
had I-Subject
a I-Subject
background I-Subject
of I-Subject
obsessive I-Treat_Disorder
compulsive I-Treat_Disorder
disorder I-Treat_Disorder
treated I-Potential_therapeutic_event.Trigger
with O
paroxetine I-Treatment.Drug
. O

Clozapine I-Treatment.Drug
is O
speculated O
to O
cause I-Adverse_event.Trigger
rhabdomyolysis I-Effect
in O
patients I-Subject
with I-Subject
defective I-Subject.Sub_Disorder
calcium I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
activated I-Subject.Sub_Disorder
K+ I-Subject.Sub_Disorder
channels I-Subject.Sub_Disorder
. O

CONCLUSIONS O
: O
We O
report O
the O
first O
case O
of O
gemcitabine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
LABD I-Effect
. O

Nitrofurantoin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lung I-Effect
disease I-Effect
: O
two O
cases O
demonstrating O
resolution O
of O
apparently O
irreversible O
CT O
abnormalities O
. O

Trazodone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
transient I-Effect
hypomanic I-Effect
symptoms I-Effect
and O
their O
management O
. O

Acute I-Effect
aluminum I-Effect
toxicity I-Effect
after I-Adverse_event.Trigger
continuous I-Treatment
intravesical I-Treatment.Route
alum I-Treatment.Drug
irrigation I-Treatment.Route
for O
hemorrhagic I-Treat_Disorder
cystitis I-Treat_Disorder
. O

Amphotericin I-Treatment.Drug
B I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cutaneous I-Effect
leucocytoclastic I-Effect
vasculitis I-Effect
: O
case O
report O
. O

When O
measured O
, O
the O
serum I-Effect
lithium I-Combination.Drug
level I-Effect
had I-Effect
increased I-Effect
4 I-Effect
- I-Effect
fold I-Effect
during I-Adverse_event.Trigger
acyclovir I-Treatment.Combination.Drug
therapy O
. O

In O
this O
paper O
it O
is O
reported O
an O
evidence O
of O
pharmacokinetic I-Effect
interaction I-Effect
between I-Adverse_event.Trigger
clarithromycin I-Treatment.Combination.Drug
and I-Treatment
sirolimus I-Treatment.Combination.Drug
in O
a I-Subject
kidney I-Subject.Sub_Disorder
transplanted I-Subject.Sub_Disorder
woman I-Subject.Gender
, I-Subject
suffering I-Subject
from I-Subject
pulmonary I-Treat_Disorder
infection I-Treat_Disorder
sustained I-Subject
by I-Subject
a I-Subject
bacterial I-Subject
pathogen I-Subject
, I-Subject
in I-Subject
particular I-Subject
Hemophilus I-Subject
Influenzae I-Subject
. O

A I-Subject
25 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
a I-Subject
history I-Subject
of I-Subject
mid I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
borderline I-Subject.Sub_Disorder
( I-Subject.Sub_Disorder
BB I-Subject.Sub_Disorder
) I-Subject.Sub_Disorder
Hansen I-Subject.Sub_Disorder
's I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
developing O
a I-Effect
reversal I-Effect
reaction I-Effect
after I-Adverse_event.Trigger
starting O
dapsone I-Treatment.Combination.Drug
and I-Treatment
rifampin I-Treatment.Combination.Drug
therapy I-Treatment
is O
presented O
. O

In O
all O
cases O
, O
drugs O
in O
addition O
to O
quetiapine I-Drug
were O
detected O
, O
but O
in O
cases I-Subject
# I-Subject
1 I-Subject
and I-Subject
# I-Subject
2 I-Subject
, O
the O
cause I-Adverse_event.Trigger
of O
death I-Effect
was O
considered O
to O
be O
a O
quetiapine I-Treatment.Drug
overdose I-Treatment.Dosage
and O
the O
other O
drugs O
were O
not O
considered O
to O
be O
contributory O
. O

Similar O
to O
antiarrhythmic I-Drug
drugs I-Drug
aggravating O
particular O
arrhythmias O
, O
antiepileptic I-Treatment.Drug
drugs I-Treatment.Drug
can O
paradoxically O
induce I-Adverse_event.Trigger
new I-Effect
seizure I-Effect
types I-Effect
or I-Effect
exacerbate I-Effect
existing I-Effect
ones I-Effect
. O

We O
report O
here O
a O
rare O
case O
of O
ritodrine I-Treatment.Drug
- I-Treatment.Drug
hydrochloride I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
rhabdomyolysis I-Effect
in O
a O
pregnant I-Subject.Gender
patient I-Subject
with I-Subject
myotonic I-Treat_Disorder
dystrophy I-Treat_Disorder
. I-Subject

OBJECTIVE O
: O
To O
report O
the O
finding O
of O
squamous I-Effect
metaplasia I-Effect
within I-Effect
endometrial I-Effect
glands I-Effect
occurring O
as I-Adverse_event.Trigger
a I-Adverse_event.Trigger
result I-Adverse_event.Trigger
of I-Adverse_event.Trigger
progestin I-Treatment.Drug
therapy I-Treatment
of O
hyperplasia I-Treat_Disorder
. O

IMPLICATIONS O
FOR O
NURSING O
PRACTICE O
: O
Nurses O
must O
understand O
the O
pharmacology O
, O
mechanism O
of O
action O
, O
clinical O
presentation O
, O
potentially O
lethal O
risks O
, O
and O
traumatic O
psychosocial O
stresses O
experienced O
by O
DPD I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
deficient I-Subject.Sub_Disorder
patients I-Subject
with I-Subject
cancer I-Treat_Disorder
receiving I-Potential_therapeutic_event.Trigger
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
therapy I-Treatment
in O
order O
to O
develop O
timely O
interventions O
and O
alternative O
plans O
of O
care O
. O

Methotrexate I-Treatment.Drug
is O
an O
effective O
but O
potentially O
toxic O
treatment I-Potential_therapeutic_event.Trigger
for O
psoriasis I-Treat_Disorder
. O

Typical I-Effect
symptoms I-Effect
of I-Effect
active I-Effect
CD I-Effect
occurred I-Adverse_event.Trigger
11 I-Time_elapsed
, I-Time_elapsed
12 I-Time_elapsed
, I-Time_elapsed
and I-Time_elapsed
26 I-Time_elapsed
months I-Time_elapsed
after I-Time_elapsed
start I-Time_elapsed
of O
etanercept I-Treatment.Drug
therapy I-Treatment
, O
respectively O
. O

This O
progressed I-Adverse_event.Trigger
to O
tracheal I-Effect
compression I-Effect
with I-Effect
stridor I-Effect
after O
he I-Subject.Gender
had O
taken O
some O
aspirin I-Treatment.Drug
for O
relief O
of O
the O
neck I-Treat_Disorder
pain I-Treat_Disorder
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
toxin I-Drug
- I-Effect
positive I-Effect
Clostridium I-Effect
difficile I-Effect
- I-Effect
induced I-Effect
colitis I-Effect
( O
CDIC O
) O
after I-Adverse_event.Trigger
use O
of O
clindamycin I-Treatment.Drug
phosphate I-Treatment.Drug
vaginal I-Treatment.Route
cream I-Treatment.Route
. O

Severe O
vancomycin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
anaphylactic I-Effect
reaction I-Effect
. O

We O
report O
the O
case O
of O
a I-Subject
74 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
patient I-Subject
who O
received I-Potential_therapeutic_event.Trigger
the O
antide I-Treatment
- I-Treatment
pressant I-Treatment
amitriptyline I-Treatment.Drug
because O
of O
a I-Subject
major I-Treat_Disorder
depression I-Treat_Disorder
. O

Rhabdomyolysis I-Effect
has O
been O
recognized O
as O
a O
complication I-Adverse_event.Trigger
of O
tocolytic O
therapy O
with O
ritodrine I-Treatment.Drug
hydrochloride I-Treatment.Drug
. I-Drug

Voriconazole I-Treatment.Drug
( I-Treatment
VRC I-Treatment
) I-Treatment
has O
not O
previously O
been O
reported O
to O
cause I-Adverse_event.Trigger
angio I-Effect
- I-Effect
oedema I-Effect
. O

CONCLUSION O
: O
Tamoxifen I-Treatment.Drug
may O
cause I-Adverse_event.Trigger
malignant I-Effect
transformation I-Effect
of I-Effect
endometriosis I-Effect
through I-Effect
atypical I-Effect
endometriosis I-Effect
even O
in O
the O
postmenopausal O
state O
. O

One I-Subject.Population
patient I-Subject
had O
an O
episode O
of O
prostatitis I-Treat_Disorder
, O
which O
was O
treated I-Potential_therapeutic_event.Trigger
with O
levofloxacin I-Treatment.Combination.Drug
immediately O
prior O
to O
tolterodine I-Treatment.Combination.Drug
initiation O
. O

The I-Subject
first I-Subject
patient I-Subject
developed O
a O
monoarthritis I-Effect
2 O
weeks O
after O
initiation I-Adverse_event.Trigger
of O
IFN I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
, O
which O
persisted O
during O
the O
14 O
months O
of O
therapy O
and O
resolved O
with O
discontinuation O
of O
the O
medication O
. O

The O
present O
report O
illustrates O
a O
rare O
case O
of O
refractory I-Effect
akathisia I-Effect
after I-Adverse_event.Trigger
interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
treatment I-Treatment
and O
also O
that O
levodopa O
treatment O
would O
be O
theoretically O
and O
practically O
useful O
in O
reducing O
the O
neurotoxicity O
associated O
with O
interferon O
- O
alpha O
. O

Rosaceiform I-Effect
eruption I-Effect
induced I-Adverse_event.Trigger
by O
erlotinib I-Treatment.Drug
. I-Treatment

The O
incidence O
of O
oral I-Treatment.Route
- I-Treatment
verapamil I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypotension I-Effect
in I-Treatment
the I-Treatment
presence I-Treatment
of I-Treatment
concomitant I-Treatment
beta I-Treatment
- I-Treatment
adrenergic I-Treatment
blockade I-Treatment
by O
the O
oral I-Route
route O
is O
quite O
rare O
. O

Until O
additional O
data O
are O
available O
, O
if O
intravenous I-Treatment.Route
acyclovir I-Treatment.Combination.Drug
is I-Treatment
administered I-Treatment
concurrently I-Treatment
with I-Treatment
lithium I-Treatment.Combination.Drug
, O
we O
recommend O
closely O
monitoring O
patients O
for O
signs I-Adverse_event.Trigger
of O
lithium I-Effect
toxicity I-Effect
and O
measuring O
serum O
lithium O
levels O
every O
second O
or O
third O
day O
. O

Disappointingly O
, O
with O
the O
dose O
schedule O
used O
in O
this O
protocol O
, O
HD I-Treatment.Combination.Drug
Ara I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
C I-Treatment.Combination.Drug
added O
to O
HD I-Treatment.Combination.Drug
MTX I-Treatment.Combination.Drug
, O
although O
well O
tolerated O
, O
failed I-Adverse_event.Trigger
to O
further I-Effect
decrease I-Effect
the I-Effect
incidence I-Effect
of I-Effect
CNS I-Effect
relapse I-Effect
or I-Effect
to I-Effect
improve I-Effect
the I-Effect
overall I-Effect
DFS I-Effect
. O

Theophylline I-Combination.Drug
intoxication I-Effect
following I-Adverse_event.Trigger
viloxazine I-Treatment.Combination.Drug
induced O
decrease O
in O
clearance O
. O

Cercarial O
encystment O
at O
concentrations O
of O
25000 O
microg O
/ O
l O
or O
higher O
was O
significantly O
impaired O
by O
all O
test O
metals O
; O
however O
, O
at O
lower I-Treatment.Dosage
concentrations I-Treatment.Dosage
only O
zinc I-Treatment.Drug
demonstrated I-Adverse_event.Trigger
toxicity I-Effect
. O

PURPOSE O
: O
We O
report O
an O
unusual I-Effect
paradoxical I-Effect
effect I-Effect
of I-Adverse_event.Trigger
brimonidine I-Treatment.Drug
. O

Renal I-Effect
failure I-Effect
after I-Adverse_event.Trigger
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
methotrexate I-Treatment.Drug
in O
a I-Subject
child I-Subject.Age
homozygous I-Subject.Sub_Disorder
for I-Subject.Sub_Disorder
MTHFR I-Subject.Sub_Disorder
C677 I-Subject.Sub_Disorder
T I-Subject.Sub_Disorder
polymorphism I-Subject.Sub_Disorder
. O

Although O
his O
renal O
function O
recovered I-Potential_therapeutic_event.Trigger
completely O
with O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
leucovorin I-Treatment.Combination.Drug
, I-Treatment
hemodialysis I-Treatment.Combination.Drug
, I-Treatment
charcoal I-Treatment.Combination.Drug
hemoperfusion I-Treatment.Route
, I-Treatment
and I-Treatment
carboxypeptidase I-Treatment.Combination.Drug
G2 I-Treatment.Combination.Drug
, O
we O
present O
this O
case O
to O
emphasize O
that O
signs O
of O
renal I-Treat_Disorder
toxicity I-Treat_Disorder
may O
be O
present O
as O
early O
as O
2 O
hours O
after O
the O
completion O
of O
a O
4 O
- O
hour O
MTX O
infusion O
, O
and O
to O
suggest O
that O
monitoring O
for O
MTX O
toxicity O
should O
perhaps O
begin O
within O
a O
few O
hours O
after O
the O
completion O
of O
4 O
- O
hour O
MTX O
infusion O
. O

Ten I-Subject.Population
to I-Subject.Population
15 I-Subject.Population
% I-Subject.Population
of I-Subject
patients I-Subject
treated O
with O
ifosfamide I-Treatment.Drug
develop I-Adverse_event.Trigger
an O
encephalopathy I-Effect
. I-Effect

METHODS O
: O
We O
queried O
35 O
rheumatologists O
at O
the O
Robert O
Breck O
Brigham O
Arthritis O
Center O
to O
determine O
if O
weight I-Effect
loss I-Effect
had O
occurred I-Adverse_event.Trigger
as O
an O
adverse O
event O
in O
patients I-Subject
treated O
with O
leflunomide I-Treatment.Drug
between O
November O
1998 O
and O
January O
2000 O
. O

This O
is O
the O
first O
report O
of O
a O
catatonic I-Effect
syndrome I-Effect
occurring I-Adverse_event.Trigger
in O
a O
patient O
receiving O
disulfiram I-Treatment.Drug
treatment I-Treatment
. O

Management I-Potential_therapeutic_event.Trigger
of O
hypophosphatemia I-Treat_Disorder
induced O
by O
high O
- O
flux O
hemodiafiltration O
for O
the O
treatment O
of O
vancomycin O
toxicity O
: O
intravenous I-Treatment.Route
phosphorus I-Treatment.Drug
therapy O
versus O
use O
of O
a O
phosphorus I-Treatment.Drug
- I-Treatment
enriched I-Treatment
dialysate I-Treatment.Route
. O

Two I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
following I-Treatment.Time_elapsed
rechallenge O
with O
alendronate I-Treatment.Drug
sodium I-Treatment.Drug
resulted I-Adverse_event.Trigger
in O
recurrence O
of O
his O
scleritis I-Effect
. O

We O
believe O
this O
is O
the O
first O
report O
of O
intrathecal I-Treatment.Route
diamorphine I-Treatment.Drug
causing I-Adverse_event.Trigger
anaphylaxis I-Effect
. O

Clearance O
rates O
of O
cerivastatin O
metabolites O
in O
a O
patient O
with O
cerivastatin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
rhabdomyolysis I-Effect
. O

This O
case O
report O
and O
several O
others O
point O
toward O
azathioprine I-Treatment.Drug
as O
a O
clinically O
significant O
inducer I-Adverse_event.Trigger
of O
warfarin I-Drug
resistance I-Effect
. O

PURPOSE O
: O
To O
report O
a O
case O
of O
nodular I-Effect
scleritis I-Effect
following I-Adverse_event.Trigger
alendronate I-Treatment.Drug
sodium I-Treatment.Drug
. O

Most I-Subject
cardiac I-Subject.Sub_Disorder
surgical I-Subject.Sub_Disorder
patients I-Subject
have O
had O
previous O
exposure O
to O
heparin I-Treatment.Drug
for O
diagnostic O
or O
therapeutic O
interventions O
and O
hence O
have O
an O
increased O
susceptibility O
to O
developing I-Adverse_event.Trigger
heparin I-Effect
- I-Effect
induced I-Effect
thrombocytopenia I-Effect
( I-Effect
HIT I-Effect
) I-Effect
postoperatively O
. O

PURPOSE O
: O
We O
studied O
a I-Subject
case I-Subject
of O
vortex I-Effect
keratopathy I-Effect
that O
was O
associated I-Adverse_event.Trigger
with O
the O
use O
of O
atovaquone I-Treatment.Drug
. O

While O
on O
a O
maximal I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
phenylephrine I-Treatment.Drug
she I-Subject.Gender
developed I-Adverse_event.Trigger
prominent O
positive I-Effect
U I-Effect
waves I-Effect
, O
which O
disappeared O
with O
the O
cessation O
of O
the O
drug O
. O

RESULTS O
: O
Two I-Subject.Population
patients I-Subject
with I-Subject
ocular I-Subject.Sub_Disorder
inflammation I-Subject.Sub_Disorder
of O
unknown O
origin O
developed I-Adverse_event.Trigger
severe I-Effect
chorioretinitis I-Effect
after O
IVTA I-Treatment.Drug
injection I-Treatment.Route
. O

Disopyramide I-Treatment.Drug
was O
started I-Potential_therapeutic_event.Trigger
on O
admission O
for O
supraventricular I-Treat_Disorder
tachycardia I-Treat_Disorder
. O

A I-Subject
50 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
a I-Subject
history I-Subject
of I-Subject
migraine I-Treat_Disorder
without I-Treat_Disorder
aura I-Treat_Disorder
, I-Subject
predominantly I-Subject
occurring I-Subject
around I-Subject
her I-Subject
menstrual I-Subject
periods I-Subject
, O
developed I-Adverse_event.Trigger
a I-Effect
spinal I-Effect
cord I-Effect
lesion I-Effect
following O
the O
use O
of O
zolmitriptan I-Treatment.Drug
. O

The O
skin I-Effect
rash I-Effect
effect I-Effect
was O
most O
probably O
due I-Adverse_event.Trigger
, O
in O
first O
line O
, O
to O
olanzapine I-Treatment.Combination.Drug
, I-Treatment
but O
the O
cutaneous I-Effect
skin I-Effect
condition I-Effect
was O
triggered O
and O
aggravated O
by I-Treatment
pravastatin I-Treatment.Combination.Drug
, I-Treatment
a I-Treatment
3 I-Treatment
- I-Treatment
hydoxy I-Treatment
- I-Treatment
3 I-Treatment
- I-Treatment
methylglutaryl I-Treatment
- I-Treatment
coenzyme I-Treatment
A I-Treatment
- I-Treatment
(HMG I-Treatment
- I-Treatment
CoA) I-Treatment
- I-Treatment
reductase I-Treatment
inhibitor I-Treatment
, I-Treatment
and I-Treatment
lithium I-Treatment.Combination.Drug
medication O
. O

CONCLUSION O
: O
Anterior I-Effect
ischemic I-Effect
optic I-Effect
neuropathy I-Effect
may O
complicate I-Adverse_event.Trigger
treatment O
with O
interferon I-Treatment.Drug
alfa I-Treatment.Drug
. O

After I-Treatment
5 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
of I-Treatment
therapy I-Treatment
, O
she O
stopped O
taking I-Treatment
pantoprazole I-Treatment.Drug
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
general I-Effect
malaise I-Effect
. O

We O
report O
the O
use O
of O
pamidronate I-Treatment.Drug
for I-Potential_therapeutic_event.Trigger
acute I-Treat_Disorder
, I-Treat_Disorder
severe I-Treat_Disorder
hypercalcemia I-Treat_Disorder
secondary I-Treat_Disorder
to I-Treat_Disorder
iatrogenic I-Treat_Disorder
vitamin I-Treat_Disorder
D I-Treat_Disorder
poisoning I-Treat_Disorder
. O

According O
to O
the O
Naranjo O
probability O
scale O
, O
the O
relationship O
of O
gemcitabine I-Treatment.Drug
treatment I-Treatment
with I-Adverse_event.Trigger
cutaneous I-Effect
eruption I-Effect
in O
our I-Subject
patient I-Subject
is O
possible O
. O

Methylene I-Treatment.Drug
blue I-Treatment.Drug
was O
administered I-Potential_therapeutic_event.Trigger
to I-Potential_therapeutic_event.Trigger
a I-Subject
58 I-Subject.Age
- I-Subject.Age
yr I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
undergoing I-Subject
a I-Subject
parathyroidectomy I-Subject
under I-Subject
general I-Subject
anesthesia I-Subject
. O

We O
describe O
two O
cases O
that O
illustrate O
the O
use O
of O
lithium I-Treatment.Drug
in O
the O
treatment O
of O
veterans I-Subject
with I-Subject
PTSD I-Treat_Disorder
who O
complained I-Adverse_event.Trigger
of I-Adverse_event.Trigger
serious I-Effect
problems I-Effect
with I-Effect
irritability I-Effect
or I-Effect
angry I-Effect
outbursts I-Effect
. O

It O
is O
well O
- O
recognized O
that O
flucloxacillin I-Treatment.Drug
may O
occasionally O
result I-Adverse_event.Trigger
in O
fatal O
hepatic I-Effect
injury I-Effect
. O

Neurologic I-Effect
toxicity I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
hepatic I-Treatment.Route
artery I-Treatment.Route
infusion I-Treatment.Route
HAI I-Treatment
of I-Treatment
FUdR. I-Treatment.Drug

Hyperkalemia I-Effect
as O
a O
late O
side O
effect O
of I-Adverse_event.Trigger
prolonged O
adrenocorticotropic I-Treatment.Drug
hormone I-Treatment.Drug
therapy O
for O
infantile I-Treat_Disorder
spasms I-Treat_Disorder
. O

METHODS O
: O
We O
report O
two I-Subject.Population
cases I-Subject
of O
pseudoporphyria I-Effect
caused I-Adverse_event.Trigger
by O
naproxen I-Treatment.Combination.Drug
and I-Treatment
oxaprozin I-Treatment.Combination.Drug
. O

She I-Subject.Gender
was O
treated I-Potential_therapeutic_event.Trigger
with O
an O
average I-Treatment
weekly I-Treatment.Freq
warfarin I-Treatment.Drug
dose I-Treatment
of I-Treatment
39 I-Treatment.Dosage
mg I-Treatment.Dosage
( I-Treatment
5.5 I-Treatment.Dosage
mg I-Treatment.Dosage
daily I-Treatment.Freq
) I-Treatment
prior I-Treatment
to I-Treatment
beginning I-Treatment
azathioprine I-Treatment.Drug
therapy I-Treatment
. O

When O
the O
disease O
recurred O
conventional O
amphotericin I-Treatment.Drug
B I-Treatment.Drug
was O
used O
again O
, O
but O
had O
to O
be O
stopped O
because O
of I-Adverse_event.Trigger
severe O
side I-Effect
effects I-Effect
. O

Widespread O
cutaneous I-Effect
vasculitis I-Effect
associated I-Adverse_event.Trigger
with O
diltiazem I-Treatment.Drug
. O

The O
following O
describes O
a I-Subject
patient I-Subject
on I-Treatment
a I-Treatment
stable I-Treatment
regimen I-Treatment
of I-Treatment
warfarin I-Treatment.Drug
who O
developed I-Adverse_event.Trigger
severe O
hypoprothrombinemia I-Effect
and I-Effect
bleeding I-Effect
4 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
starting I-Treatment
gemfibrozil I-Treatment.Drug
. O

We O
report O
the O
case O
of O
a I-Subject
40 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
who O
developed I-Adverse_event.Trigger
fulminant I-Effect
hepatic I-Effect
failure I-Effect
and I-Effect
aplastic I-Effect
anaemia I-Effect
following O
a I-Treatment.Duration
course I-Treatment.Duration
of I-Treatment
oral I-Treatment.Route
flucloxacillin I-Treatment.Drug
. O

This I-Subject
case I-Subject
highlights O
the O
possible O
development I-Adverse_event.Trigger
of O
acute I-Effect
coronary I-Effect
syndrome I-Effect
as O
a O
side O
effect O
of O
Capecitabine I-Treatment.Drug
therapy O
. O

These O
results O
indicate O
that O
lithium I-Treatment.Drug
may I-Adverse_event.Trigger
cause O
biochemical I-Effect
hyperparathyroidism I-Effect
. O

The O
relationship O
between I-Adverse_event.Trigger
infliximab I-Treatment.Drug
treatment O
and O
lymphoma I-Effect
in O
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
. O

CONCLUSION O
: O
There O
may O
be O
an O
association I-Adverse_event.Trigger
between O
raloxifene I-Treatment.Drug
and O
the O
development O
of O
malignant I-Effect
mixed I-Effect
mesodermal I-Effect
tumor I-Effect
. O

Early O
recognition I-Adverse_event.Trigger
of O
renal I-Effect
toxicity I-Effect
of O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
methotrexate I-Treatment.Drug
therapy I-Treatment
: O
a O
case O
report O
. O

The O
mild I-Effect
immunosuppression I-Effect
that O
occurs O
with O
methotrexate I-Treatment.Drug
therapy O
probably O
places O
patients I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
at O
added O
risk O
of O
developing I-Adverse_event.Trigger
lymphoproliferative I-Effect
diseases I-Effect
, O
but O
coincidence O
can O
not O
be O
excluded O
. O

We O
attribute I-Adverse_event.Trigger
the O
clinical O
and O
radiographic O
findings O
to O
cytotoxic I-Effect
edema I-Effect
secondary O
to O
intrathecal I-Treatment
methotrexate I-Treatment.Drug
. O

Morphine I-Treatment.Drug
, O
an O
opium O
alkaloid O
, O
frequently O
causes I-Adverse_event.Trigger
side O
effects O
such O
as O
hyperhidrosis I-Effect
and O
facial I-Effect
flushing I-Effect
, O
but O
serious O
cutaneous O
adverse O
drug O
reactions O
are O
seldom O
observed O
. O

Severe I-Effect
aphthous I-Effect
stomatitis I-Effect
associated I-Adverse_event.Trigger
with O
oral I-Treatment.Route
calcineurin I-Treatment.Combination.Drug
and I-Treatment
mTOR I-Treatment.Combination.Drug
inhibitors I-Treatment.Combination.Drug
. O

A I-Subject
79 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
ischemic I-Subject.Sub_Disorder
heart I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
, I-Subject
chronic I-Subject.Sub_Disorder
atrial I-Subject.Sub_Disorder
fibrillation I-Subject.Sub_Disorder
, I-Subject
chronic I-Subject.Sub_Disorder
renal I-Subject.Sub_Disorder
failure I-Subject.Sub_Disorder
, I-Subject
hypothyroidism I-Subject.Sub_Disorder
, I-Subject
and I-Subject
gout I-Treat_Disorder
arthritis I-Treat_Disorder
was O
hospitalized O
because O
of O
fatigue I-Effect
, I-Effect
myalgia I-Effect
, I-Effect
and I-Effect
leg I-Effect
weakness I-Effect
, O
shortly I-Time_elapsed
after I-Adverse_event.Trigger
starting O
treatment I-Treatment
with I-Treatment
colchicine I-Treatment.Drug
. O

This O
report O
describes O
a O
case O
of O
paradoxical O
, O
intravenous I-Treatment.Route
valproic I-Treatment.Drug
acid I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
seizure I-Effect
exacerbation I-Effect
in O
a I-Subject
child I-Subject.Age
with I-Subject
juvenile I-Treat_Disorder
absence I-Treat_Disorder
epilepsy I-Treat_Disorder
, O
documented O
by O
video O
- O
electroencephalography O
. O

She I-Subject.Gender
was O
treated O
with O
acyclovir I-Treatment.Drug
and O
subsequently O
developed I-Adverse_event.Trigger
VZV I-Effect
antigen I-Effect
- I-Effect
positive I-Effect
zoster I-Effect
. O

CONCLUSIONS O
: O
In O
these O
3 O
cases O
, O
the O
unique O
positive O
ocular O
finding O
was O
corneal I-Effect
endothelial I-Effect
deposits I-Effect
, O
which O
may O
be O
related I-Adverse_event.Trigger
to O
the O
use O
of O
rifabutin I-Treatment.Drug
. O

Response O
of O
a O
promethazine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
coma I-Effect
to O
flumazenil O
. O

First O
, O
a O
review O
of O
the O
literature O
produced O
41 I-Subject.Population
anecdotic I-Subject
cases I-Subject
of O
neutropenia I-Effect
or I-Effect
agranulocytosis I-Effect
during I-Adverse_event.Trigger
treatment O
with O
olanzapine I-Treatment.Drug
( I-Treatment
Zyprexa I-Treatment
) I-Treatment
reported O
in O
a O
total O
of O
24 O
publications O
. O

Neurologic I-Effect
degeneration I-Effect
associated I-Adverse_event.Trigger
with O
nitrous I-Treatment.Drug
oxide I-Treatment.Drug
anesthesia I-Treatment
in O
patients I-Subject
with I-Subject
vitamin I-Subject.Sub_Disorder
B12 I-Subject.Sub_Disorder
deficiency I-Subject.Sub_Disorder
. O

Previous O
therapy O
with O
antiarrhythmics I-Treatment.Drug
had O
resulted I-Adverse_event.Trigger
in O
intolerable I-Effect
adverse I-Effect
effects I-Effect
or O
no O
effect O
on O
the O
arrhythmia I-Treat_Disorder
. O

Allergic I-Effect
contact I-Effect
dermatitis I-Effect
to I-Adverse_event.Trigger
compound I-Treatment
tincture I-Treatment
of I-Treatment
benzoin I-Treatment.Drug
. O

PURPOSE O
: O
To O
determine O
the O
cause O
of O
spontaneous I-Effect
choroidal I-Effect
hemorrhage I-Effect
in I-Adverse_event.Trigger
a O
67 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
after I-Subject
a I-Subject
myocardial I-Treat_Disorder
infarction I-Treat_Disorder
and O
administration O
of O
tissue I-Treatment.Drug
plasminogen I-Treatment.Drug
activator I-Treatment.Drug
. O

Forty I-Effect
- I-Effect
one I-Effect
days I-Effect
later I-Effect
, O
she I-Subject.Gender
developed I-Adverse_event.Trigger
severe I-Effect
iatrogenic I-Effect
Cushing I-Effect
's I-Effect
syndrome I-Effect
due O
to O
the O
drug O
- O
drug O
interaction O
between O
triamcinolone I-Treatment.Combination.Drug
and I-Treatment
her I-Treatment
boosted I-Treatment
protease I-Treatment.Combination.Drug
inhibitor I-Treatment.Combination.Drug
therapy O
. O

Pheripheral I-Effect
edema I-Effect
was O
observed O
in O
five I-Subject.Population
female I-Subject.Gender
patients I-Subject
after O
taking I-Adverse_event.Trigger
proton O
pump O
inhibitors O
omeprazole I-Treatment.Drug
, I-Treatment
lansoprazole I-Treatment.Drug
, I-Treatment
or I-Treatment
pantoprazole I-Treatment.Drug
for O
7 I-Freq
- I-Freq
15 I-Freq
days I-Freq
for O
peptic I-Treat_Disorder
acid I-Treat_Disorder
diseases I-Treat_Disorder
in O
recommended O
standard I-Dosage
doses I-Dosage
. I-Dosage

We O
report O
the O
case O
of O
a I-Subject
child I-Subject.Age
with I-Subject
metastatic I-Subject
osteosarcoma I-Subject
, O
who O
experienced I-Adverse_event.Trigger
an O
anaphylactic I-Effect
/ I-Effect
anaphylactoid I-Effect
reaction I-Effect
to O
methotrexate I-Treatment.Drug
. O

It O
is O
tempting O
to O
speculate O
that O
interferon I-Treatment.Drug
alpha I-Treatment.Drug
may O
be O
involved I-Adverse_event.Trigger
in O
the O
pathogenesis O
of O
lichen I-Effect
nitidus I-Effect
. O

CONCLUSION O
: O
Alendronate I-Treatment.Drug
led I-Adverse_event.Trigger
to I-Adverse_event.Trigger
nodular I-Effect
scleritis I-Effect
and O
rechallenge O
caused O
recurrence O
of O
scleritis O
. O

A I-Subject
massive I-Treat_Disorder
digitoxin I-Treat_Disorder
( I-Treat_Disorder
DGTX I-Treat_Disorder
) I-Treat_Disorder
intoxication I-Treat_Disorder
in I-Subject
a I-Subject
36 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
( I-Subject
35 I-Subject
mg I-Subject
DGTX I-Subject
) I-Subject
was O
treated I-Potential_therapeutic_event.Trigger
by O
prolonged I-Treatment
and I-Treatment
repeated I-Treatment
i.v I-Treatment.Route
.- I-Treatment.Route
infusions I-Treatment.Route
of I-Treatment
Fab I-Treatment
fragments I-Treatment
of I-Treatment
anti I-Treatment.Drug
- I-Treatment.Drug
digitalis I-Treatment.Drug
antibodies I-Treatment.Drug
( I-Treatment
FAB I-Treatment
) I-Treatment
. O

Gold I-Treatment.Drug
- I-Treatment.Drug
salt I-Treatment.Drug
therapy O
may O
result I-Adverse_event.Trigger
in O
damage I-Effect
to I-Effect
proximal I-Effect
tubules I-Effect
that O
leak O
renal O
tubular O
antigens O
, O
which O
in O
turn O
complex O
with O
autoantibody O
and O
produce O
an O
autoimmune O
membranous O
nephropathy O
. O

Only O
two O
case O
reports O
of O
adults O
with O
allergic O
contact O
dermatitis O
to O
this O
chemical O
exist O
in O
the O
literature O
, O
and O
we O
describe O
three I-Subject.Population
more I-Subject
cases I-Subject
of I-Subject
children I-Subject.Age
with I-Subject
recalcitrant I-Treat_Disorder
atopic I-Treat_Disorder
dermatitis I-Treat_Disorder
found O
to O
have I-Adverse_event.Trigger
potential I-Effect
allergic I-Effect
contact I-Effect
dermatitis I-Effect
to O
bisabolol I-Treatment.Drug
- I-Treatment
a I-Treatment
component I-Treatment
of I-Treatment
the I-Treatment
Aquaphor I-Treatment
emollient I-Treatment
they O
were O
using O
to O
treat O
their O
atopic O
dermatitis O
. O

Recently O
, O
CD20 I-Effect
- I-Effect
negative I-Effect
tumors I-Effect
have O
been O
described O
after I-Adverse_event.Trigger
Rituximab I-Treatment.Drug
therapy O
. O

A I-Subject
48 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
who O
was O
treated O
for O
thyrotoxicosis I-Treat_Disorder
with O
methimazole I-Treatment.Drug
developed I-Adverse_event.Trigger
agranulocytosis I-Effect
. O

Methylene O
blue O
in O
the O
treatment O
and O
prevention O
of O
ifosfamide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
encephalopathy I-Effect
: O
report O
of O
12 O
cases O
and O
a O
review O
of O
the O
literature O
. O

We O
report O
a O
case O
of O
a I-Subject
women I-Subject.Gender
in O
whom O
a I-Effect
malignant I-Effect
mixed I-Effect
mesodermal I-Effect
tumor I-Effect
was O
diagnosed I-Adverse_event.Trigger
while I-Treatment
she I-Treatment
was I-Treatment
taking I-Treatment
raloxifene I-Treatment.Drug
, O
which O
is O
also O
a O
selective O
estrogen O
receptor O
modulator O
. O

Interactions I-Treatment
between I-Treatment
warfarin I-Treatment.Combination.Drug
and I-Treatment
cloxacillin I-Treatment.Combination.Drug
can O
result I-Adverse_event.Trigger
in O
serious I-Effect
adverse I-Effect
reactions I-Effect
. O

However O
, O
a O
large O
case O
- O
control O
study O
included O
three I-Subject.Population
cases I-Subject
of O
either O
Stevens I-Effect
- I-Effect
Johnson I-Effect
syndrome I-Effect
or I-Effect
toxic I-Effect
epidermal I-Effect
necrolysis I-Effect
associated I-Adverse_event.Trigger
with O
ofloxacin I-Treatment.Drug
use O
, O
but O
no O
details O
of O
the O
cases O
were O
given O
. O

Acetazolamide I-Treatment.Drug
may O
have O
accelerated I-Adverse_event.Trigger
the O
development O
of O
osteomalacia I-Effect
by O
several O
mechanisms O
, O
including O
increased O
renal O
calcium O
excretion O
. O

In O
conclusion O
, O
RSDS I-Effect
is O
a O
relevant O
osteoarticular I-Adverse_event.Trigger
complication I-Adverse_event.Trigger
in O
patients O
receiving O
either O
anticalcineurinic I-Treatment
drug I-Treatment
( I-Treatment
CyA I-Treatment.Drug
or I-Treatment
tacrolimus I-Treatment.Drug
) I-Treatment
, O
even O
under O
monotherapy O
or O
with O
a O
low O
steroid O
dose O
. O

There O
have O
been O
several O
reported O
cases O
of O
omeprazole I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
AIN I-Effect
. O

This O
interaction O
may O
be O
overlooked O
by O
clinicians O
, O
which O
may O
result I-Adverse_event.Trigger
in I-Adverse_event.Trigger
a O
serious I-Effect
bleeding I-Effect
risk I-Effect
for O
patients I-Subject
on O
warfarin I-Treatment.Drug
. O

Adriamycin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cardiomyopathy I-Effect
aggravated O
by O
cis O
- O
platinum O
nephrotoxicity O
requiring O
dialysis O
. O

An I-Subject
11 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
who O
was O
treated O
with O
a O
relatively I-Treatment.Dosage
high I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
methotrimeprazine I-Treatment.Drug
meleate I-Treatment.Drug
( I-Treatment
Levemepromazine I-Treatment
) I-Treatment
a O
phenothiazine O
antipsychotic O
drug O
, O
was O
admitted O
to O
the O
pediatric O
intensive O
care O
unit O
suffering I-Adverse_event.Trigger
from O
respiratory I-Effect
distress I-Effect
syndrome I-Effect
. O

An I-Subject
adult I-Subject.Age
male I-Subject.Gender
presented I-Adverse_event.Trigger
with O
central I-Effect
blindness I-Effect
after O
ingesting I-Treatment.Route
methanol I-Treatment.Drug
. O

All O
developed O
mucocutaneous I-Effect
side I-Effect
effects I-Effect
within I-Time_elapsed
20 I-Time_elapsed
weeks I-Time_elapsed
of O
beginning I-Adverse_event.Trigger
i I-Treatment.Route
m I-Treatment.Route
gold I-Treatment.Drug
therapy I-Treatment
, O
at O
a O
time O
when O
RA I-Treat_Disorder
had O
improved O
markedly O
compared O
to O
pretreatment O
status O
. O

Two I-Subject.Population
children I-Subject
, I-Subject
1 I-Subject
with I-Subject
idiopathic I-Treat_Disorder
nephrotic I-Treat_Disorder
syndrome I-Treat_Disorder
and I-Subject
1 I-Subject
with I-Subject
endo I-Treat_Disorder
- I-Treat_Disorder
extracapillary I-Treat_Disorder
glomerulonephritis I-Treat_Disorder
, I-Treat_Disorder
presented O
an O
episode O
of O
seizures I-Effect
and I-Effect
transient I-Effect
blindness I-Effect
at O
different O
times O
after I-Adverse_event.Trigger
i.v I-Treatment.Route
. I-Treatment.Route
pulse I-Treatment.Route
methylprednisolone I-Treatment.Drug
( I-Treatment
IVPMP I-Treatment
) I-Treatment
treatment I-Treatment
. O

Stevens I-Effect
- I-Effect
Johnson I-Effect
syndrome I-Effect
in O
a I-Subject
boy I-Subject.Gender
with I-Subject
nephrotic I-Treat_Disorder
syndrome I-Treat_Disorder
during I-Adverse_event.Trigger
prednisolone I-Treatment.Drug
therapy O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
an O
angio I-Effect
- I-Effect
oedema I-Effect
associated I-Adverse_event.Trigger
with O
VRC I-Treatment.Drug
. O

Insulin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cardiac I-Effect
failure I-Effect
. O

The I-Effect
symptoms I-Effect
disappeared I-Effect
with O
clemastine I-Treatment.Combination.Drug
and I-Treatment
betametasone I-Treatment.Combination.Drug
treatment O
. O

This O
report O
rules O
out O
other O
causes O
of O
toxic O
epidermal O
necrolysis O
and O
implicates O
ofloxacin I-Treatment.Drug
in O
what O
appears O
to O
be O
an O
atypical O
presentation O
of O
drug I-Adverse_event.Trigger
- I-Adverse_event.Trigger
induced I-Adverse_event.Trigger
toxic I-Effect
epidermal I-Effect
necrolysis I-Effect
. O

Controversy O
concerning O
the O
nephrotoxicity I-Effect
of I-Adverse_event.Trigger
lithium I-Treatment.Drug
is O
discussed O
, O
and O
recommendations O
for O
the O
evaluation I-Effect
of I-Effect
renal I-Effect
failure I-Effect
during O
lithium O
therapy O
are O
provided O
. O

A I-Subject
56 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
parkinsonian I-Subject.Sub_Disorder
patient I-Subject
developed I-Adverse_event.Trigger
a I-Effect
unique I-Effect
behavioral I-Effect
change I-Effect
following O
the I-Treatment
oral I-Treatment.Route
administration I-Treatment.Route
of I-Treatment
cinepazide I-Treatment.Drug
, I-Treatment
a I-Treatment
cerebral I-Treatment
vasodilator I-Treatment
. O

The O
currently O
available O
clinical O
and O
neuropharmacologic O
data O
suggest O
that O
carbamazepine I-Treatment.Drug
may O
be O
an O
antagonist O
of O
dopamine O
and O
that O
this O
property O
is O
responsible I-Adverse_event.Trigger
for O
the O
production O
of O
dystonia I-Effect
. O

Metamizole I-Treatment.Drug
, O
a O
nonsteroidal O
antiinflammatory O
agent O
, O
is O
prohibited O
in O
the O
United O
States O
because O
of O
the O
risk I-Adverse_event.Trigger
of O
agranulocytosis I-Effect
but O
is O
widely O
used O
in O
Mexico O
and O
other O
countries O
. O

We O
conclude O
that O
the O
use O
of O
hemopoietic O
colony O
stimulating O
factors O
might O
be O
a O
suitable O
means O
to O
achieve O
the O
correction O
of O
severe O
thionamide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hematologic I-Effect
adverse I-Effect
reactions I-Effect
. I-Effect

Two I-Subject.Population
case I-Subject
reports I-Subject
of I-Subject
bilateral I-Subject.Sub_Disorder
granulomatous I-Subject.Sub_Disorder
anterior I-Subject.Sub_Disorder
uveitis I-Subject.Sub_Disorder
are O
described O
in O
patients I-Subject
with I-Subject
open I-Treat_Disorder
angle I-Treat_Disorder
glaucoma I-Treat_Disorder
treated I-Adverse_event.Trigger
with O
metripranolol I-Treatment.Drug
0.6 I-Treatment.Dosage
% I-Treatment.Dosage
eye I-Treatment.Route
drops I-Treatment.Route
. O

Regardless O
of O
a O
negative O
history O
of O
asthma O
, O
therefore O
, O
life I-Effect
- I-Effect
threatening I-Effect
bronchospasm I-Effect
must O
be O
considered O
a O
possible O
complication I-Adverse_event.Trigger
of O
propranolol I-Treatment.Drug
therapy O
. O

In O
the O
present O
paper O
the O
authors O
describe O
2 I-Subject.Population
female I-Subject.Gender
patients I-Subject
who O
developed I-Adverse_event.Trigger
incontinence I-Effect
secondary O
to O
the I-Treatment
selective I-Treatment
serotonin I-Treatment
reuptake I-Treatment
inhibitors I-Treatment
paroxetine I-Treatment.Combination.Drug
and I-Treatment
sertraline I-Treatment.Combination.Drug
, O
as O
well O
as O
a O
third O
who O
developed O
this O
side O
effect O
on O
venlafaxine I-Drug
. O

Presented O
is O
a O
case O
story O
of O
a I-Subject
woman I-Subject.Gender
with I-Subject
classical I-Treat_Disorder
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
, O
who O
during I-Treatment
introduction I-Treatment
of I-Treatment
sulphasalazine I-Treatment.Drug
( I-Treatment
SASP I-Treatment
) I-Treatment
therapy I-Treatment
developed I-Adverse_event.Trigger
a O
severe O
and O
lasting O
psoriasis I-Effect
- I-Effect
like I-Effect
skin I-Effect
reaction I-Effect
. O

Interstitial I-Effect
granulomatous I-Effect
dermatitis I-Effect
associated I-Adverse_event.Trigger
with O
darifenacin I-Treatment.Drug
. O

Reversal O
of O
severe O
methanol I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
visual I-Effect
impairment I-Effect
: O
no O
evidence O
of O
retinal O
toxicity O
due O
to O
fomepizole O
. O

Proton I-Treatment.Drug
- I-Treatment.Drug
pump I-Treatment.Drug
inhibitors I-Treatment.Drug
( I-Treatment.Drug
PPIs I-Treatment.Drug
) I-Treatment.Drug
are O
believed I-Potential_therapeutic_event.Trigger
to O
decrease O
the O
risk O
of O
such O
complications O
, O
though O
no O
randomized O
trial O
has O
proved O
this O
in O
patients O
receiving O
dual O
antiplatelet I-Drug
therapy O
. O

The O
clinical O
course O
suggests O
that O
caffeine I-Treatment.Drug
, I-Treatment
which I-Treatment
is I-Treatment
present I-Treatment
in I-Treatment
oolong I-Treatment
tea I-Treatment
, O
was O
mainly O
responsible I-Adverse_event.Trigger
for O
the O
rhabdomyolysis I-Effect
as I-Effect
well I-Effect
as I-Effect
the I-Effect
delirium I-Effect
, O
although O
severe O
hyponatremia O
has O
been O
reported O
to O
cause O
rhabdomyolysis O
on O
rare O
occasions O
. O

Prevention I-Potential_therapeutic_event.Trigger
of O
CNS I-Treat_Disorder
relapse I-Treat_Disorder
was O
satisfactorily O
achieved O
with O
HD I-Treatment.Route
IV I-Treatment.Route
MTX I-Treatment.Combination.Drug
and I-Treatment
intrathecal I-Treatment.Route
injections I-Treatment.Route
of I-Treatment
MTX I-Treatment.Combination.Drug
in O
children I-Subject.Age
with I-Subject
increased I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
risk I-Subject.Sub_Disorder
ALL I-Subject.Sub_Disorder
or I-Subject.Sub_Disorder
stage I-Subject.Sub_Disorder
III I-Subject.Sub_Disorder
and I-Subject.Sub_Disorder
IV I-Subject.Sub_Disorder
lymphoblastic I-Subject.Sub_Disorder
lymphoma I-Subject.Sub_Disorder
treated O
with O
our O
BFM O
- O
based O
treatment O
protocol O
in O
which O
cranial O
irradiation O
was O
omitted O
. O

Generalized I-Effect
lichen I-Effect
nitidus I-Effect
with I-Effect
involvement I-Effect
of I-Effect
the I-Effect
palms I-Effect
following I-Adverse_event.Trigger
interferon I-Treatment.Drug
alpha I-Treatment.Drug
treatment I-Treatment
. O

Hemorrhagic I-Effect
cystitis I-Effect
is O
a O
significant I-Adverse_event.Trigger
toxic I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
cyclophosphamide I-Treatment.Drug
therapy O
. O

Secondary I-Effect
hyperparathyroidism I-Effect
in I-Adverse_event.Trigger
certain I-Subject
patients I-Subject
with O
lithium I-Treatment.Drug
nephrotoxicity I-Effect
is O
also O
possible O
. O

We O
report O
a I-Subject
case I-Subject
in O
which O
hemorrhage I-Effect
occurred I-Adverse_event.Trigger
in O
an O
asymptomatic O
falx O
meningioma O
known O
beforehand O
, O
after O
the O
internal O
use O
of O
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
aspirin I-Treatment.Drug
for I-Treatment
16 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
. O

Minor O
electrocardiographical I-Effect
changes I-Effect
were O
noted O
in O
five I-Subject.Population
out I-Subject
of I-Subject
six I-Subject
patients I-Subject
who O
were O
not O
receiving I-Adverse_event.Trigger
a O
cardiac I-Treatment.Drug
glycoside I-Treatment.Drug
and O
four O
out O
of O
six O
who O
were O
receiving O
ouabain O
, O
and O
none O
of O
the O
16 O
who O
were O
receiving O
digoxin O
. O

The O
allergic I-Effect
reaction I-Effect
started O
to O
develop I-Adverse_event.Trigger
after O
co I-Treatment
- I-Treatment
administration I-Treatment
of I-Treatment
pravastatin I-Treatment.Drug
. O

We O
propose O
that O
cyclophosphamide I-Treatment.Drug
be O
added O
to O
the O
list O
of O
exposures O
potentially O
associated I-Adverse_event.Trigger
with O
hepatic I-Effect
angiosarcoma I-Effect
. O

The I-Effect
ocular I-Effect
motor I-Effect
disturbances I-Effect
are O
probably O
an O
expression I-Adverse_event.Trigger
of O
regional O
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
neurotoxicity I-Effect
primarily O
affecting O
the O
brain O
stem O
. O

Complications O
of O
chemotherapy O
for O
a O
synovial I-Treat_Disorder
sarcoma I-Treat_Disorder
in O
an I-Subject
eight I-Subject.Age
- I-Subject.Age
year I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
included O
cisplatinum O
nephrotoxicity O
and O
adriamycin I-Treatment.Drug
cardiotoxicity I-Effect
. O

Bacterial I-Effect
infection I-Effect
is O
a O
frequent O
event I-Adverse_event.Trigger
in O
renal I-Subject.Sub_Disorder
transplant I-Subject.Sub_Disorder
recipients I-Subject
and O
often O
requires O
the O
use O
of O
antimicrobial I-Treatment.Drug
agents I-Treatment.Drug
. O

Study O
results O
suggest O
that O
ciclesonide I-Treatment.Drug
significantly O
reduces I-Potential_therapeutic_event.Trigger
the O
need O
for O
OCS I-Drug
in O
patients I-Subject
with I-Subject
severe I-Treat_Disorder
, I-Treat_Disorder
persistent I-Treat_Disorder
asthma I-Treat_Disorder
, O
while O
maintaining O
asthma O
control O
. O

CONCLUSION O
: O
This O
is O
, O
to O
our O
knowledge O
, O
the O
first O
report O
of O
severe I-Effect
myelopathy I-Effect
following I-Adverse_event.Trigger
accidental O
intrathecal I-Treatment.Route
administration I-Treatment.Route
of I-Treatment
doxorubicin I-Treatment.Drug
. O

Multiple I-Effect
sclerosis I-Effect
- I-Effect
like I-Effect
disease I-Effect
secondary I-Adverse_event.Trigger
to O
alpha I-Treatment.Drug
interferon I-Treatment.Drug
. O

We O
report O
a O
case O
of O
a I-Subject
patient I-Subject
with I-Subject
mild I-Subject.Sub_Disorder
chronic I-Subject.Sub_Disorder
renal I-Subject.Sub_Disorder
insufficiency I-Subject.Sub_Disorder
who O
had O
been O
taking I-Treatment
simvastatin I-Treatment.Combination.Drug
for I-Treatment
over I-Treatment.Time_elapsed
a I-Treatment.Time_elapsed
year I-Treatment.Time_elapsed
and O
developed I-Adverse_event.Trigger
acute I-Effect
weakness I-Effect
within O
3 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
the I-Treatment
start I-Treatment
of I-Treatment
treatment I-Treatment
with I-Treatment
colchicine I-Treatment.Combination.Drug
for I-Treatment
acute I-Treatment.Treat_Disorder
gouty I-Treatment.Treat_Disorder
bursitis I-Treatment.Treat_Disorder
. O

Shortly O
after O
chemotherapy O
and O
an O
injection O
of O
pegfilgrastim I-Treatment.Drug
, O
the I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
poorly I-Effect
defined I-Effect
, I-Effect
rapidly I-Effect
progressive I-Effect
erythema I-Effect
, I-Effect
edema I-Effect
, I-Effect
and I-Effect
pain I-Effect
in I-Effect
his I-Effect
right I-Effect
forearm I-Effect
. O

To O
describe O
a O
probable O
interaction I-Treatment
between I-Treatment
enteral I-Treatment.Combination.Drug
feeds I-Treatment.Combination.Drug
and I-Treatment
levodopa I-Treatment.Combination.Drug
leading I-Adverse_event.Trigger
to O
neuroleptic I-Effect
malignant I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
( I-Effect
NMLS I-Effect
) I-Effect
in O
a I-Subject
polytrauma I-Subject.Sub_Disorder
patient I-Subject
with I-Subject
Parkinson I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
( I-Treat_Disorder
PD I-Treat_Disorder
) I-Treat_Disorder
. O

Second O
, O
we O
report O
a O
case O
of O
neutropenia I-Effect
, O
which O
proved O
to O
be O
fatal O
in O
a I-Subject
schizophrenia I-Treat_Disorder
patient I-Subject
receiving I-Adverse_event.Trigger
olanzapine I-Treatment.Combination.Drug
and I-Treatment
thiazide I-Treatment.Combination.Drug
. O

While O
mild O
to O
moderate O
application O
site O
reactions O
( O
ASRs O
) O
are O
a O
well O
- O
known O
and O
common O
phenomenon O
associated O
with O
imiquimod O
, O
the O
potential O
of O
TNF I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
blockers I-Treatment.Drug
to O
elicit I-Adverse_event.Trigger
cutaneous I-Effect
inflammatory I-Effect
reactions I-Effect
has O
only O
recently O
been O
recognized O
. O

Nineteen I-Subject.Population
cases I-Subject
of O
allergic I-Effect
contact I-Effect
dermatitis I-Effect
to O
compound I-Treatment
tincture I-Treatment
of I-Treatment
benzoin I-Treatment.Drug
are O
described I-Adverse_event.Trigger
. O

We O
report O
3 I-Subject.Population
children I-Subject.Age
with I-Subject
epilepsy I-Treat_Disorder
who O
developed O
facial I-Effect
motor I-Effect
tics I-Effect
after I-Adverse_event.Trigger
initiation O
of O
CBZ I-Treatment.Drug
for O
complex O
partial O
seizures O
. O

The O
toxicity I-Effect
of O
cadmium I-Treatment.Drug
, I-Treatment
zinc I-Treatment.Drug
and I-Treatment
cadmium I-Treatment.Combination.Drug
/ I-Treatment
zinc I-Treatment.Combination.Drug
mixtures I-Treatment
at I-Treatment
concentrations I-Treatment
ranging I-Treatment
from I-Treatment
1000 I-Treatment.Dosage
to I-Treatment.Dosage
50000 I-Treatment.Dosage
microg I-Treatment.Dosage
/ I-Treatment.Dosage
l I-Treatment.Dosage
were O
investigated O
against I-Adverse_event.Trigger
cercariae O
and O
metacercariae O
of O
Parorchis O
acanthus O
obtained O
from O
the O
dog O
whelk O
Nucella O
lapillus O
. O

We O
report O
the O
syndrome I-Effect
of I-Effect
inappropriate I-Effect
antidiuresis I-Effect
as O
a O
much I-Time_elapsed
earlier I-Time_elapsed
side I-Adverse_event.Trigger
- I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
carbamazepine I-Treatment.Drug
administration O
in O
a I-Subject
29 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
Nigerian I-Subject.Race
female I-Subject.Gender
patient I-Subject
with I-Subject
generalized I-Treat_Disorder
tonic I-Treat_Disorder
- I-Treat_Disorder
elonic I-Treat_Disorder
seizures I-Treat_Disorder
. O

A I-Subject
patient I-Subject
was O
treated I-Potential_therapeutic_event.Trigger
with O
warfarin I-Treatment.Drug
for O
atrial I-Treat_Disorder
fibrillation I-Treat_Disorder
. O

Mood I-Treatment.Combination.Drug
stabilizer I-Treatment.Combination.Drug
therapy I-Treatment
and I-Treatment
pravastatin I-Treatment.Combination.Drug
: O
higher O
risk I-Adverse_event.Trigger
for O
adverse I-Effect
skin I-Effect
reactions I-Effect
? O

Pulmonary I-Effect
leukostasis I-Effect
secondary I-Adverse_event.Trigger
to O
all I-Treatment.Drug
- I-Treatment.Drug
trans I-Treatment.Drug
retinoic I-Treatment.Drug
acid I-Treatment.Drug
in O
the O
treatment O
of O
acute I-Treat_Disorder
promyelocytic I-Treat_Disorder
leukemia I-Treat_Disorder
in I-Treat_Disorder
first I-Treat_Disorder
relapse I-Treat_Disorder
. O

A I-Subject
74 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
hypercholestrerolaemic I-Treat_Disorder
woman I-Subject.Gender
taking O
cerivastatin I-Treatment.Drug
( I-Treatment
0.15 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
) I-Treatment
for O
22 I-Duration
days I-Duration
complained I-Adverse_event.Trigger
of O
general I-Effect
muscle I-Effect
weakness I-Effect
and I-Effect
muscle I-Effect
pain I-Effect
. I-Effect

There O
have O
been O
only O
two O
reports O
of O
cimetidine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hepatitis I-Effect
. O

A O
case O
is O
reported O
of O
theophylline I-Effect
intoxication I-Effect
due I-Adverse_event.Trigger
to O
a O
dramatic O
decrease O
in O
theophylline I-Combination.Drug
clearance O
following O
concomitant I-Treatment
administration I-Treatment
of I-Treatment
viloxazine I-Treatment.Combination.Drug
. O

Anterior I-Effect
ischemic I-Effect
optic I-Effect
neuropathy I-Effect
secondary I-Adverse_event.Trigger
to O
interferon I-Treatment.Drug
alfa I-Treatment.Drug
. O

PURPOSE O
: O
To O
describe O
bilateral I-Effect
optic I-Effect
neuritis I-Effect
that O
occurred I-Adverse_event.Trigger
as O
an O
adverse O
effect O
of O
recombinant I-Treatment.Drug
and I-Treatment.Drug
natural I-Treatment.Drug
interferon I-Treatment.Drug
alpha I-Treatment.Drug
administration I-Treatment
. O

Rofecoxib I-Treatment.Drug
, O
used O
for O
dysmenorrhea I-Treat_Disorder
, O
caused I-Adverse_event.Trigger
a O
herpetiform I-Effect
fixed I-Effect
drug I-Effect
eruption I-Effect
predominantly I-Effect
involving I-Effect
the I-Effect
lips I-Effect
with I-Effect
classic I-Effect
clinical I-Effect
and I-Effect
histological I-Effect
findings I-Effect
in I-Effect
a I-Effect
red I-Effect
- I-Effect
brown I-Effect
lesion I-Effect
on I-Effect
the I-Effect
dorsal I-Effect
hand I-Effect
. O

Statin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
myasthenia I-Effect
gravis I-Effect
: O
report O
of O
4 I-Subject.Population
cases I-Subject
and O
review O
of O
the O
literature O
. O

Two I-Subject.Population
reports I-Subject
of O
spindle I-Effect
coma I-Effect
are O
noted I-Adverse_event.Trigger
with O
alcohol I-Treatment.Combination.Drug
and I-Treatment
imipramine I-Treatment.Combination.Drug
. O

Cataracts I-Effect
induced I-Adverse_event.Trigger
by O
intermittent O
Decadron I-Treatment.Drug
used O
as O
an O
antiemetic O
. O

Severe O
osteomalacia I-Effect
was O
present I-Adverse_event.Trigger
in O
two I-Subject.Population
epileptic I-Treat_Disorder
patients I-Subject
who O
were O
under O
long I-Treatment
- I-Treatment
term I-Treatment
treatment I-Treatment
with I-Treatment
congeners I-Treatment
of I-Treatment
phenytoin I-Treatment.Combination.Drug
, I-Treatment
phenobarbital I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
acetazolamide I-Treatment.Combination.Drug
. O

Careful O
observations O
on O
hepatotoxicity I-Effect
are O
suggested O
when O
acetaminophen I-Treatment.Drug
is O
prescribed O
with I-Adverse_event.Trigger
caffeine I-Treatment.Drug
. O

Erosion I-Effect
of I-Effect
psoriatic I-Effect
plaques I-Effect
: O
an O
early O
sign O
of I-Adverse_event.Trigger
methotrexate I-Treatment.Drug
toxicity O
. O

After O
extensive O
neurological O
' O
work O
up O
' O
, O
we O
realized O
that O
the O
anisocoria I-Effect
was O
related I-Adverse_event.Trigger
to O
the O
transdermal I-Treatment.Route
scopolamine I-Treatment.Drug
patch I-Treatment.Route
that O
we O
had O
prescribed O
for O
weaning I-Treat_Disorder
off I-Treat_Disorder
the I-Treat_Disorder
opioid I-Treat_Disorder
. O

Efficacy O
and O
safety O
of O
tifacogin I-Treatment.Drug
( I-Treatment.Drug
recombinant I-Treatment.Drug
tissue I-Treatment.Drug
factor I-Treatment.Drug
pathway I-Treatment.Drug
inhibitor I-Treatment.Drug
) I-Treatment.Drug
in I-Potential_therapeutic_event.Trigger
severe I-Treat_Disorder
sepsis I-Treat_Disorder
: O
a O
randomized O
controlled O
trial O
. O

CASE O
: O
A I-Effect
malignant I-Effect
mixed I-Effect
mesodermal I-Effect
tumor I-Effect
was O
diagnosed I-Adverse_event.Trigger
in O
a I-Subject
64 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
a I-Subject
bicornuate I-Subject.Sub_Disorder
uterus I-Subject.Sub_Disorder
while O
she O
was O
taking O
raloxifene I-Treatment.Drug
for O
osteoporosis I-Treat_Disorder
prevention O
. O

After O
rechallenge O
with O
monotherapy O
pegvisomant O
, O
however O
, O
the O
hepatic I-Effect
enzyme I-Effect
disturbances I-Effect
reappeared I-Effect
within I-Time_elapsed
a I-Time_elapsed
few I-Time_elapsed
weeks I-Time_elapsed
, O
indicating O
that O
most O
likely O
pegvisomant I-Treatment.Drug
alone O
and O
not O
the O
long O
- O
acting O
somatostatin O
analog O
or O
the O
combination O
of O
these O
two O
drugs O
was O
responsible I-Adverse_event.Trigger
for O
this O
case O
of O
drug O
- O
induced O
hepatitis I-Effect
. O

To O
evaluate O
the O
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
( I-Treatment.Duration
up I-Treatment.Duration
to I-Treatment.Duration
5 I-Treatment.Duration
years I-Treatment.Duration
exposure I-Treatment.Duration
) I-Treatment.Duration
safety O
and O
efficacy O
of O
lacosamide I-Treatment.Combination.Drug
as I-Treatment
adjunctive I-Treatment
therapy I-Treatment
in I-Potential_therapeutic_event.Trigger
patients O
with O
uncontrolled I-Treat_Disorder
partial I-Treat_Disorder
- I-Treat_Disorder
onset I-Treat_Disorder
seizures I-Treat_Disorder
taking I-Treatment
one I-Treatment
to I-Treatment
three I-Treatment
concomitant I-Treatment
antiepileptic I-Treatment.Combination.Drug
drugs I-Treatment.Combination.Drug
( I-Treatment
AEDs I-Treatment
) I-Treatment
in O
open O
- O
label O
extension O
trial O
SP756 O
( O
NCT00522275 O
) O
. O

Complete O
remission O
of O
the O
nephrosis I-Effect
occurred I-Potential_therapeutic_event.Trigger
after O
discontinuation I-Treatment.Route
of I-Treatment
hydroxychloroquine I-Treatment.Drug
therapy O
. O

CONCLUSIONS O
: O
Clinicians O
treating O
elderly I-Subject.Age
patients I-Subject
with I-Adverse_event.Trigger
olanzapine I-Treatment.Drug
should O
be O
aware O
of O
the O
potential O
for O
rapidly I-Effect
developing I-Effect
hyperglycemia I-Effect
and O
monitor O
such O
patients O
accordingly O
. O

We O
describe O
a O
case O
of O
PRES I-Treat_Disorder
in O
a I-Subject
patient I-Subject
with I-Subject
collapsing I-Subject.Sub_Disorder
focal I-Subject.Sub_Disorder
glomeruloesclerosis I-Subject.Sub_Disorder
( I-Subject
collapsing I-Subject
FGS I-Subject
) I-Subject
with O
complete I-Potential_therapeutic_event.Trigger
recovery I-Potential_therapeutic_event.Trigger
after O
withdrawal I-Treatment
of I-Treatment
cyclosporine I-Treatment.Drug
( I-Treatment
CSA I-Treatment
) I-Treatment
. O

DISCUSSION O
: O
The O
occurrence O
of O
priapism I-Effect
in O
our I-Subject
patient I-Subject
was O
related I-Adverse_event.Trigger
to O
zuclopenthixol I-Treatment.Drug
. O

Hepatic I-Effect
angiosarcoma I-Effect
occurring I-Adverse_event.Trigger
after O
cyclophosphamide I-Treatment.Drug
therapy I-Treatment
: O
case O
report O
and O
review O
of O
the O
literature O
. O

After I-Treatment
completion I-Treatment
of I-Treatment
induction I-Treatment
- I-Treatment
consolidation I-Treatment
phase I-Treatment
, O
children I-Subject.Age
with I-Subject
increased I-Subject
- I-Subject
risk I-Subject
( I-Subject
risk I-Subject
factor I-Subject
> I-Subject
0.8 I-Subject
or I-Subject
T I-Subject
- I-Subject
lineage I-Subject
) I-Subject
ALL I-Subject
or I-Subject
stage I-Subject
III I-Subject
and I-Subject
IV I-Subject
lymphoblastic I-Treat_Disorder
lymphoma I-Treat_Disorder
were O
randomized O
to O
receive I-Potential_therapeutic_event.Trigger
four I-Treatment
courses I-Treatment
of I-Treatment
HD I-Treatment.Drug
MTX I-Treatment.Drug
( I-Treatment
5 I-Treatment.Dosage
g I-Treatment.Dosage
/ I-Treatment.Dosage
m(2 I-Treatment.Dosage
) I-Treatment.Dosage
over I-Treatment.Freq
24 I-Treatment.Freq
hours I-Treatment.Freq
every I-Treatment.Freq
2 I-Treatment.Freq
weeks I-Treatment.Freq
) I-Treatment
and I-Treatment
four I-Treatment
intrathecal I-Treatment
administrations I-Treatment
of I-Treatment
MTX I-Treatment.Combination.Drug
( I-Treatment
Arm I-Treatment
A I-Treatment
) I-Treatment
or I-Treatment
the I-Treatment
same I-Treatment
treatment I-Treatment
schedule I-Treatment
with I-Treatment
additional I-Treatment
HD I-Treatment.Combination.Drug
IV I-Treatment.Combination.Drug
Ara I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
C I-Treatment.Combination.Drug
( I-Treatment
1 I-Treatment.Dosage
g I-Treatment.Dosage
/ I-Treatment.Dosage
m(2 I-Treatment.Dosage
) I-Treatment.Dosage
in I-Treatment
bolus I-Treatment.Route
injection I-Treatment.Route
12 I-Treatment
and I-Treatment
24 I-Treatment
hours I-Treatment
after I-Treatment
the I-Treatment
start I-Treatment
of I-Treatment
each I-Treatment
MTX I-Treatment.Drug
infusion I-Treatment
) I-Treatment
( I-Treatment
Arm I-Treatment
B I-Treatment
) I-Treatment
. O

The O
dose O
- O
limiting O
toxicity O
of O
KW I-Treatment.Drug
- I-Treatment.Drug
2149 I-Treatment.Drug
is O
pulmonary I-Effect
toxicity I-Adverse_event.Trigger
. O

Flucloxacillin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
aplastic I-Effect
anaemia I-Effect
and I-Effect
liver I-Effect
failure I-Effect
. O

Thus O
, O
we O
confirm O
that O
desensitization O
may O
be O
a O
safe O
procedure O
in O
patients I-Subject
with I-Subject
cancer I-Subject.Sub_Disorder
who O
experience O
methotrexate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
anaphylaxis I-Effect
. O

We O
further O
used O
immunohistochemistry O
( O
IHC O
) O
to O
examine O
the O
relative O
role O
of O
platelet O
- O
derived O
growth O
factor O
- O
B O
( O
PDGF O
- O
B O
) O
, O
insulin O
- O
like O
growth O
factor O
I O
( O
IGF O
- O
I O
) O
, O
transforming O
growth O
factor O
- O
beta1 O
( O
TGF O
- O
beta1 O
) O
and O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
in O
the O
pathogenesis O
of O
BCNU I-Treatment.Drug
- O
related I-Adverse_event.Trigger
pulmonary I-Effect
fibrosis I-Effect
. O

Physicians O
using O
this O
" O
new O
" O
drug O
must O
be O
aware O
of O
the O
potential O
danger O
of O
sulfonamide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
injury I-Effect
to I-Effect
the I-Effect
urinary I-Effect
tract I-Effect
. O

RESULTS O
: O
Brimonidine I-Treatment.Drug
was O
observed O
to O
cause I-Adverse_event.Trigger
IOP I-Effect
elevation I-Effect
, O
confirmed O
on O
rechallenge O
, O
scoring O
8 O
( O
strong O
probability O
) O
on O
an O
adverse O
drug O
reaction O
probability O
score O
. O

Severe O
leukopenia I-Effect
associated O
with O
mild O
hepatotoxicity O
in O
an I-Subject
HIV I-Treat_Disorder
carrier I-Treat_Disorder
treated O
with I-Adverse_event.Trigger
nevirapine I-Treatment.Drug
. O

The O
clinical O
effect I-Potential_therapeutic_event.Trigger
and I-Potential_therapeutic_event.Trigger
safety I-Potential_therapeutic_event.Trigger
of O
Lp I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
TAE I-Treatment.Combination.Drug
alone I-Treatment
and I-Treatment
combined I-Treatment
with I-Treatment
radiofrequency I-Treatment.Combination.Drug
( I-Treatment.Combination.Drug
RF I-Treatment.Combination.Drug
) I-Treatment.Combination.Drug
capacitive I-Treatment.Combination.Drug
hyperthermia I-Treatment.Combination.Drug
( I-Treatment
HT I-Treatment
) I-Treatment
were O
evaluated O
in O
20 I-Subject.Population
patients I-Subject
with I-Subject
hepatocellular I-Subject.Sub_Disorder
carcinoma I-Subject.Sub_Disorder
( I-Subject
HCC I-Subject
) I-Subject
associated O
with O
cirrhosis I-Treat_Disorder
of I-Treat_Disorder
the I-Treat_Disorder
liver I-Treat_Disorder
. O

Fibrosis I-Effect
of I-Effect
corpus I-Effect
cavernosum I-Effect
after I-Adverse_event.Trigger
intracavernous I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
phentolamine I-Treatment.Combination.Drug
/ I-Treatment
papaverine I-Treatment.Combination.Drug
. O

We O
have O
cared O
for O
three I-Subject.Population
children I-Subject.Age
in O
whom O
four I-Effect
episodes I-Effect
of I-Effect
dystonia I-Effect
proceeding I-Effect
to I-Effect
opisthotonus I-Effect
occurred I-Adverse_event.Trigger
in O
association O
with O
carbamazepine I-Treatment.Drug
use O
. O

Juvenile I-Effect
absence I-Treat_Disorder
epilepsy I-Treat_Disorder
exacerbated I-Effect
by O
valproic I-Treatment.Drug
acid I-Treatment.Drug
. O

These O
cases O
were O
chosen O
for O
study O
because O
they I-Effect
were I-Effect
all I-Effect
deaths I-Effect
as O
a O
result O
of O
suicidal O
ingestion O
of O
drugs O
in O
which O
quetiapine I-Treatment.Drug
was O
considered I-Adverse_event.Trigger
a O
significant O
factor O
. O

We O
present O
a I-Subject
case I-Subject
of O
hypereosinophilia I-Effect
related I-Adverse_event.Trigger
to O
zafirlukast I-Treatment.Drug
therapy I-Treatment
. I-Treatment

In I-Subject
patients I-Subject
with I-Subject
methotrexate I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
anaphylaxis I-Treat_Disorder
, O
discontinuation I-Adverse_event.Trigger
of O
treatment I-Treatment
may O
increase O
the O
risk O
of O
death I-Effect
due I-Effect
to I-Effect
cancer I-Effect
progression I-Effect
. O

Pentazocine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
fibrous I-Effect
myopathy I-Effect
and I-Effect
localized I-Effect
neuropathy I-Effect
. O

Intensive I-Treatment
high I-Treatment
- I-Treatment
flux I-Treatment
hemodiafiltration I-Treatment
is O
often O
used O
in O
the O
management I-Potential_therapeutic_event.Trigger
of O
vancomycin I-Treat_Disorder
toxicity I-Treat_Disorder
. O

Here O
we O
present O
the O
case O
of O
a I-Effect
generalized I-Effect
lichen I-Effect
nitidus I-Effect
with I-Effect
involvement I-Effect
of I-Effect
the I-Effect
palms I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
hepatitis I-Treat_Disorder
C I-Treat_Disorder
after I-Adverse_event.Trigger
systemic I-Treatment.Route
treatment I-Treatment
with I-Treatment
interferon I-Treatment.Combination.Drug
alpha I-Treatment.Combination.Drug
and I-Treatment
ribavirin I-Treatment.Combination.Drug
. O

The O
authors O
describe O
a I-Subject
woman I-Subject.Gender
with I-Subject
chronic I-Treat_Disorder
schizophrenia I-Treat_Disorder
who O
experienced O
delirium I-Effect
, I-Effect
grand I-Effect
mal I-Effect
seizure I-Effect
, I-Effect
and I-Effect
photosensitivity I-Effect
after I-Adverse_event.Trigger
the O
addition O
of O
propranolol I-Treatment.Drug
to O
her O
neuroleptic O
regimen O
. O

We O
report O
a O
case O
of O
an I-Subject
infant I-Subject.Age
with I-Subject
complex I-Subject
congenital I-Treat_Disorder
heart I-Treat_Disorder
disease I-Treat_Disorder
who O
was O
placed O
on O
captopril I-Treatment.Drug
for O
afterload O
reduction O
following O
cardiac O
surgery O
and O
subsequently O
developed I-Adverse_event.Trigger
pulmonary I-Effect
infiltrates I-Effect
with I-Effect
eosinophilia I-Effect
. O

Possible O
pathophysiological O
mechanisms O
which O
may O
have O
been O
operative O
in O
this O
case O
include O
: O
a I-Effect
direct I-Effect
central I-Effect
nervous I-Effect
system I-Effect
( I-Effect
CNS I-Effect
) I-Effect
toxic I-Effect
effect I-Effect
of O
valproic I-Treatment.Drug
acid I-Treatment.Drug
; O
a I-Effect
paradoxical I-Effect
epileptogenic I-Effect
effect I-Effect
secondary O
to O
the O
drug O
; O
and O
an O
indirect O
CNS O
toxic O
effect O
mediated O
through O
valproic O
acid O
- O
induced I-Adverse_event.Trigger
hyperammonemia I-Effect
. O

We O
report O
a I-Subject
case I-Subject
of O
serotonin I-Effect
syndrome I-Effect
induced I-Adverse_event.Trigger
by O
pharmacokinetic O
and O
pharmacodynamic O
interactions I-Treatment
between I-Treatment
three I-Treatment
different I-Treatment
selective I-Treatment.Combination.Drug
serotonin I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
reuptake I-Treatment.Combination.Drug
inhibitors I-Treatment.Combination.Drug
( I-Treatment
SSRI I-Treatment
) I-Treatment
and I-Treatment
possibly I-Treatment
ciprofloxacin I-Treatment.Combination.Drug
. O

Generalised I-Effect
pustular I-Effect
psoriasis I-Effect
induced I-Adverse_event.Trigger
by O
cyclosporin I-Treatment.Drug
a I-Treatment
withdrawal I-Treatment
responding O
to O
the O
tumour O
necrosis O
factor O
alpha O
inhibitor O
etanercept O
. O

A I-Subject
36 I-Subject.Age
- I-Subject.Age
y I-Subject.Age
- I-Subject.Age
o I-Subject.Age
patient I-Subject
with I-Subject
schizophrenia I-Subject.Sub_Disorder
, O
who O
had O
consumed O
gradually I-Treatment
increasing I-Treatment
quantities I-Treatment
of I-Treatment
oolong I-Treatment.Drug
tea I-Treatment.Drug
that I-Treatment
eventually I-Treatment
reached I-Treatment
15 I-Treatment.Dosage
L I-Treatment.Dosage
each I-Treatment.Freq
day I-Treatment.Freq
, O
became I-Adverse_event.Trigger
delirious I-Effect
and O
was O
admitted O
to O
a O
psychiatric O
hospital O
. O

Intraventricular I-Effect
nafcillin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
seizures I-Effect
in O
a I-Subject
neonate I-Subject.Age
. O

Nevertheless O
, O
the O
coagulopathy I-Effect
seemed O
to O
be O
most O
closely O
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
the O
administration O
of O
the O
cephalosporin I-Treatment.Drug
. O

Intrahepatic I-Effect
cholestasis I-Effect
and I-Effect
sicca I-Effect
complex I-Effect
after I-Adverse_event.Trigger
thiabendazole I-Treatment.Drug
. O

We O
recommended O
periodic O
examination O
of O
the O
serum O
proteins O
in O
patients I-Subject
receiving I-Adverse_event.Trigger
diphenylhydantoin I-Treatment.Drug
in O
order O
to O
detect I-Effect
development I-Effect
of I-Effect
monoclonal I-Effect
gammopathy I-Effect
. O

Moxalactam I-Treatment.Drug
is O
more O
likely O
to O
be O
associated I-Adverse_event.Trigger
with O
platelet I-Effect
dysfunction I-Effect
. O

This O
prompted O
us O
to O
suspect O
that O
ddI I-Treatment.Drug
might O
be I-Adverse_event.Trigger
responsible I-Adverse_event.Trigger
for I-Adverse_event.Trigger
fulminant I-Effect
hepatitis I-Effect
in O
all O
three I-Subject.Population
AIDS I-Treat_Disorder
patients I-Subject
. O

Two I-Subject.Population
patients I-Subject
, O
each O
receiving I-Treatment
warfarin I-Treatment.Combination.Drug
for I-Treatment
stroke I-Treatment.Treat_Disorder
prophylaxis I-Treatment
in I-Treatment
association I-Treatment
with I-Treatment
chronic I-Treatment
atrial I-Treatment
fibrillation I-Treatment
, O
developed I-Adverse_event.Trigger
adverse I-Effect
effects I-Effect
after I-Treatment
the I-Treatment
initiation I-Treatment
of I-Treatment
tolterodine I-Treatment.Combination.Drug
for I-Treatment
urinary I-Treatment.Treat_Disorder
disorders I-Treatment.Treat_Disorder
. O

CASE O
SUMMARY O
: O
A I-Subject
45 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
HIV I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
positive I-Subject.Sub_Disorder
man I-Subject
( I-Subject
CD4 I-Subject
+ I-Subject
count I-Subject
450 I-Subject
cells I-Subject
/ I-Subject
mm(3 I-Subject
) I-Subject
and I-Subject
history I-Subject
of I-Subject
AIDS I-Subject
- I-Subject
defining I-Subject
illness I-Subject
) I-Subject
presented O
with O
JHR I-Effect
after I-Adverse_event.Trigger
an I-Treatment.Dosage
initial I-Treatment.Dosage
intravenous I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
penicillin I-Treatment.Drug
G I-Treatment.Drug
for O
presumed O
neurosyphilis I-Treat_Disorder
. O

The O
second I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
both I-Effect
autoimmune I-Effect
thyroid I-Effect
disease I-Effect
and I-Effect
a I-Effect
refractory I-Effect
pre I-Effect
- I-Effect
patellar I-Effect
bursitis I-Effect
after O
50 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
of I-Treatment
IFN I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
therapy I-Treatment
. O

We O
report O
an O
additional O
case O
of O
isotretinoin I-Treatment.Drug
teratogenicity I-Adverse_event.Trigger
in O
which O
the O
patient I-Subject
had O
agenesis I-Effect
of I-Effect
the I-Effect
cerebellar I-Effect
vermis I-Effect
, I-Effect
multiple I-Effect
leptomeningeal I-Effect
neuroglial I-Effect
heterotopias I-Effect
, I-Effect
hydrocephalus I-Effect
, I-Effect
and I-Effect
abnormalities I-Effect
of I-Effect
the I-Effect
corticospinal I-Effect
tracts I-Effect
. O

Reversible I-Effect
sclerotic I-Effect
changes I-Effect
of I-Effect
lumbar I-Effect
spine I-Effect
and I-Effect
femur I-Effect
due I-Adverse_event.Trigger
to O
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
oral I-Treatment.Route
isotretinoin I-Treatment.Drug
therapy O
. O

A I-Subject
case I-Subject
of O
priapism I-Effect
associated I-Adverse_event.Trigger
with O
trazodone I-Treatment.Drug
is O
described O
. O

Severe O
adenovirus I-Effect
pneumonia I-Effect
( O
AVP O
) O
following I-Adverse_event.Trigger
infliximab I-Treatment.Drug
infusion I-Treatment.Route
for O
the O
treatment O
of O
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
. O

No O
other O
endogenous O
or O
exogenous O
cause I-Adverse_event.Trigger
for O
the O
gynecomastia I-Effect
could O
be O
found O
except O
for O
the O
theophylline I-Treatment.Drug
. O

This O
is O
a O
case O
of O
pseudoephedrine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
intracerebral I-Effect
hemorrhage I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
an I-Subject
underlying I-Subject
vascular I-Subject.Sub_Disorder
malformation I-Subject.Sub_Disorder
. O

A I-Subject
58 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
developed O
unilateral I-Effect
acute I-Effect
angle I-Effect
- I-Effect
closure I-Effect
glaucoma I-Effect
four I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment
the I-Treatment
application I-Treatment
of I-Treatment
a I-Treatment
patch I-Treatment.Route
of I-Treatment
transdermal I-Treatment
scopolamine I-Treatment.Drug
delivery I-Treatment
system I-Treatment
( I-Treatment
TRANSDERM I-Treatment
- I-Treatment
V I-Treatment
) I-Treatment
. O

We O
report O
a I-Subject
50 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
patient I-Subject
with I-Subject
a I-Subject
15 I-Subject
- I-Subject
year I-Subject
history I-Subject
of I-Subject
psoriasis I-Subject.Sub_Disorder
including I-Subject.Sub_Disorder
mutilating I-Subject.Sub_Disorder
psoriatic I-Subject.Sub_Disorder
arthritis I-Subject.Sub_Disorder
, O
in O
whom O
the I-Treatment
withdrawal I-Treatment
of I-Treatment
cyclosporin I-Treatment.Drug
A I-Treatment.Drug
induced I-Adverse_event.Trigger
a I-Effect
generalised I-Effect
pustular I-Effect
exacerbation I-Effect
and I-Effect
a I-Effect
aggravation I-Effect
of I-Effect
the I-Effect
joint I-Effect
condition I-Effect
. O

Six I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment
starting I-Treatment
acyclovir I-Treatment.Drug
she I-Subject.Gender
exhibited O
signs O
of O
lithium I-Effect
toxicity I-Effect
. O

Toxicity I-Effect
of O
cadmium I-Treatment.Drug
and I-Treatment
zinc I-Treatment.Drug
to O
encystment O
and O
in O
vitro O
excystment O
of O
Parorchis O
acanthus O
( O
Digenea O
: O
Philophthalmidae O
) O
. O

The O
syndrome I-Effect
of I-Effect
irreversible I-Effect
lithium I-Treatment.Drug
- I-Effect
effectuated I-Effect
neurotoxicity I-Effect
( I-Effect
SILENT I-Effect
) I-Effect
. O

One I-Subject.Population
patient I-Subject
on O
ouabain I-Treatment.Drug
also O
developed I-Adverse_event.Trigger
cardiomyopathy I-Effect
. O

Data O
suggest O
that O
tamoxifen I-Treatment.Drug
is O
involved I-Adverse_event.Trigger
in O
the O
pathogenesis I-Effect
. O

Intrahepatic I-Effect
cholestasis I-Effect
and I-Effect
cutaneous I-Effect
bullae I-Effect
associated I-Adverse_event.Trigger
with O
glibenclamide I-Treatment.Drug
therapy I-Treatment
. O

Prolonged I-Treatment.Drug
- I-Treatment.Drug
release I-Treatment.Drug
oxycodone I-Treatment.Drug
enhances I-Potential_therapeutic_event.Trigger
the O
effects O
of O
existing O
gabapentin I-Treatment
therapy I-Treatment
in O
painful I-Subject
diabetic I-Treat_Disorder
neuropathy I-Treat_Disorder
patients I-Subject
. O

OBJECTIVE O
: O
To O
describe O
what O
is O
believed O
, O
as O
of O
November O
4 O
, O
2003 O
, O
to O
be O
the O
first O
case O
published O
in O
the O
literature O
of O
acute I-Effect
interstitial I-Effect
nephritis I-Effect
( I-Effect
AIN I-Effect
) I-Effect
due I-Adverse_event.Trigger
to O
pantoprazole I-Treatment.Drug
. O

We O
report O
a I-Subject
patient I-Subject
of I-Subject
organic I-Treat_Disorder
bipolar I-Treat_Disorder
affective I-Treat_Disorder
disorder I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
hiccups I-Effect
with O
the I-Treatment
atypical I-Treatment
antipsychotic I-Treatment
aripiprazole I-Treatment.Drug
. O

A I-Subject
28 I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
B I-Treat_Disorder
was O
administered I-Potential_therapeutic_event.Trigger
interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
( I-Treatment
5 I-Treatment
x I-Treatment
10(6 I-Treatment
) I-Treatment
IU I-Treatment
) I-Treatment
intramuscularly I-Treatment.Route
once I-Treatment.Freq
a I-Treatment.Freq
day I-Treatment.Freq
for I-Treatment
28 I-Treatment
days I-Treatment
. O

The O
case O
of O
a I-Subject
patient I-Subject
taking O
high I-Treatment.Dosage
- I-Treatment.Dosage
dosage I-Treatment.Dosage
olanzapine I-Treatment.Drug
who O
experienced I-Adverse_event.Trigger
parkinsonism I-Effect
after O
smoking I-Treatment
cessation I-Treatment
is O
reported O
. O

A I-Subject
65 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
bipolar I-Subject.Sub_Disorder
disorder I-Subject.Sub_Disorder
and I-Subject
complicated I-Subject
cardiovascular I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
who I-Subject
was I-Subject
on I-Subject
maintenance I-Subject
lithium I-Combination.Drug
therapy I-Subject
developed O
a I-Effect
movement I-Effect
disorder I-Effect
following I-Adverse_event.Trigger
high I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
trazodone I-Treatment.Combination.Drug
for O
treatment O
of O
an O
acute I-Treat_Disorder
depression I-Treat_Disorder
. O

The O
most O
common O
complication O
of O
warfarin I-Treatment.Drug
use I-Adverse_event.Trigger
is O
adverse I-Effect
bleeding I-Effect
. O

To O
report O
a O
case O
of O
autonomic I-Effect
, I-Effect
neurological I-Effect
and I-Effect
neuromuscular I-Effect
instability I-Effect
following I-Adverse_event.Trigger
methylene I-Treatment.Drug
blue I-Treatment.Drug
infusion I-Treatment.Route
for I-Treatment
parathyroidectomy I-Treatment
; O
to O
advance O
the O
argument O
for O
a O
diagnosis O
of O
serotonin O
syndrome O
; O
and O
to O
consider O
this O
diagnosis O
in O
previous O
, O
unexplained O
reports O
of O
adverse O
reactions O
amongst O
patients O
undergoing O
parathyroidectomy O
using O
methylene O
blue O
. O

PVT I-Effect
during O
chemotherapy O
in O
children O
is O
a O
rare O
event O
and O
appears O
to O
be O
closely O
related I-Adverse_event.Trigger
to O
intensive I-Treatment
chemotherapy I-Treatment
containing I-Treatment
busulfan I-Treatment.Combination.Drug
and I-Treatment
to I-Treatment
be I-Treatment
associated I-Treatment
with I-Treatment
HVOD I-Treatment.Combination.Drug
. O

It O
is O
hoped O
that O
this O
case O
report O
creates O
awareness O
that O
ofloxacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
toxic I-Effect
epidermal I-Effect
necrolysis I-Effect
is I-Effect
possible I-Effect
. O

Concomitant I-Treatment
use I-Treatment
of I-Treatment
simvastatin I-Treatment.Combination.Drug
and I-Treatment
amiodarone I-Treatment.Combination.Drug
resulting I-Adverse_event.Trigger
in O
severe O
rhabdomyolysis I-Effect
: O
a I-Subject
case I-Subject
report O
and O
review O
of O
the O
literature O
. O

CONCLUSIONS O
: O
This O
report O
indicates O
clindamycin I-Treatment.Drug
phosphate I-Treatment.Drug
vaginal I-Treatment.Route
cream I-Treatment.Route
as O
the O
most O
probable O
cause I-Adverse_event.Trigger
of O
CDIC I-Effect
due O
to O
the O
temporal O
relationship O
between O
the O
occurrence O
of O
diarrhea O
and O
clindamycin O
administration O
, O
lack O
of O
concomitant O
medications O
, O
and O
documentation O
of O
C. O
difficile O
toxin O
. O

A O
case O
of O
intercerebral I-Effect
hematoma I-Effect
due O
to O
warfarin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
coagulopathy I-Effect
is O
presented O
. O

Severe I-Effect
visual I-Effect
loss I-Effect
after I-Adverse_event.Trigger
a I-Treatment.Freq
single I-Treatment.Freq
dose I-Treatment.Freq
of I-Treatment
vincristine I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
spinal I-Treat_Disorder
cord I-Treat_Disorder
astrocytoma I-Treat_Disorder
. O

Clonazepam I-Treatment.Drug
, I-Treatment
thioridazine I-Treatment.Drug
, I-Treatment
beta I-Treatment.Drug
- I-Treatment.Drug
blockers I-Treatment.Drug
, I-Treatment
anticholinergics I-Treatment.Drug
, I-Treatment
and I-Treatment
bromocriptine I-Treatment.Drug
did O
not O
ameliorate I-Potential_therapeutic_event.Trigger
his I-Subject.Gender
akathisia I-Treat_Disorder
. O

Musculoskeletal I-Effect
complaints I-Effect
were O
the O
presenting O
symptoms O
in O
four I-Subject.Population
of I-Subject.Population
44 I-Subject.Population
children I-Subject.Age
( I-Subject
9 I-Subject
% I-Subject
) I-Subject
treated O
for O
relapsed I-Treat_Disorder
Wilms I-Treat_Disorder
' I-Treat_Disorder
tumors I-Treat_Disorder
with I-Adverse_event.Trigger
ifosfamide I-Treatment.Drug
, O
a O
derivative O
of O
cyclophosphamide O
. O

Cutaneous I-Treatment
exposure I-Treatment
to I-Treatment
warfarin I-Treatment.Drug
- I-Treatment.Drug
like I-Treatment.Drug
anticoagulant I-Treatment.Drug
causing I-Adverse_event.Trigger
an I-Effect
intracerebral I-Effect
hemorrhage I-Effect
: O
a I-Subject
case I-Subject
report O
. O

Gemcitabine I-Treatment.Drug
should O
be O
added O
to O
the O
list O
of O
drugs O
known O
to O
cause I-Adverse_event.Trigger
radiation I-Effect
recall I-Effect
. O

A O
paradoxical I-Effect
ocular I-Effect
effect I-Effect
of I-Adverse_event.Trigger
brimonidine I-Treatment.Drug
. O

Fixed I-Effect
drug I-Effect
eruption I-Effect
to I-Adverse_event.Trigger
rofecoxib I-Treatment.Drug
. O

DISCUSSION O
: O
No O
published O
clinical O
studies O
in O
patients I-Subject
receiving I-Treatment
clindamycin I-Treatment.Drug
vaginal I-Treatment.Route
cream I-Treatment.Route
for I-Potential_therapeutic_event.Trigger
bacterial I-Treat_Disorder
vaginosis I-Treat_Disorder
have O
documented O
C. O
difficile O
toxin O
in O
stool O
samples O
of O
patients O
with O
diarrhea O
. O

Acute I-Effect
interstitial I-Effect
nephritis I-Effect
due I-Adverse_event.Trigger
to O
pantoprazole I-Treatment.Drug
. O

Physicians O
should O
keep O
in O
mind O
that O
taxanes I-Treatment.Drug
such I-Treatment
as I-Treatment
paclitaxel I-Treatment
have O
the O
potential O
to O
cause I-Adverse_event.Trigger
pneumonitis I-Effect
and I-Effect
lung I-Effect
fibrosis I-Effect
. O

Infant I-Subject.Age
twins I-Subject
sustained I-Adverse_event.Trigger
severe I-Effect
circumoral I-Effect
and I-Effect
pharyngeal I-Effect
burns I-Effect
from O
a I-Treatment
concentrated I-Treatment
solution I-Treatment
of I-Treatment
benzalkonium I-Treatment.Drug
( I-Treatment.Drug
Zephiran I-Treatment.Drug
) I-Treatment.Drug
chloride I-Treatment.Drug
prescribed O
for O
treatment O
of O
candidiasis I-Treat_Disorder
. O

Isotretinoin I-Treatment.Drug
teratogenicity I-Effect
. O

Hepatitis I-Effect
following I-Adverse_event.Trigger
cimetidine I-Treatment.Drug
administration O
. O

We O
report O
the O
case O
of O
an I-Subject
11 I-Subject.Age
- I-Subject.Age
month I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
infant I-Subject.Age
with O
a I-Effect
depressed I-Effect
level I-Effect
of I-Effect
consciousness I-Effect
after I-Adverse_event.Trigger
ingestion I-Treatment.Route
of I-Treatment
ibuprofen I-Treatment.Drug
whose O
mental O
status O
markedly O
improved O
with O
administration O
of O
naloxone O
. O

Investigation O
confirmed O
the O
diagnosis O
of O
rhabdomyolysis O
, O
and O
discontinuation O
of O
colchicine I-Treatment.Drug
resulted I-Adverse_event.Trigger
in O
resolution O
of O
clinical O
and O
biochemical O
features O
of O
rhabdomylysis I-Effect
. O

A O
73 I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
patient I-Subject
with I-Subject
Wolff I-Treat_Disorder
- I-Treat_Disorder
Parkinson I-Treat_Disorder
- I-Treat_Disorder
White I-Treat_Disorder
syndrome I-Treat_Disorder
and I-Subject
paroxysmic I-Treat_Disorder
supraventricular I-Treat_Disorder
tachycardia I-Treat_Disorder
developed I-Adverse_event.Trigger
an O
acute I-Effect
reversible I-Effect
encephalopathy I-Effect
within I-Time_elapsed
15 I-Time_elapsed
days I-Time_elapsed
of O
initiation O
of O
flecainide I-Treatment.Drug
. O

Since O
the O
depressive I-Treat_Disorder
symptoms I-Treat_Disorder
returned O
sertraline I-Treatment.Drug
medication O
was O
initiated I-Potential_therapeutic_event.Trigger
. O

Supravenous I-Effect
hyperpigmentation I-Effect
in O
association I-Adverse_event.Trigger
with O
CHOP I-Treatment.Drug
chemotherapy I-Treatment.Route
of O
a I-Treat_Disorder
CD30 I-Treat_Disorder
( I-Treat_Disorder
Ki I-Treat_Disorder
- I-Treat_Disorder
1) I-Treat_Disorder
- I-Treat_Disorder
positive I-Treat_Disorder
anaplastic I-Treat_Disorder
large I-Treat_Disorder
- I-Treat_Disorder
cell I-Treat_Disorder
lymphoma I-Treat_Disorder
. O

A I-Subject
33 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
presented O
with O
brown I-Effect
discolouration I-Effect
of I-Effect
the I-Effect
fingernails I-Effect
following O
the O
application I-Adverse_event.Trigger
of O
4 I-Treatment.Dosage
% I-Treatment.Dosage
hydroquinone I-Treatment.Drug
in I-Treatment
sorbolene I-Treatment
cream I-Treatment.Route
and I-Treatment
0.1 I-Treatment.Dosage
% I-Treatment.Dosage
tretinoin I-Treatment.Drug
cream I-Treatment.Route
to I-Treatment
the I-Treatment
face I-Treatment.Route
intermittently I-Treatment.Freq
for I-Treatment
9 I-Treatment.Duration
months I-Treatment.Duration
. O

We O
describe O
two I-Subject.Population
cases I-Subject
of O
sulfadiazine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
crystalluria I-Effect
and I-Effect
renal I-Effect
failure I-Effect
in O
patients I-Subject
with I-Subject
acquired I-Treat_Disorder
immunodeficiency I-Treat_Disorder
syndrome I-Treat_Disorder
, O
review O
the O
pertinent O
literature O
, O
and O
discuss O
the O
pathogenesis O
. O

Acute I-Effect
eosinophilic I-Effect
pneumonia I-Effect
caused I-Adverse_event.Trigger
by O
calcium I-Treatment.Drug
stearate I-Treatment.Drug
, I-Treatment
an I-Treatment
additive I-Treatment
agent I-Treatment
for I-Treatment
an I-Treatment
oral I-Treatment.Route
antihistaminic I-Treatment
medication I-Treatment
. O

The O
cause O
of O
death I-Effect
was O
determined O
to O
be O
acute I-Effect
intoxication I-Effect
by I-Adverse_event.Trigger
olanzapine I-Treatment.Drug
, O
and O
the O
manner O
of O
death O
was O
accidental O
. O

Long I-Effect
lasting I-Effect
respiratory I-Effect
depression I-Effect
induced I-Adverse_event.Trigger
by O
morphine I-Treatment.Drug
- I-Treatment.Drug
6 I-Treatment.Drug
- I-Treatment.Drug
glucuronide I-Treatment.Drug
? O

A I-Effect
toxic I-Effect
encephalopathy I-Effect
characterized I-Effect
by I-Effect
depressed I-Effect
level I-Effect
of I-Effect
consciousness I-Effect
, I-Effect
marked I-Effect
irritability I-Effect
, I-Effect
and I-Effect
ataxia I-Effect
developed I-Adverse_event.Trigger
in O
seven I-Subject.Population
children I-Subject.Age
, I-Subject.Age
5 I-Subject.Age
years I-Subject.Age
of I-Subject.Age
age I-Subject.Age
and I-Subject.Age
younger I-Subject.Age
, O
following O
administration I-Treatment
of I-Treatment
an I-Treatment
antiemetic I-Treatment
combination I-Treatment
of I-Treatment
pentobarbital I-Treatment.Combination.Drug
and I-Treatment
pyrilamine I-Treatment.Combination.Drug
maleate I-Treatment.Combination.Drug
. O

Oculomotor I-Effect
disturbances I-Effect
associated I-Adverse_event.Trigger
with O
5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
chemotherapy I-Treatment.Route
. O

While O
doxorubicin I-Treatment.Drug
was O
administered O
, O
the O
patient I-Subject
presented I-Adverse_event.Trigger
thoracic I-Effect
pain I-Effect
and I-Effect
breathing I-Effect
distress I-Effect
due O
to O
superior O
vena O
cava O
perforation O
by O
the O
central O
catheter O
and O
subsequent O
extravasation O
of O
the O
drug O
into O
the O
mediastinum O
. O

An I-Subject
18 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
Japanese I-Subject.Race
man I-Subject.Gender
weighing I-Subject
53 I-Subject
kg I-Subject
with I-Subject
an I-Subject
anaplastic I-Subject
large I-Subject
cell I-Treat_Disorder
lymphoma I-Treat_Disorder
received I-Treatment
continuous I-Treatment
IV I-Treatment.Route
administration I-Treatment.Route
of I-Treatment
TAC I-Treatment.Drug
as O
post O
- O
transplantation O
prophylaxis I-Potential_therapeutic_event.Trigger
against O
graft I-Effect
- I-Effect
versus I-Effect
- I-Effect
host I-Effect
disease I-Effect
( I-Effect
GVHD I-Effect
) I-Effect
after O
an O
allogeneic I-Treatment
bone I-Treatment
marrow I-Treatment
transplantation I-Treatment
( I-Treatment
BMT I-Treatment
) I-Treatment
. O

Intravenous I-Treatment.Route
administration I-Treatment
of I-Treatment
levodopa I-Treatment.Drug
ameliorated I-Potential_therapeutic_event.Trigger
a I-Treat_Disorder
refractory I-Treat_Disorder
akathisia I-Treat_Disorder
case I-Treat_Disorder
induced I-Treat_Disorder
by I-Treat_Disorder
interferon I-Treat_Disorder
- I-Treat_Disorder
alpha I-Treat_Disorder
. O

Patients I-Subject
with I-Subject
lymphoblastic I-Treat_Disorder
lymphoma I-Treat_Disorder
who O
had O
treatment O
with O
L I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
asparaginase I-Treatment.Combination.Drug
and I-Treatment
steroid I-Treatment.Combination.Drug
are O
predisposed I-Adverse_event.Trigger
to O
the O
development O
of O
cortical I-Effect
venous I-Effect
thrombosis I-Effect
and O
may O
have O
this O
syndrome O
in O
addition O
to O
a O
dural I-Effect
puncture I-Effect
headache I-Effect
. O

Because O
sumatriptan I-Treatment.Drug
can O
cause I-Adverse_event.Trigger
coronary I-Effect
artery I-Effect
vasospasm I-Effect
, O
patients O
with O
significant O
risk O
factors O
for O
coronary O
artery O
disease O
should O
be O
carefully O
evaluated O
for O
cardiovascular O
disease O
prior O
to O
the O
use O
of O
sumatriptan O
. O

This O
article O
describes O
the O
case O
of O
a O
25 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
found I-Adverse_event.Trigger
dead I-Effect
at O
home O
who O
had O
been O
prescribed O
olanzapine I-Treatment.Drug
for O
schizophrenia I-Treat_Disorder
. O

A I-Subject
67 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
developed I-Adverse_event.Trigger
diarrhea I-Effect
shortly O
after O
a I-Treatment
10 I-Treatment.Duration
- I-Treatment.Duration
day I-Treatment.Duration
course I-Treatment
of I-Treatment
oral I-Treatment.Route
ampicillin I-Treatment.Drug
. O

Prominent I-Effect
positive I-Effect
U I-Effect
waves I-Effect
appearing I-Adverse_event.Trigger
with O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
intravenous I-Treatment.Route
phenylephrine I-Treatment.Drug
. O

Severe I-Effect
acidosis I-Effect
in O
patients I-Subject
taking I-Adverse_event.Trigger
metformin I-Treatment.Drug
-- O
rapid O
reversal O
and O
survival O
despite O
high O
APACHE O
score O
. O

Seizures I-Effect
and I-Effect
transient I-Effect
blindness I-Effect
following I-Adverse_event.Trigger
intravenous I-Treatment.Route
pulse I-Treatment
methylprednisolone I-Treatment.Drug
in O
children I-Subject.Age
with I-Subject
primary I-Treat_Disorder
glomerulonephritis I-Treat_Disorder
. O

We O
report O
on O
a I-Subject
patient I-Subject
with I-Subject
acromegaly I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
severe O
drug O
- O
induced O
hepatitis I-Effect
during O
combined O
treatment O
with O
the O
long I-Treatment
- I-Treatment
acting I-Treatment
somatostatin I-Treatment
- I-Treatment
analog I-Treatment
octreotide I-Treatment.Combination.Drug
and O
the O
GH I-Treatment
receptor I-Treatment
antagonist I-Treatment
pegvisomant I-Treatment.Combination.Drug
. O

The O
primary O
efficacy O
population O
consisted O
of O
1754 I-Subject.Age
patients I-Subject
( I-Subject
> I-Subject
or I-Subject
= I-Subject
18 I-Subject
years I-Subject
) I-Subject
with I-Subject
severe I-Treat_Disorder
sepsis I-Treat_Disorder
and I-Subject
a I-Subject
high I-Subject
INR I-Subject
( O
> O
or O
= O
1.2 O
) O
randomly O
assigned I-Potential_therapeutic_event.Trigger
to O
intravenous O
infusion O
of O
either O
tifacogin I-Treatment.Drug
( O
0.025 O
mg O
/ O
kg O
per O
hour O
for O
96 O
hours O
, O
n O
= O
880 O
) O
or O
placebo O
( O
arginine O
citrate O
buffer O
, O
n O
= O
874 O
) O
, O
and O
201 O
patients O
with O
a O
low O
INR O
( O
< O
1.2 O
) O
randomly O
assigned O
to O
receive O
the O
same O
dose O
of O
either O
tifacogin O
or O
placebo O
. O

We O
report O
a O
case O
of O
a I-Subject
23 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
who O
developed I-Adverse_event.Trigger
a I-Effect
vancomycin I-Treatment.Drug
- I-Effect
induced I-Effect
anaphylactic I-Effect
reaction I-Effect
in O
the O
treatment O
of O
methicillin I-Treat_Disorder
- I-Treat_Disorder
resistant I-Treat_Disorder
Staphylococcus I-Treat_Disorder
aureus I-Treat_Disorder
infection I-Treat_Disorder
. O

Recovery I-Potential_therapeutic_event.Trigger
of O
the O
tubular I-Treat_Disorder
dysfunction I-Treat_Disorder
took O
15 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
following I-Treatment
cessation I-Treatment.Dosage
of I-Treatment
the I-Treatment
offending I-Treatment
drug I-Treatment
, I-Treatment
Amikacin I-Treatment.Drug
. O

L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pancreatitis I-Effect
has O
been O
reported O
during O
or O
closely O
following O
administration O
of O
the O
drug O
. O

These O
novel O
findings O
may O
offer O
specific O
therapeutic O
targets O
in O
the O
treatment O
of O
BCNU I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
pulmonary I-Effect
fibrosis I-Effect
. O

A I-Subject
58 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
advanced I-Subject
renal I-Treat_Disorder
cell I-Treat_Disorder
carcinoma I-Treat_Disorder
developed I-Adverse_event.Trigger
grade I-Effect
3 I-Effect
proteinuria I-Effect
( I-Effect
8.5 I-Effect
g/24 I-Effect
h I-Effect
) I-Effect
without I-Effect
microscopic I-Effect
hematuria I-Effect
or I-Effect
renal I-Effect
insufficiency I-Effect
five I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment
temsirolimus I-Treatment.Drug
infusion I-Treatment.Route
. O

A I-Subject
2 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
mentally I-Subject
retarded I-Subject
boy I-Subject.Gender
with I-Subject
frontal I-Treat_Disorder
lobe I-Treat_Disorder
epilepsy I-Treat_Disorder
presented O
with O
an I-Effect
episode I-Effect
that I-Effect
resembled I-Effect
heat I-Effect
stroke I-Effect
during I-Adverse_event.Trigger
the O
administration O
of O
zonisamide I-Treatment.Drug
. O

[ O
Serotonin I-Effect
syndrome I-Effect
following I-Adverse_event.Trigger
methylene I-Treatment.Drug
blue I-Treatment.Drug
infusion I-Treatment.Route
during I-Treatment
parathyroidectomy I-Treatment
: O
a O
case O
report O
and O
literature O
review O
] O
. O

Two I-Subject.Population
patients I-Subject
treated I-Adverse_event.Trigger
with O
5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
( I-Treatment
5 I-Treatment
- I-Treatment
FU I-Treatment
) I-Treatment
for O
disseminated I-Treat_Disorder
adenocarcinoma I-Treat_Disorder
of I-Treat_Disorder
the I-Treat_Disorder
colon I-Treat_Disorder
developed O
cerebellar I-Effect
dysfunction I-Effect
typical O
of O
5 O
- O
FU O
neurotoxicity O
. O

Once O
extensive O
microbiological O
studies O
proved O
negative O
, O
corticosteroids I-Treatment.Drug
were O
given O
and O
a I-Effect
complete I-Effect
remission I-Effect
of I-Effect
clinical I-Treat_Disorder
and I-Treat_Disorder
radiological I-Treat_Disorder
abnormalities I-Treat_Disorder
was I-Effect
achieved I-Effect
. O

Disseminated I-Effect
muscular I-Effect
cysticercosis I-Effect
with I-Effect
myositis I-Effect
induced I-Adverse_event.Trigger
by O
praziquantel I-Treatment.Drug
therapy I-Treatment
. O

Cardiomyopathy I-Effect
after O
widely I-Treatment
separated I-Treatment
courses I-Treatment
of I-Treatment
adriamycin I-Treatment.Combination.Drug
exacerbated I-Effect
by O
actinomycin I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
D I-Treatment.Combination.Drug
and I-Treatment
mithramycin I-Treatment.Combination.Drug
. O

Linear I-Effect
immunoglobulin I-Effect
A I-Effect
bullous I-Effect
dermatosis I-Effect
induced I-Adverse_event.Trigger
by O
gemcitabine I-Treatment.Drug
. O

The O
temporal O
association O
of O
the O
course O
of O
tolterodine O
with O
an O
elevated I-Treat_Disorder
INR I-Treat_Disorder
, O
the O
return I-Effect
to I-Effect
the I-Effect
previous I-Effect
warfarin I-Effect
dose I-Effect
- I-Effect
INR I-Effect
response I-Effect
relationship I-Effect
after O
tolterodine I-Treatment.Drug
discontinuation I-Treatment
, O
and O
the O
absence O
of O
other O
causes O
for O
the O
elevated O
INR O
were O
factors O
found O
in O
both I-Subject.Population
patients I-Subject
. O

The O
harlequin I-Effect
color I-Effect
change I-Effect
and O
association I-Adverse_event.Trigger
with O
prostaglandin I-Treatment.Drug
E1 I-Treatment.Drug
. O

A O
case O
of O
tuberculosis I-Effect
in O
a I-Subject
patient I-Subject
on O
Efalizumab I-Treatment.Combination.Drug
and I-Treatment
Etanercept I-Treatment.Combination.Drug
for O
treatment I-Adverse_event.Trigger
of O
refractory I-Treat_Disorder
palmopustular I-Treat_Disorder
psoriasis I-Treat_Disorder
and I-Treat_Disorder
psoriatic I-Treat_Disorder
arthritis I-Treat_Disorder
. O

Although O
the O
two O
local O
anesthetics O
usually O
do O
not O
cause O
methemoglobinemia O
, O
we O
suspect O
that O
the I-Treatment
displacement I-Treatment
of I-Treatment
lidocaine I-Treatment.Combination.Drug
from I-Treatment
protein I-Treatment
binding I-Treatment
by I-Treatment
bupivacaine I-Treatment.Combination.Drug
, I-Treatment
in I-Treatment
combination I-Treatment
with I-Treatment
metabolic I-Treatment.Combination.Drug
acidosis I-Treatment.Combination.Drug
and I-Treatment
treatment I-Treatment
with I-Treatment
other I-Treatment
oxidants I-Treatment.Combination.Drug
, O
was O
the O
reason I-Adverse_event.Trigger
for O
the O
development O
of O
methemoglobinemia I-Effect
. O

Nephrotic I-Effect
range I-Effect
pseudoproteinuria I-Effect
in I-Adverse_event.Trigger
a O
tolmetin I-Treatment.Drug
- O
treated O
patient I-Subject
. O

With I-Subject
the O
first I-Treatment
cyclosporine I-Treatment.Drug
dose I-Treatment
, O
the O
patient O
complained I-Adverse_event.Trigger
of O
leg I-Effect
pain I-Effect
that O
was O
most O
severe O
during O
the O
cyclosporine O
infusion I-Route
. O

We O
report O
on O
a I-Subject
patient I-Subject
who O
developed O
acute I-Effect
rhabdomyolysis I-Effect
after I-Adverse_event.Trigger
taking O
cerivastatin I-Treatment.Drug
. O

In O
a O
patient I-Subject
suffering I-Subject
from I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
, O
we O
report O
the O
first O
simultaneous O
occurrence O
of O
two O
side O
effects O
of O
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
methotrexate I-Treatment.Drug
: O
an I-Adverse_event.Trigger
acute I-Effect
megaloblastic I-Effect
anaemia I-Effect
and I-Effect
a I-Effect
pneumonitis I-Effect
. O

We O
describe O
a I-Subject
57 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
acral I-Subject.Sub_Disorder
erythrocyanosis I-Subject.Sub_Disorder
progressing O
to O
acute I-Effect
digital I-Effect
ischemia I-Effect
and I-Effect
gangrene I-Effect
that O
developed I-Adverse_event.Trigger
after O
combined I-Treatment
chemotherapy I-Treatment
( I-Treatment
bleomycin I-Treatment.Combination.Drug
and I-Treatment
methotrexate I-Treatment.Combination.Drug
) I-Treatment
used O
to O
treat O
a O
metastatic I-Treat_Disorder
squamous I-Treat_Disorder
cell I-Treat_Disorder
carcinoma I-Treat_Disorder
of I-Treat_Disorder
the I-Treat_Disorder
hypopharynx I-Treat_Disorder
. O

We O
report O
a I-Effect
case I-Effect
of I-Effect
long I-Effect
lasting I-Effect
respiratory I-Effect
depression I-Effect
after I-Adverse_event.Trigger
intravenous I-Treatment.Route
administration I-Treatment
of I-Treatment
morphine I-Treatment.Drug
to O
a I-Subject
7 I-Subject.Age
year I-Subject.Age
old I-Subject.Age
girl I-Subject.Gender
with I-Subject
haemolytic I-Subject.Sub_Disorder
uraemic I-Subject.Sub_Disorder
syndrome I-Subject.Sub_Disorder
. O

Although O
adverse O
effects O
are O
usually O
mild O
, O
the O
author O
reports O
here O
a I-Subject
case I-Subject
of O
leucocytopenia I-Effect
and I-Effect
thrombocytopenia I-Effect
with I-Adverse_event.Trigger
quetiapine I-Treatment.Drug
treatment O
that O
required O
its O
discontinuation O
. O

Noncardiogenic I-Effect
pulmonary I-Effect
edema I-Effect
during I-Adverse_event.Trigger
intrabiliary I-Treatment.Route
infusion I-Treatment.Route
of I-Treatment
mono I-Treatment.Drug
- I-Treatment.Drug
octanoin I-Treatment.Drug
. O

Cardiac I-Treatment
glycosides I-Treatment
are O
thought I-Potential_therapeutic_event.Trigger
to I-Potential_therapeutic_event.Trigger
prevent O
doxorubicin I-Drug
cardiomyopathy O
by O
competitively O
inhibiting O
doxorubicin O
at O
its O
receptor O
sites O
, O
but O
ouabain O
has O
a O
much O
shorter O
half O
life O
than O
doxorubicin O
and O
its O
metabolites O
and O
so O
is O
less O
effective O
than O
digoxin O
. O

Three I-Subject.Population
hundred I-Subject.Population
and I-Subject.Population
thirty I-Subject.Population
eight I-Subject.Population
patients I-Subject
with I-Subject
moderate I-Subject
to I-Subject
severe I-Subject
painful I-Treat_Disorder
diabetic I-Treat_Disorder
neuropathy I-Treat_Disorder
despite O
receiving I-Potential_therapeutic_event.Trigger
their O
maximum I-Dosage
tolerated I-Dosage
dose I-Dosage
of O
gabapentin I-Treatment.Drug
, O
had O
oral I-Treatment.Route
prolonged I-Treatment.Drug
- I-Treatment.Drug
release I-Treatment.Drug
oxycodone I-Treatment.Drug
or I-Treatment
placebo I-Treatment.Drug
tablets I-Treatment.Route
added I-Treatment
to I-Treatment
their I-Treatment
therapy I-Treatment
for I-Treatment.Time_elapsed
up I-Treatment.Time_elapsed
to I-Treatment.Time_elapsed
12 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
. O

We O
assessed O
the O
bleeding I-Effect
risk O
in O
patients I-Subject
treated I-Adverse_event.Trigger
with O
thromboprophylactic I-Treatment
dabigatran I-Treatment.Combination.Drug
etexilate I-Treatment.Combination.Drug
, I-Treatment
with I-Treatment
and I-Treatment
without I-Treatment
concomitant I-Treatment
NSAID I-Treatment.Combination.Drug
or I-Treatment
ASA I-Treatment.Combination.Drug
. O

Dapsone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
erythroderma I-Effect
with I-Effect
Beau I-Effect
's I-Effect
lines I-Effect
. O

Methotrexate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hepatic I-Effect
necrosis I-Effect
requiring O
liver O
transplantation O
in O
a I-Subject
patient I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

We O
present O
three O
cases O
from O
the O
Provincial O
Toxicology O
Center O
of O
British O
Columbia O
, O
Canada O
in O
which O
suicidal I-Effect
overdose I-Effect
deaths I-Effect
were O
associated I-Adverse_event.Trigger
with O
quetiapine I-Treatment.Drug
. O

Both I-Subject
patients I-Subject
developed I-Adverse_event.Trigger
hypoadrenalism I-Effect
while O
on O
o I-Treatment.Combination.Drug
, I-Treatment.Combination.Drug
p' I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
DDD I-Treatment.Combination.Drug
and I-Treatment
apparently I-Treatment
adequate I-Treatment
dexamethasone I-Treatment.Combination.Drug
replacement I-Treatment
therapy I-Treatment
. O

In O
the O
other O
patient O
, O
a I-Subject
78 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
, O
Neisseria I-Effect
mucosa I-Effect
knee I-Effect
arthritis I-Effect
occurred I-Adverse_event.Trigger
after O
a I-Treatment
single I-Treatment.Dosage
sodium I-Treatment.Drug
hyaluronate I-Treatment.Drug
injection I-Treatment.Dosage
. O

Implanon I-Treatment
failure I-Treatment
in O
an I-Subject
HIV I-Treat_Disorder
- I-Treat_Disorder
positive I-Treat_Disorder
woman I-Subject.Gender
on I-Treatment
antiretroviral I-Treatment
therapy I-Treatment
resulting I-Adverse_event.Trigger
in O
two I-Effect
ectopic I-Effect
pregnancies I-Effect
. O

Massive I-Effect
prolapse I-Effect
of I-Effect
the I-Effect
urethral I-Effect
mucosa I-Effect
following I-Adverse_event.Trigger
periurethral I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
calcium I-Treatment.Drug
hydroxylapatite I-Treatment.Drug
for O
stress I-Treat_Disorder
urinary I-Treat_Disorder
incontinence I-Treat_Disorder
. O

A I-Subject
35 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
with I-Subject
borderline I-Treat_Disorder
lepromatous I-Treat_Disorder
( I-Treat_Disorder
BL I-Treat_Disorder
) I-Treat_Disorder
leprosy I-Treat_Disorder
who O
suffered O
from O
dapsone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
erythroderma I-Effect
is O
reported O
. O

Well O
- O
known O
signs I-Adverse_event.Trigger
of O
methotrexate I-Treatment.Drug
toxicity O
include O
bone I-Effect
marrow I-Effect
suppression I-Effect
and I-Effect
oral I-Effect
and I-Effect
gastrointestinal I-Effect
ulceration I-Effect
. O

Hemorrhage I-Effect
from I-Effect
a I-Effect
falx I-Treat_Disorder
meningioma I-Treat_Disorder
after I-Adverse_event.Trigger
internal I-Treatment.Route
use I-Treatment
of I-Treatment
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
aspirin I-Treatment.Drug
. O

Severe I-Effect
respiratory I-Effect
syncytial I-Effect
virus I-Effect
pulmonary I-Effect
infection I-Effect
in O
a I-Subject
patient I-Subject
treated I-Adverse_event.Trigger
with O
fludarabine I-Treatment.Drug
for O
chronic I-Treat_Disorder
lymphocytic I-Treat_Disorder
leukemia I-Treat_Disorder
. O

Nonsustained I-Effect
polymorphous I-Effect
ventricular I-Effect
tachycardia I-Effect
during I-Adverse_event.Trigger
amiodarone I-Treatment.Drug
therapy I-Treatment
for O
atrial I-Treat_Disorder
fibrillation I-Treat_Disorder
complicating I-Treat_Disorder
cardiomyopathy I-Treat_Disorder
. O

Severe O
abdominal I-Effect
pain I-Effect
in I-Adverse_event.Trigger
low I-Treatment.Dosage
dosage I-Treatment.Dosage
clofazimine I-Treatment.Drug
. O

Behavioral O
side O
effects O
associated I-Adverse_event.Trigger
with O
clonazepam I-Treatment.Drug
may O
include O
agitation I-Effect
, I-Effect
aggression I-Effect
, I-Effect
hyperactivity I-Effect
, I-Effect
irritability I-Effect
, I-Effect
property I-Effect
destruction I-Effect
, I-Effect
and I-Effect
temper I-Effect
tantrums I-Effect
. O

Coagulopathy I-Effect
associated I-Adverse_event.Trigger
with O
the O
use O
of O
cephalosporin I-Treatment.Drug
or I-Treatment
moxalactam I-Treatment.Drug
antibiotics I-Treatment
in O
acute I-Treat_Disorder
and I-Treat_Disorder
chronic I-Treat_Disorder
renal I-Treat_Disorder
failure I-Treat_Disorder
. O

Pamidronate O
therapy O
should O
be O
considered O
in O
patients O
with O
hypercalcemia I-Effect
secondary I-Adverse_event.Trigger
to O
acute O
vitamin I-Treatment.Drug
D I-Treatment.Drug
poisoning O
. O

Use O
of O
the O
Naranjo O
probability O
scale O
indicated O
a O
highly O
probable O
relationship I-Adverse_event.Trigger
between O
the O
observed O
cardiac I-Effect
toxicity I-Effect
and O
amphotericin I-Treatment.Drug
B I-Treatment.Drug
deoxycholate I-Treatment.Drug
therapy O
in O
this O
patient I-Subject
. O

Captopril I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pulmonary I-Effect
infiltrates I-Effect
with I-Effect
eosinophilia I-Effect
in O
an I-Subject
infant I-Subject.Age
with I-Subject
congenital I-Subject.Sub_Disorder
heart I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
. O

Chronic I-Treatment.Duration
fentanyl I-Treatment.Drug
application O
induces I-Adverse_event.Trigger
adrenocortical I-Effect
insufficiency I-Effect
. O

After O
discontinuing I-Treatment
captopril I-Treatment.Drug
and I-Treatment
starting I-Treatment
systemic I-Treatment
steroids I-Treatment.Drug
, O
her O
symptomatology O
rapidly O
improved O
, O
and O
her I-Effect
eosinophilia I-Treat_Disorder
and I-Effect
radiographic I-Treat_Disorder
abnormalities I-Treat_Disorder
both I-Effect
resolved I-Effect
. O

We O
present O
a O
surprising O
case O
of O
a I-Subject
woman I-Subject.Gender
schizophrenic I-Treat_Disorder
patient I-Subject
treated O
with O
clozapine I-Treatment.Drug
suffering I-Adverse_event.Trigger
from O
EPS I-Effect
. O

Therefore O
, O
we O
concluded O
that O
this I-Subject
patient I-Subject
's I-Subject
pulmonary I-Effect
disease I-Effect
was O
caused I-Adverse_event.Trigger
by O
calcium I-Treatment.Drug
stearate I-Treatment.Drug
, O
an I-Treatment
additive I-Treatment
for I-Treatment
an I-Treatment
antihistaminic I-Treatment
drug I-Treatment
. O

Benzocaine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
methemoglobinemia I-Effect
has O
been O
reported O
in O
man I-Subject
, I-Subject
dogs I-Subject
, I-Subject
and I-Subject
cats I-Subject
. O

We O
report O
two O
cases O
of I-Adverse_event.Trigger
fulminant I-Effect
hepatic I-Effect
failure I-Effect
in O
HIV I-Treat_Disorder
- I-Treat_Disorder
1 I-Treat_Disorder
- I-Subject
infected I-Subject
patients I-Subject
treated O
with O
didanosine I-Treatment.Drug
( I-Treatment
ddI I-Treatment
) I-Treatment
. O

Leflunomide I-Treatment
- O
associated I-Adverse_event.Trigger
weight I-Effect
loss I-Effect
in O
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

Antiretroviral I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hepatic I-Effect
steatosis I-Effect
and I-Effect
lactic I-Effect
acidosis I-Effect
: O
case I-Subject
report O
and O
review O
of O
the O
literature O
. O

A I-Subject
woman I-Subject.Gender
developed I-Adverse_event.Trigger
delusional I-Effect
parasitosis I-Effect
when O
taking O
phenelzine I-Treatment.Drug
. O

Percutaneous I-Treatment.Route
absorption I-Treatment.Route
of I-Treatment
warfarin I-Treatment.Drug
causing I-Adverse_event.Trigger
coagulopathy I-Effect
, O
reported O
three O
times O
in O
the O
past O
, O
is O
a O
significant O
risk O
if O
protective O
measures O
, O
such O
as O
gloves O
, O
are O
not O
used O
. O

We O
present O
two O
cases O
of O
nitrofurantoin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pulmonary I-Effect
toxicity I-Effect
in I-Effect
which I-Effect
the I-Effect
initial I-Effect
HRCT I-Effect
showed I-Effect
a I-Effect
widespread I-Effect
reticular I-Effect
pattern I-Effect
and I-Effect
associated I-Effect
distortion I-Effect
of I-Effect
the I-Effect
lung I-Effect
parenchyma I-Effect
, I-Effect
thought I-Effect
to I-Effect
represent I-Effect
established I-Effect
fibrosis I-Effect
. O

Colchicine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
rhabdomyolysis I-Effect
. O

We O
report O
a O
case O
of O
severe O
AVP I-Effect
three I-Time_elapsed
weeks I-Time_elapsed
following I-Adverse_event.Trigger
the O
administration O
of O
infliximab I-Treatment.Drug
for O
the O
treatment O
of O
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
( O
CD O
) O
. O

In O
each I-Subject
patient I-Subject
, O
the I-Treatment
initiation I-Treatment
of I-Treatment
tolterodine I-Treatment.Drug
was O
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
a O
significant I-Effect
increase I-Effect
in I-Effect
the I-Effect
patient I-Effect
's I-Effect
INR I-Effect
measured O
10 I-Time_elapsed
- I-Time_elapsed
14 I-Time_elapsed
days I-Time_elapsed
later I-Time_elapsed
. I-Time_elapsed

DATA O
SYNTHESIS O
: O
Genetic I-Subject.Sub_Disorder
deficiencies I-Subject.Sub_Disorder
in I-Subject.Sub_Disorder
DPD I-Subject.Sub_Disorder
, I-Subject
the I-Subject
rate I-Subject
- I-Subject
limiting I-Subject
enzyme I-Subject
responsible I-Subject
for I-Subject
5 I-Subject
- I-Subject
FU I-Subject
catabolism I-Subject
, I-Subject
may I-Subject
occur I-Subject
in I-Subject
3 I-Subject.Population
% I-Subject.Population
or I-Subject.Population
more I-Subject.Population
of I-Subject
patients I-Subject
with I-Subject
cancer I-Treat_Disorder
putting I-Adverse_event.Trigger
them O
at O
increased I-Effect
risk I-Effect
for I-Effect
unusually I-Effect
severe I-Effect
adverse I-Effect
reactions I-Effect
( I-Effect
e.g. I-Effect
, I-Effect
diarrhea I-Effect
, I-Effect
stomatitis I-Effect
, I-Effect
mucositis I-Effect
, I-Effect
myelosuppression I-Effect
, I-Effect
neurotoxicity I-Effect
) I-Effect
to O
standard I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
. O

According O
to O
the O
Drug O
Interaction O
Probability O
Scale O
, O
the O
development I-Effect
of I-Effect
supratherapeutic I-Effect
INRs I-Effect
was O
probably O
associated I-Adverse_event.Trigger
with O
concomitant I-Treatment
acetaminophen I-Treatment.Combination.Drug
and I-Treatment
moxifloxacin I-Treatment.Combination.Drug
use I-Treatment
. O

Both O
colchicine I-Treatment.Combination.Drug
and I-Treatment
statin I-Treatment.Combination.Drug
therapy I-Treatment
may O
be O
associated I-Adverse_event.Trigger
with O
myopathy I-Effect
, O
which O
usually O
occurs O
after O
several O
months O
of O
therapy O
. O

Cephalosporins I-Treatment.Drug
are O
most O
likely O
associated I-Adverse_event.Trigger
with O
Vitamin I-Effect
K I-Effect
deficiency I-Effect
. I-Effect

Embolia I-Effect
cutis I-Effect
medicamentosa I-Effect
following I-Adverse_event.Trigger
subcutaneous I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
glatiramer I-Treatment.Drug
acetate I-Treatment.Drug
. O

Reversible I-Effect
valproic I-Treatment.Drug
acid I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
dementia I-Effect
was O
documented O
in O
a I-Subject
21 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
epilepsy I-Treat_Disorder
who I-Subject
had I-Subject
a I-Subject
3 I-Subject
- I-Subject
year I-Subject
history I-Subject
of I-Subject
insidious I-Subject.Sub_Disorder
progressive I-Subject.Sub_Disorder
decline I-Subject.Sub_Disorder
in I-Subject.Sub_Disorder
global I-Subject.Sub_Disorder
cognitive I-Subject.Sub_Disorder
abilities I-Subject.Sub_Disorder
documented O
by O
serial O
neuropsychological O
studies O
. O

We O
describe O
the O
case O
of O
a I-Subject
50 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
advanced I-Subject
non I-Subject
- I-Subject
small I-Subject
cell I-Subject
lung I-Treat_Disorder
cancer I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
status I-Effect
epilepticus I-Effect
shortly O
after O
receiving O
cisplatin I-Treatment.Combination.Drug
and I-Treatment
gemcitabine I-Treatment.Combination.Drug
chemotherapy I-Treatment.Route
. O

Here O
, O
we O
report O
a O
case O
of O
angio I-Effect
- I-Effect
oedema I-Effect
associated I-Adverse_event.Trigger
with O
VRC I-Treatment.Drug
therapy I-Treatment
. O

Multiple I-Effect
syncopal I-Effect
episodes I-Effect
started O
to O
occur I-Adverse_event.Trigger
during I-Treatment.Duration
thalidomide I-Treatment.Drug
treatment I-Treatment
, O
and I-Effect
a I-Effect
Holter I-Effect
electrocardiogram I-Effect
showed I-Effect
multiple I-Effect
abnormalities I-Effect
, I-Effect
with I-Effect
an I-Effect
episode I-Effect
of I-Effect
sustained I-Effect
ventricular I-Effect
tachycardia I-Effect
. O

A I-Subject
25 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
sought O
medical O
attention O
because O
of O
iliocaval I-Effect
manifestations I-Effect
of I-Effect
retroperitoneal I-Effect
fibrosis I-Effect
while I-Adverse_event.Trigger
she I-Subject
was O
taking O
methysergide I-Treatment.Drug
. O

Nodular I-Effect
scleritis I-Effect
following I-Adverse_event.Trigger
alendronate I-Treatment.Drug
therapy O
. O

Thus O
, O
tolterodine I-Treatment.Drug
was O
ineffective I-Potential_therapeutic_event.Trigger
in O
both I-Subject
patients I-Subject
and O
was O
discontinued O
one O
to O
two O
days O
before O
the O
elevated O
INRs O
were O
determined O
during O
routine O
clinic O
visits O
. O

However O
, O
the O
use O
of O
lithium I-Treatment.Drug
should O
be O
avoided O
with O
any O
patient I-Subject
who I-Subject
is I-Subject
purging I-Subject
, O
since O
it O
may O
exacerbate I-Adverse_event.Trigger
the O
loss I-Effect
of I-Effect
intracellular I-Effect
potassium I-Effect
, O
thereby O
increasing I-Effect
the I-Effect
risk I-Effect
of I-Effect
cardiac I-Effect
toxicity I-Effect
. O

Neurophysiological O
mechanisms O
which O
aid O
in O
elucidating O
the O
role O
of O
disulfiram I-Treatment.Drug
in O
the O
etiology I-Adverse_event.Trigger
of O
catatonia I-Effect
are O
discussed O
. O

Sagittal I-Effect
sinus I-Effect
thrombosis I-Effect
associated I-Effect
with I-Effect
transient I-Effect
free I-Effect
protein I-Effect
S I-Effect
deficiency I-Effect
after I-Adverse_event.Trigger
L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
treatment I-Treatment
: O
case O
report O
and O
review O
of O
the O
literature O
. O

This I-Subject
case I-Subject
demonstrates O
the O
association O
of O
selective I-Sub_Disorder
IgA I-Sub_Disorder
deficiency I-Sub_Disorder
with O
remission I-Effect
in I-Effect
rheumatoid I-Effect
arthritis I-Effect
induced I-Adverse_event.Trigger
by O
fenclofenac I-Treatment.Drug
as O
well O
as O
aurothiomalate I-Treatment.Drug
and O
sulphasalazine I-Treatment.Drug
. O

This O
study O
provides O
the O
first O
evidence O
that O
co I-Treatment
- I-Treatment
administration I-Treatment
of I-Treatment
prolonged I-Treatment
- I-Treatment
release I-Treatment
oxycodone I-Treatment.Combination.Drug
and I-Treatment
existing I-Treatment
gabapentin I-Treatment.Combination.Drug
therapy I-Treatment
has I-Potential_therapeutic_event.Trigger
a O
clinically I-Effect
meaningful I-Effect
effect I-Effect
in O
painful I-Treat_Disorder
diabetic I-Treat_Disorder
neuropathy I-Treat_Disorder
. O

In O
the O
present O
case O
report O
, O
the I-Treatment
concomitant I-Treatment
administration I-Treatment
of I-Treatment
clarithromycin I-Treatment.Combination.Drug
and I-Treatment
sirolimus I-Treatment.Combination.Drug
determined O
impressive O
increase O
of O
sirolimus O
trough O
blood O
concentrations O
from O
6.2 O
up O
to O
54 O
ng O
/ O
mL O
and O
this O
increase O
was O
associated I-Adverse_event.Trigger
with O
an O
acute I-Effect
impairment I-Effect
of I-Effect
renal I-Effect
function I-Effect
, O
almost O
completely O
reversed O
upon O
both O
drugs O
discontinuation O
. O

In O
one O
case O
, O
the O
readministration I-Adverse_event.Trigger
of O
riluzole I-Treatment.Drug
was O
followed O
by O
the I-Effect
relapse I-Effect
of I-Effect
hepatitis I-Effect
. O

Pseudoephedrine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hemorrhage I-Effect
associated I-Effect
with I-Effect
a I-Effect
cerebral I-Effect
vascular I-Effect
malformation I-Effect
. O

PURPOSE O
: O
To O
report O
a O
case O
of O
severe O
corticosteroid I-Drug
- O
induced I-Adverse_event.Trigger
glaucoma I-Effect
after O
intravitreal I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
triamcinolone I-Treatment.Drug
acetate I-Treatment.Drug
in O
a I-Subject
34 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
without I-Subject
a I-Subject
history I-Subject
of I-Subject
glaucoma I-Subject
. O

A O
transient I-Effect
tonic I-Effect
pupillary I-Effect
response I-Effect
, I-Effect
denervation I-Effect
supersensitivity I-Effect
, I-Effect
and I-Effect
abnormal I-Effect
visual I-Effect
- I-Effect
evoked I-Effect
potentials I-Effect
in O
quinine I-Treatment.Drug
toxicity O
, O
to O
our O
knowledge O
, O
have O
not O
been O
previously O
reported I-Adverse_event.Trigger
. O

Two I-Treatment.Duration
days I-Treatment.Duration
' I-Treatment
administration I-Treatment
of I-Treatment
levomepromazine I-Treatment.Drug
100 I-Treatment.Dosage
mg I-Treatment.Dosage
led I-Adverse_event.Trigger
him O
to O
a I-Effect
coma I-Effect
for I-Effect
2 I-Effect
days I-Effect
. O

Methimazole I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
aplastic I-Effect
anemia I-Effect
in O
third O
exposure O
: O
successful O
treatment O
with O
recombinant O
human O
granulocyte I-Drug
colony I-Drug
- I-Drug
stimulating I-Drug
factor I-Drug
. O

BACKGROUND O
: O
We O
describe O
the O
ophthalmic O
features O
and O
clinical O
course O
of O
two O
cases O
of O
acute I-Effect
syphilitic I-Effect
posterior I-Effect
placoid I-Effect
chorioretinitis I-Effect
( O
ASPPC O
) O
that O
developed I-Adverse_event.Trigger
after O
intravitreal I-Treatment
triamcinolone I-Treatment.Drug
acetonide I-Treatment.Drug
( I-Treatment.Drug
IVTA I-Treatment.Drug
) I-Treatment.Drug
injection I-Treatment.Route
. O

Skin I-Effect
rash I-Effect
and I-Effect
splinter I-Effect
hemorrhages I-Effect
from I-Adverse_event.Trigger
ganciclovir I-Treatment.Drug
. O

We O
present O
a O
pediatric I-Subject.Age
patient I-Subject
with I-Subject
leukemia I-Subject.Sub_Disorder
and I-Subject
a I-Subject
severe I-Subject
, I-Subject
L I-Treat_Disorder
- I-Treat_Disorder
asparaginase I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
necrotizing I-Treat_Disorder
pancreatitis I-Treat_Disorder
, O
treated O
successfully O
with O
percutaneous I-Treatment
drainage I-Treatment
used I-Adverse_event.Trigger
to I-Adverse_event.Trigger
flush I-Effect
the I-Effect
infected I-Effect
necrotic I-Effect
parts I-Effect
. I-Effect

Such O
anagen I-Effect
effluvium I-Effect
with I-Effect
lichenoid I-Effect
eruption I-Effect
following I-Adverse_event.Trigger
INH I-Treatment.Drug
therapy O
has O
not O
been O
observed O
previously O
. O

We O
conclude O
that O
MB O
is O
an O
effective O
treatment O
for O
ifosfamide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
encephalopathy I-Effect
. O

Hyponatraemia I-Effect
during I-Adverse_event.Trigger
low I-Treatment.Drug
- I-Treatment.Drug
dose I-Treatment.Drug
carbamazepine I-Treatment.Drug
therapy O
. O

Acute I-Effect
coronary I-Effect
syndrome I-Effect
induced I-Adverse_event.Trigger
by O
capecitabine I-Treatment.Drug
therapy I-Treatment
. O

A I-Subject
case I-Subject
of O
severe I-Effect
visual I-Effect
loss I-Effect
following I-Adverse_event.Trigger
a I-Treatment.Dosage
single I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
vincristine I-Treatment.Drug
is O
described O
. O

We O
report O
a O
case O
of O
a O
young I-Subject.Age
woman I-Subject.Gender
with I-Subject
SLE I-Treat_Disorder
and I-Subject
thrombocytopenia I-Subject.Sub_Disorder
, O
who O
developed O
severe I-Effect
perspiration I-Effect
, I-Effect
headache I-Effect
, I-Effect
and I-Effect
seizure I-Effect
after I-Adverse_event.Trigger
receiving O
cyclosporine I-Treatment.Drug
. O

Although O
gabapentin O
withdrawal O
has O
been O
previously O
reported O
and O
usually O
consists O
of O
anxiety O
, O
diaphoresis O
, O
and O
palpitations O
, O
this O
is O
the O
first O
reported O
patient I-Subject
with I-Adverse_event.Trigger
generalized I-Effect
seizures I-Effect
and I-Effect
status I-Effect
epilepticus I-Effect
secondary I-Treatment
to I-Treatment
gabapentin I-Treatment.Drug
withdrawal I-Treatment.Dosage
. O

Self I-Effect
- I-Effect
limited I-Effect
edema I-Effect
is O
a O
well O
- O
recognized O
complication I-Adverse_event.Trigger
of O
insulin I-Treatment.Drug
therapy O
. O

It O
is O
very O
likely O
that O
the O
dexamethasone I-Treatment.Drug
used O
in O
the O
antiemetic O
drug O
regimen O
contributed I-Adverse_event.Trigger
to O
the O
development O
of O
osteonecrosis I-Effect
in O
these I-Subject
patients I-Subject
. O

A O
case O
is O
presented O
of O
a I-Subject
patient I-Subject
who O
experienced O
benzodiazepine I-Effect
withdrawal I-Effect
symptoms I-Effect
on O
discontinuation I-Adverse_event.Trigger
of O
nefazodone I-Treatment.Drug
, O
an O
antidepressant O
that O
inhibits O
the O
cytochrome O
P450 O
3A4 O
isoenzyme O
. O

Isotretinoin I-Treatment.Drug
, O
a O
drug O
used O
for O
the O
treatment O
of O
acne I-Treat_Disorder
, O
has O
been O
shown O
to O
have I-Adverse_event.Trigger
teratogenic I-Effect
effects I-Effect
. O

The O
capacity O
of O
zuclopenthixol I-Treatment.Drug
to O
induce I-Adverse_event.Trigger
priapism I-Effect
is O
thought O
to O
be O
due O
to O
its O
antagonist O
activity O
on O
alpha O
- O
adrenergic O
receptors O
. O

Two I-Subject.Population
patients I-Subject
treated O
for O
chronic I-Treat_Disorder
myeloid I-Treat_Disorder
leukemia I-Treat_Disorder
with O
high O
doses O
of O
CCNU I-Treatment.Drug
( I-Treatment
1100 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m2 I-Treatment.Dosage
and I-Treatment
1240 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m2 I-Treatment.Dosage
, I-Treatment
respectively I-Treatment
) I-Treatment
developed I-Adverse_event.Trigger
a O
fatal O
pulmonary I-Effect
fibrosis I-Effect
. O

CONCLUSIONS O
: O
There O
is O
very O
little O
published O
information O
regarding O
ofloxacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
toxic I-Effect
epidermal I-Effect
necrolysis I-Effect
. O

Our I-Subject
case I-Subject
is I-Subject
the I-Subject
second I-Subject.Population
one I-Subject
in O
which O
hemorrhage I-Effect
from I-Effect
a I-Effect
meningioma I-Effect
may O
have O
been O
induced I-Adverse_event.Trigger
by O
aspirin I-Treatment.Drug
prophylaxis I-Treatment
. O

Methemoglobinemia I-Effect
after I-Adverse_event.Trigger
axillary I-Treatment
block I-Treatment
with I-Treatment
bupivacaine I-Treatment.Combination.Drug
and I-Treatment
additional I-Treatment
injection I-Treatment.Route
of I-Treatment
lidocaine I-Treatment.Combination.Drug
in I-Treatment
the I-Treatment
operative I-Treatment
field I-Treatment
. O

Nonconvulsive I-Effect
status I-Effect
epilepticus I-Effect
: O
the I-Adverse_event.Trigger
role I-Adverse_event.Trigger
of O
morphine I-Treatment.Drug
and I-Treatment
its I-Treatment
antagonist I-Treatment
. O

Acute I-Effect
myeloid I-Effect
leukemia I-Effect
evolving O
from O
essential I-Treat_Disorder
thrombocythemia I-Treat_Disorder
in O
two I-Subject.Population
patients I-Subject
treated I-Adverse_event.Trigger
with O
hydroxyurea I-Treatment.Drug
. O

Central I-Treat_Disorder
nervous I-Treat_Disorder
system I-Treat_Disorder
manifestations I-Treat_Disorder
of O
an O
ibuprofen I-Drug
overdose O
reversed O
by I-Potential_therapeutic_event.Trigger
naloxone I-Treatment.Drug
. O

BACKGROUND O
: O
Aphthous I-Effect
stomatitis I-Effect
, O
a O
common O
mucocutaneous O
disorder O
, O
is O
a O
well O
accepted O
complication I-Adverse_event.Trigger
of O
sirolimus I-Treatment.Drug
therapy O
. O

The O
goal O
of O
this O
article O
was O
to O
describe O
a O
potential O
drug I-Treatment
- I-Treatment
drug I-Treatment
interaction I-Treatment
between I-Treatment
propafenone I-Treatment.Combination.Drug
and I-Treatment
citalopram I-Treatment.Combination.Drug
, O
which O
caused I-Adverse_event.Trigger
symptoms I-Effect
of I-Effect
propafenone I-Drug
adverse I-Effect
effects I-Effect
. O

Temporary I-Effect
neurologic I-Effect
abnormalities I-Effect
were O
observed I-Adverse_event.Trigger
in O
one I-Subject.Population
out I-Subject.Population
of I-Subject.Population
23 I-Subject.Population
patients I-Subject
undergoing O
chemotherapy I-Treatment.Route
with I-Treatment
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
methotrexate I-Treatment.Drug
( I-Treatment
HD I-Treatment
- I-Treatment
MTX I-Treatment
) I-Treatment
for O
osteogenic I-Treat_Disorder
sarcoma I-Treat_Disorder
. O

This O
is O
the O
first O
report O
of O
a O
possible O
interaction O
between O
propafenone I-Treatment.Combination.Drug
and I-Treatment
citalopram I-Treatment.Combination.Drug
, O
which O
caused I-Adverse_event.Trigger
propafenone I-Treatment.Drug
adverse I-Effect
effects I-Effect
( I-Effect
eg I-Effect
, I-Effect
dizziness I-Effect
, I-Effect
falls I-Effect
) I-Effect
and I-Effect
mimicked I-Effect
coronary I-Effect
artery I-Effect
disease I-Effect
. O

Spontaneous I-Effect
bacterial I-Effect
peritonitis I-Effect
induced I-Adverse_event.Trigger
by O
intraarterial I-Treatment.Route
vasopressin I-Treatment.Drug
therapy I-Treatment
. O

Ciclesonide I-Treatment.Drug
reduces I-Potential_therapeutic_event.Trigger
the O
need O
for O
oral I-Route
steroid I-Drug
use O
in O
adult I-Subject.Age
patients I-Subject
with O
severe O
, O
persistent O
asthma I-Treat_Disorder
. O

Five I-Subject.Population
cases I-Subject
( I-Subject
four I-Subject
from I-Subject
the I-Subject
literature I-Subject
and I-Subject
one I-Subject
new I-Subject
case I-Subject
) I-Subject
are I-Subject
presented I-Subject
in I-Subject
which I-Subject
patients I-Subject
unsuspected I-Subject
of I-Subject
having I-Subject
vitamin I-Treat_Disorder
B12 I-Treat_Disorder
deficiency I-Treat_Disorder
developed I-Adverse_event.Trigger
subacute I-Effect
combined I-Effect
degeneration I-Effect
of I-Effect
the I-Effect
spinal I-Effect
cord I-Effect
following O
nitrous I-Treatment.Drug
oxide I-Treatment.Drug
anesthesia I-Treatment
. O

CASE O
SUMMARY O
: O
We O
report O
the O
case O
of O
a I-Subject
31 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
patient I-Subject
hospitalized O
due O
to O
behavioral I-Treat_Disorder
alterations I-Treat_Disorder
and O
treated O
with O
oral I-Treatment.Route
zuclopenthixol I-Treatment.Drug
, O
an O
antipsychotic O
from O
the O
thioxanthene O
family O
, O
who O
developed I-Adverse_event.Trigger
an O
acute I-Effect
, I-Effect
painful I-Effect
erection I-Effect
. O

Three O
cases O
of O
acute I-Effect
renal I-Effect
toxicity I-Effect
in O
patients I-Subject
receiving O
long O
- O
term O
therapy O
with O
mitomycin I-Treatment.Drug
C I-Treatment.Drug
and I-Treatment
5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
are O
reported I-Adverse_event.Trigger
. O

A I-Subject
40 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
a I-Subject
long I-Subject
standing I-Subject
history I-Subject
of I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
was O
treated O
with O
MTX I-Treatment.Drug
over I-Treatment
a I-Treatment
6 I-Treatment.Time_elapsed
month I-Treatment.Time_elapsed
period I-Treatment
and O
developed I-Adverse_event.Trigger
an I-Effect
overwhelming I-Effect
hepatic I-Effect
necrosis I-Effect
. O

In I-Subject
case I-Subject
1 I-Subject
, O
a I-Treatment
total I-Treatment
daily I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment.Dosage
25 I-Treatment.Dosage
mg I-Treatment.Dosage
sertraline I-Treatment.Drug
, O
with O
nondetectable O
sertraline O
and O
desmethylsertraline O
blood O
levels O
, O
resulted I-Adverse_event.Trigger
in O
a O
doubling I-Effect
of I-Effect
the I-Effect
lamotrigine I-Effect
blood I-Effect
level I-Effect
with I-Effect
symptoms I-Effect
of I-Effect
toxicity I-Effect
. O

Since O
the O
bronchospasm O
was O
relieved O
with O
discontinuation O
of O
propranolol I-Drug
and O
supportive O
bronchodilator O
therapy O
, O
the O
bronchospasm I-Effect
was O
believed O
to O
be O
caused I-Adverse_event.Trigger
by O
propranolol I-Treatment.Drug
. O

A I-Subject
depressed I-Treat_Disorder
woman I-Subject.Gender
with I-Subject
no I-Subject
history I-Subject
of I-Subject
bipolar I-Subject
illness I-Subject
developed O
a O
manic I-Effect
episode I-Effect
during I-Adverse_event.Trigger
treatment O
with O
fluoxetine I-Treatment.Drug
. O

Priapism I-Effect
associated I-Adverse_event.Trigger
with O
trazodone I-Treatment.Drug
therapy I-Treatment
: O
case O
report O
. O

OBJECTIVE O
: O
To O
report O
the O
occurrence O
of O
anterior I-Effect
ischemic I-Effect
optic I-Effect
neuropathy I-Effect
as O
a O
complication I-Adverse_event.Trigger
of O
treatment O
with O
interferon I-Treatment.Drug
alfa I-Treatment.Drug
and O
to O
consider O
the O
possible O
underlying O
mechanisms O
for O
this O
association O
. O

Mequitazine O
seemed O
to O
play O
a O
part O
similar O
to O
chlorpromazine O
, O
and O
absence O
of O
mequitazine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
photosensitivity I-Effect
may O
be O
due I-Treatment
to I-Treatment
a I-Treatment
relatively I-Treatment
low I-Treatment.Dosage
dosage I-Treatment.Dosage
of I-Treatment
the I-Treatment
drug I-Treatment
. O

Although O
various O
manifestations O
of O
pentamidine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cardiotoxicity I-Effect
have O
been O
reported O
, O
to O
our O
knowledge O
, O
second O
- O
degree O
heart O
block O
associated O
with O
this O
agent O
has O
not O
been O
described O
. O

The I-Treatment
mean I-Treatment
weekly I-Treatment.Freq
warfarin I-Treatment.Drug
dose I-Treatment
while O
the I-Subject
patient I-Subject
was O
receiving I-Potential_therapeutic_event.Trigger
emtricitabine I-Treatment.Drug
monotherapy I-Treatment
was I-Treatment
13.3 I-Treatment.Dosage
mg I-Treatment.Dosage
( I-Treatment
95 I-Treatment
% I-Treatment
CI I-Treatment
12.7 I-Treatment
to I-Treatment
13.8 I-Treatment
) I-Treatment
, O
with O
a O
mean O
international O
normalized O
ratio O
( O
INR O
) O
of O
2.8 O
( O
95 O
% O
CI O
2.5 O
to O
3.1 O
) O
. O

We O
report O
a O
case O
of O
penile I-Effect
fibrosis I-Effect
after I-Adverse_event.Trigger
intracavernous I-Treatment.Route
self I-Treatment.Route
- I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
a I-Treatment
combination I-Treatment
of I-Treatment
phentolamine I-Treatment.Combination.Drug
and I-Treatment
papaverine I-Treatment.Combination.Drug
. O

This O
is O
, O
to O
the O
best O
of O
our O
knowledge O
, O
the O
first O
report O
of O
a O
case O
in O
which O
agranulocytosis I-Effect
followed I-Adverse_event.Trigger
treatment O
with O
both I-Treatment
propylthiouracil I-Treatment.Combination.Drug
and I-Treatment
methimazole I-Treatment.Combination.Drug
in O
the I-Subject
same I-Subject
patient I-Subject
. O

Itch I-Effect
and I-Effect
skin I-Effect
rash I-Effect
from I-Adverse_event.Trigger
chocolate I-Treatment.Combination.Drug
during I-Treatment
fluoxetine I-Treatment.Combination.Drug
and I-Treatment
sertraline I-Treatment.Combination.Drug
treatment I-Treatment
: O
case O
report O
. O

Oxycodone I-Treatment.Combination.Drug
- I-Treatment
gabapentin I-Treatment.Combination.Drug
co I-Treatment
- I-Treatment
administration I-Treatment
was O
associated I-Adverse_event.Trigger
with O
less I-Effect
escape I-Effect
medication I-Effect
use I-Effect
( I-Effect
P I-Effect
= I-Effect
0.03 I-Effect
) I-Effect
and I-Effect
fewer I-Effect
nights I-Effect
of I-Effect
disturbed I-Effect
sleep I-Effect
( I-Effect
P I-Effect
< I-Effect
0.05 I-Effect
) I-Effect
. O

Gynecomastia I-Effect
in O
epileptics I-Treat_Disorder
treated O
with I-Adverse_event.Trigger
phenobarbital I-Treatment.Combination.Drug
, I-Treatment
phenytoin I-Treatment.Combination.Drug
and I-Treatment
fluoresone I-Treatment.Combination.Drug
: O
two O
case O
reports O
. O

Captopril I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lichen I-Effect
planus I-Effect
pemphigoides I-Effect
with O
pemphigus O
- O
like O
features O
. O

The O
literature O
on O
thiabendazole I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cholestasis I-Effect
and O
its O
association O
with O
sicca O
complex O
is O
reviewed O
. O

How O
low O
can O
you O
go O
? O
Use I-Potential_therapeutic_event.Trigger
of O
very I-Treatment.Dosage
low I-Treatment.Dosage
dosage I-Treatment.Dosage
of I-Treatment
gold I-Treatment.Drug
in O
patients I-Subject
with I-Subject
mucocutaneous I-Subject.Sub_Disorder
reactions I-Subject.Sub_Disorder
. O

A I-Subject
55 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
HIV I-Subject.Sub_Disorder
- I-Subject
positive I-Subject
African I-Subject.Race
woman I-Subject.Gender
received I-Potential_therapeutic_event.Trigger
a I-Treatment
single I-Treatment
epidural I-Treatment
triamcinolone I-Treatment.Drug
injection I-Treatment.Route
for O
pain I-Treat_Disorder
relief I-Treat_Disorder
of I-Treat_Disorder
postherpetic I-Treat_Disorder
neuralgia I-Treat_Disorder
. O

Anaphylactoid I-Effect
shock I-Effect
, I-Effect
disseminated I-Effect
intravascular I-Effect
coagulation I-Effect
, I-Effect
and I-Effect
anuric I-Effect
renal I-Effect
failure I-Effect
requiring I-Effect
dialysis I-Effect
occurred I-Adverse_event.Trigger
in O
a I-Subject
patient I-Subject
receiving O
zomepirac I-Treatment.Drug
sodium I-Treatment.Drug
for O
toothache I-Treat_Disorder
. O

During O
dose O
- O
finding O
studies O
for O
intravenous O
proton O
pump O
inhibitors O
omeprazole O
and O
pantoprazole O
, O
three I-Subject.Population
of I-Subject
six I-Subject
young I-Subject.Age
female I-Subject.Gender
volunteers I-Subject
receiving O
omeprazole I-Treatment.Drug
and O
two O
young O
female O
volunteers O
receiving O
pantoprazole O
developed I-Adverse_event.Trigger
peripheral I-Effect
edema I-Effect
within I-Effect
8 I-Effect
hr I-Effect
when O
high I-Treatment
doses I-Treatment
of I-Treatment
the I-Treatment
proton I-Treatment
pump I-Treatment
inhibitors I-Treatment
were I-Treatment
applied I-Treatment
by I-Treatment
continuous I-Treatment
infusion I-Treatment
together I-Treatment
with I-Treatment
large I-Treatment
volumes I-Treatment
of I-Treatment
fluid I-Treatment
. O

Intravenous I-Treatment.Route
levodopa I-Treatment.Drug
25 I-Treatment
mg I-Treatment
ameliorated I-Potential_therapeutic_event.Trigger
his O
akathisia I-Treat_Disorder
symptoms O
drastically O
. O

Cyclosporine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pain I-Effect
syndrome I-Effect
in O
a I-Subject
child I-Subject.Age
undergoing I-Subject
hematopoietic I-Subject.Sub_Disorder
stem I-Subject.Sub_Disorder
cell I-Subject.Sub_Disorder
transplant I-Subject.Sub_Disorder
. O

Visual I-Effect
loss I-Effect
after I-Adverse_event.Trigger
a I-Treatment
single I-Treatment.Duration
small I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
vincristine I-Treatment.Drug
has O
never O
been O
reported O
. O

Slow O
acetylator O
genotypes O
as O
a O
possible O
risk O
factor O
for O
infectious I-Effect
mononucleosis I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
induced I-Adverse_event.Trigger
by I-Adverse_event.Trigger
salazosulfapyridine I-Treatment.Drug
. O

Clinicians O
should O
be O
aware O
of O
raltegravir I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
DRESS I-Effect
syndrome I-Effect
as O
well O
as O
the O
potential O
for O
drug O
- O
drug O
interactions O
due O
to O
protease O
inhibitor O
- O
based O
therapy O
. O

CONCLUSION O
: O
Under O
certain O
circumstances O
topical I-Treatment.Route
brimonidine I-Treatment.Drug
can O
cause I-Adverse_event.Trigger
paradoxical O
raised I-Effect
IOP I-Effect
necessitating O
vigilance O
in O
follow O
- O
up O
of O
patients I-Subject
on I-Subject
topical I-Subject
brimonidine I-Subject
. O

Pharmacokinetic O
modeling O
suggested O
that O
the I-Subject
patient I-Subject
's I-Subject
initial O
over I-Adverse_event.Trigger
- I-Adverse_event.Trigger
treatment I-Adverse_event.Trigger
was O
as O
reported O
and O
that O
the O
predicted O
maximum O
serum O
concentration O
of O
chloroquine I-Treatment.Drug
( I-Treatment
902 I-Treatment.Dosage
micro I-Treatment.Dosage
g I-Treatment.Dosage
/ I-Treatment.Dosage
L I-Treatment.Dosage
) I-Treatment
was O
within O
the O
range O
seen O
in O
fatal I-Effect
chloroquine O
overdose O
. O

There O
was O
no O
apparent O
cardiovascular O
interaction O
between O
clopidogrel O
and O
omeprazole O
, O
but O
our O
results O
do O
not O
rule O
out O
a O
clinically O
meaningful O
difference O
in O
cardiovascular I-Effect
events O
due I-Adverse_event.Trigger
to O
use O
of O
a O
PPI I-Treatment.Drug
. O

Anaphylactic I-Effect
/ I-Effect
anaphylactoid I-Effect
reactions I-Effect
to I-Adverse_event.Trigger
methotrexate I-Treatment.Drug
are O
rare O
. O

Continuous I-Treatment.Freq
bladder I-Treatment.Route
irrigation I-Treatment.Route
of I-Treatment
a I-Treatment
1 I-Treatment.Drug
% I-Treatment.Drug
alum I-Treatment.Drug
solution I-Treatment
is O
a O
simple O
and O
generally O
safe O
method O
of O
chemical O
cautery O
to O
treat I-Potential_therapeutic_event.Trigger
the O
bleeding I-Treat_Disorder
urothelium I-Treat_Disorder
. O

The O
temporal O
relationship O
suggests O
that O
the O
spinal I-Effect
cord I-Effect
infarction I-Effect
may O
be O
related I-Adverse_event.Trigger
to O
the O
use O
of O
zolmitriptan I-Treatment.Drug
. O

Delusional I-Effect
parasitosis I-Effect
associated I-Adverse_event.Trigger
with O
phenelzine I-Treatment.Drug
. O

CONCLUSION O
: O
The O
administration O
of O
tissue I-Treatment.Drug
plasminogen I-Treatment.Drug
activator I-Treatment.Drug
was O
responsible I-Adverse_event.Trigger
for O
the O
large I-Effect
extent I-Effect
of I-Effect
hemorrhage I-Effect
and O
should O
be O
considered O
in O
the O
differential O
diagnosis O
of O
hemorrhagic O
choroidal O
detachment O
. O

Dihydropyrimidine I-Treat_Disorder
dehydrogenase I-Treat_Disorder
deficiency I-Treat_Disorder
: O
a O
pharmacogenetic O
defect O
causing O
severe I-Effect
adverse I-Effect
reactions I-Effect
to I-Adverse_event.Trigger
5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
- I-Treatment
based I-Treatment
chemotherapy I-Treatment.Route
. O

Interferon I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
( I-Treatment.Drug
IFN I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
) I-Treatment.Drug
is I-Treatment
a I-Treatment
type I-Treatment.Drug
I I-Treatment.Drug
interferon I-Treatment.Drug
used I-Potential_therapeutic_event.Trigger
in I-Potential_therapeutic_event.Trigger
the O
management O
of O
multiple I-Treat_Disorder
sclerosis I-Treat_Disorder
. O

Quetiapine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
leucopenia I-Effect
and I-Effect
thrombocytopenia I-Effect
. I-Effect

CONCLUSION O
: O
Severe I-Effect
and I-Effect
sustained I-Effect
ocular I-Effect
hypertension I-Effect
may O
occur O
after I-Adverse_event.Trigger
intravitreal I-Treatment.Route
ranibizumab I-Treatment.Drug
. O

BACKGROUND O
: O
To O
describe O
the O
occurrence I-Adverse_event.Trigger
of O
ocular I-Effect
hypertension I-Effect
in O
four I-Subject.Population
patients I-Subject
following O
injection O
of O
ranibizumab I-Treatment.Drug
intravitreally O
. O

Vancomycin I-Treatment.Drug
is O
widely O
used O
against O
methicillin I-Treat_Disorder
- I-Treat_Disorder
resistant I-Treat_Disorder
Staphylococcus I-Treat_Disorder
aureus I-Treat_Disorder
infections I-Treat_Disorder
, O
but O
it O
is O
associated I-Adverse_event.Trigger
with O
many O
adverse O
effects O
such O
as O
nephrotoxicity I-Effect
, I-Effect
ototoxicity I-Effect
, I-Effect
gastrointestinal I-Effect
disturbances I-Effect
, I-Effect
blood I-Effect
disorders I-Effect
, I-Effect
and I-Effect
two I-Effect
types I-Effect
of I-Effect
hypersensitivity I-Effect
reactions I-Effect
- I-Effect
an I-Effect
anaphylactoid I-Effect
reaction I-Effect
known I-Effect
as I-Effect
" I-Effect
red I-Effect
man I-Effect
syndrome I-Effect
" I-Effect
and I-Effect
anaphylaxis I-Effect
. O

We O
report O
a O
case O
of O
unintentional O
overdose O
of O
oral I-Route
pilocarpine I-Treatment.Drug
tablets O
that O
resulted I-Adverse_event.Trigger
in O
bradycardia I-Effect
, I-Effect
mild I-Effect
hypotension I-Effect
, I-Effect
and I-Effect
muscarinic I-Effect
symptoms I-Effect
in O
a O
patient O
with O
Sjogren O
's O
syndrome O
. O

Moreover O
, O
treatment O
with O
immunosuppressive I-Treatment
drugs I-Treatment
such I-Treatment
as I-Treatment
cyclosporine I-Treatment.Drug
, I-Treatment
cisplatin I-Treatment.Drug
, I-Treatment
tacrolimus I-Treatment.Drug
, I-Treatment
and I-Treatment
interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
can O
induce I-Adverse_event.Trigger
a O
condition O
resembling O
RPLS I-Effect
. O

Case O
1 O
, O
a I-Subject
62 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
, O
developed O
bilateral I-Effect
optic I-Effect
neuritis I-Effect
with I-Effect
decreased I-Effect
sensation I-Effect
of I-Effect
vibration I-Effect
and I-Effect
increased I-Effect
deep I-Effect
tendon I-Effect
reflex I-Effect
in I-Effect
the I-Effect
lower I-Effect
extremities I-Effect
after I-Adverse_event.Trigger
a I-Treatment.Time_elapsed
seven I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
month I-Treatment.Time_elapsed
use I-Treatment
of I-Treatment
recombinant I-Treatment.Drug
interferon I-Treatment.Drug
alpha I-Treatment.Drug
- I-Treatment.Drug
2a I-Treatment.Drug
for I-Treatment
chronic I-Treatment.Treat_Disorder
active I-Treatment.Treat_Disorder
hepatitis I-Treatment.Treat_Disorder
C. I-Treatment.Treat_Disorder

A I-Effect
syndrome I-Effect
of I-Effect
increased I-Effect
affect I-Effect
in O
response I-Adverse_event.Trigger
to O
risperidone I-Treatment.Drug
among O
patients I-Subject
with I-Subject
schizophrenia I-Treat_Disorder
. O

Therapy O
with O
IFN I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
has O
rarely O
been O
associated O
with O
the O
development I-Adverse_event.Trigger
of O
autoimmune I-Effect
disorders I-Effect
. O

Despite O
these O
antithrombotic O
effects O
, O
the O
patient O
developed O
repeated I-Effect
venous I-Effect
thromboembolism I-Effect
during I-Adverse_event.Trigger
treatment I-Treatment
with I-Treatment
low I-Treatment.Drug
- I-Treatment.Drug
molecular I-Treatment.Drug
- I-Treatment.Drug
weight I-Treatment.Drug
heparin I-Treatment.Drug
. O

Hyponatraemia I-Effect
developed I-Adverse_event.Trigger
after O
rechallenge I-Treatment
with I-Treatment
controlled I-Treatment
release I-Treatment
carbamazepine I-Treatment.Drug
. O

Azathioprine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
warfarin I-Effect
resistance I-Effect
. I-Effect

Reversible O
valproic I-Treatment.Drug
acid I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
dementia I-Effect
: O
a O
case O
report O
. O

Parenteral I-Treatment.Route
- I-Treatment
verapamil I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
sustained I-Effect
hypotension I-Effect
. O

The O
main O
side I-Adverse_event.Trigger
- I-Adverse_event.Trigger
effects I-Adverse_event.Trigger
of O
Lp I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
TAE I-Treatment.Combination.Drug
combined I-Treatment
with I-Treatment
HT I-Treatment.Combination.Drug
were O
low I-Effect
- I-Effect
grade I-Effect
fever I-Effect
, I-Effect
localized I-Effect
pain I-Effect
, I-Effect
myelo I-Effect
- I-Effect
suppression I-Effect
and I-Effect
liver I-Effect
dysfunction I-Effect
, O
but O
these O
were O
transient O
and O
eventually O
disappeared O
. O

Unique I-Effect
behavioral I-Effect
change I-Effect
with I-Adverse_event.Trigger
cinepazide I-Treatment.Drug
in O
parkinsonism I-Treat_Disorder
. O

The O
literature O
of O
vincristine I-Treatment.Drug
optic I-Effect
nerve I-Effect
toxicity I-Effect
is O
reviewed O
. O

PATIENTS O
: O
Two I-Subject.Population
patients I-Subject
, I-Subject
ages I-Subject.Age
40 I-Subject.Age
and I-Subject.Age
51 I-Subject.Age
years I-Subject.Age
, O
undergoing O
treatment O
with O
interferon I-Treatment.Drug
alfa I-Treatment.Drug
for O
malignant I-Treat_Disorder
neoplasms I-Treat_Disorder
experienced I-Adverse_event.Trigger
sudden O
bilateral I-Effect
, I-Effect
sequential I-Effect
visual I-Effect
loss I-Effect
with I-Effect
disc I-Effect
- I-Effect
related I-Effect
field I-Effect
defects I-Effect
and I-Effect
segmental I-Effect
optic I-Effect
disc I-Effect
edema I-Effect
. O

Neurological O
improvement O
and O
rehabilitation O
potential O
following O
toxic I-Effect
myelopathy I-Effect
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
intrathecal I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
doxorubicin I-Treatment.Drug
. O

Generalised I-Effect
cutaneous I-Effect
rash I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
ganciclovir I-Treatment.Drug
therapy I-Treatment
has O
rarely O
been O
reported O
in O
literature O
. O

Anaphylaxis I-Effect
after O
the I-Treatment
injection I-Treatment.Route
of I-Treatment
chymopapain I-Treatment.Drug
occurs I-Adverse_event.Trigger
in O
about O
1 O
% O
of O
such O
cases I-Subject
. O

Heat I-Effect
stroke I-Effect
- I-Effect
like I-Effect
episode I-Effect
in O
a I-Subject
child I-Subject.Age
caused I-Adverse_event.Trigger
by O
zonisamide I-Treatment.Drug
. O

An O
interaction O
between O
methylene I-Treatment.Combination.Drug
blue I-Treatment.Combination.Drug
and I-Treatment
serotonergic I-Treatment.Combination.Drug
agents I-Treatment.Combination.Drug
may O
give O
rise I-Adverse_event.Trigger
to O
the O
serotonin I-Effect
syndrome I-Effect
. O

These O
cases O
suggest O
the O
possibility O
that O
, O
in I-Subject
some I-Subject
patients I-Subject
, O
leukopenia I-Effect
or I-Effect
agranulocytosis I-Effect
during I-Adverse_event.Trigger
olanzapine I-Treatment.Drug
treatment I-Treatment
might O
be O
dose O
- O
related O
. O

Adult I-Effect
respiratory I-Effect
distress I-Effect
syndrome I-Effect
after O
treatment O
with I-Adverse_event.Trigger
pegylated I-Treatment.Combination.Drug
interferon I-Treatment.Combination.Drug
alpha I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
2a I-Treatment.Combination.Drug
and I-Treatment
ribavirin I-Treatment.Combination.Drug
. O

CONCLUSIONS O
: O
The O
increasing O
prevalence O
of O
Type I-Treat_Disorder
2 I-Treat_Disorder
diabetes I-Treat_Disorder
and O
its O
treatment O
with O
metformin I-Treatment.Drug
might O
result I-Adverse_event.Trigger
in O
more O
cases O
of O
lactic I-Effect
acidosis I-Effect
. O

Sustained I-Effect
ventricular I-Effect
tachycardia I-Effect
in O
a O
thalidomide I-Treatment.Drug
- O
treated I-Adverse_event.Trigger
patient I-Subject
with I-Subject
primary I-Treat_Disorder
plasma I-Treat_Disorder
- I-Treat_Disorder
cell I-Treat_Disorder
leukemia I-Treat_Disorder
. O

The O
second O
is O
a I-Subject
29 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
CD I-Treat_Disorder
in O
whom O
nodular I-Effect
sclerosing I-Effect
Hodgkin I-Effect
's I-Effect
lymphoma I-Effect
was O
diagnosed I-Adverse_event.Trigger
3 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
infusion I-Treatment.Route
with I-Treatment
infliximab I-Treatment.Drug
. O

We O
suggest O
discontinuing I-Treatment
gemcitabine I-Treatment.Drug
if I-Adverse_event.Trigger
radiation I-Effect
recall I-Effect
is O
observed O
. O

OBJECTIVE O
: O
To O
report O
the O
occurrence O
of O
acute I-Effect
cytolytic I-Effect
hepatitis I-Effect
in O
a I-Subject
patient I-Subject
exposed I-Adverse_event.Trigger
to I-Adverse_event.Trigger
pulse I-Treatment
itraconazole I-Treatment.Drug
therapy I-Treatment
for I-Treatment
24 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
and O
provide O
a O
concise O
review O
of O
the O
literature O
on O
cases O
of O
itraconazole O
- O
induced O
hepatitis O
. O

These O
findings O
should O
lead O
to O
further O
study O
of O
the O
role O
of O
lithium I-Treatment.Drug
in O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
this O
symptom O
complex O
in O
patients I-Subject
with I-Subject
PTSD I-Treat_Disorder
. O

She I-Subject.Gender
was O
placed O
on O
adjuvant I-Treatment
Adriamycin I-Treatment.Drug
( I-Treatment
doxorubicin I-Treatment
) I-Treatment
chemotherapy I-Treatment.Route
, O
but O
6 I-Time_elapsed
months I-Time_elapsed
later O
died I-Effect
of I-Effect
Adriamycin I-Effect
toxicity I-Effect
. O

BACKGROUND O
: O
Ovarian I-Effect
cancer I-Effect
arising I-Adverse_event.Trigger
from O
an I-Treat_Disorder
endometriotic I-Treat_Disorder
cyst I-Treat_Disorder
in O
a I-Subject
postmenopausal I-Subject.Age
woman I-Subject.Gender
under O
tamoxifen I-Treatment.Drug
therapy O
is O
rare O
. O

L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pancreatitis I-Effect
is O
an O
uncommon O
but O
potential O
lethal O
complication O
of O
the O
treatment O
of O
leukemia I-Treat_Disorder
. O

An I-Subject
89 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject
receiving I-Potential_therapeutic_event.Trigger
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
anticoagulation I-Treatment
with I-Treatment
warfarin I-Treatment.Drug
sodium I-Treatment.Drug
( I-Treatment
total I-Treatment
weekly I-Treatment.Freq
dosage I-Treatment
of I-Treatment
19 I-Treatment.Dosage
mg I-Treatment.Dosage
) I-Treatment
arrived O
at O
the O
anticoagulation O
clinic O
for O
his O
monthly O
visit O
. O

Treatment O
with O
tifacogin I-Treatment.Drug
had O
no O
effect I-Adverse_event.Trigger
on O
all O
- O
cause O
mortality I-Effect
in O
patients I-Subject
with I-Subject
severe I-Subject
sepsis I-Treat_Disorder
and I-Subject
high I-Subject.Sub_Disorder
INR I-Subject.Sub_Disorder
. O

Although O
lung O
specimens O
were O
lacking O
from O
these O
three I-Subject.Population
patients I-Subject
, O
it O
is O
suggested O
that O
the O
pulmonary I-Effect
toxicity I-Effect
of O
CCNU I-Treatment.Drug
may O
be O
dose O
- O
related I-Adverse_event.Trigger
. O

Concomitant I-Treatment
use I-Treatment
of I-Treatment
clarithromycin I-Treatment.Combination.Drug
or I-Treatment
other I-Treatment
potent I-Treatment.Combination.Drug
inhibitors I-Treatment.Combination.Drug
of I-Treatment.Combination.Drug
CYP3A4 I-Treatment.Combination.Drug
with I-Treatment
repaglinide I-Treatment.Combination.Drug
may O
enhance I-Adverse_event.Trigger
its O
blood I-Effect
glucose I-Effect
- I-Effect
lowering I-Effect
effect I-Effect
and I-Effect
increase I-Effect
the I-Effect
risk I-Effect
of I-Effect
hypoglycemia I-Effect
. O

Drug O
- O
induced O
fever I-Effect
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
diltiazem I-Treatment.Drug
. O
